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“Ik word daar enigszins filosofisch van.  
Dan vraag ik me af: wanneer is iets eigenlijk waar?  
Als de wetenschap het heeft bewezen? 
Als genoeg mensen erin geloven?  
Of als de júíste mensen erin geloven?“ 
 
“That makes me somewhat philosophical. 
Then I wonder: when is something actually true? 
If science has proven it? 
If enough people believe in it? 
Or if the ríght people believe in it?" 
 
 
General Zobel in “Duel met Paard” (Duel with Horse), a historical novel written by Paulien Genee. The general is 
discussing whether or not to start a scientific investigation on the intelligence of Hans, the horse of Wilhelm 
von Osten. Hans could perform square roots and his owner, Wilhelm von Osten, was inspired by him and 
hoped to show that animals have intelligence comparable to men. 
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Abbreviations and glossary 
1,25(OH)2D 1,25-dihydroxyvitamin D 
-2LL log likelihood ratio 
25(OH)D 25-hydroxyvitamin D 
7-DHC 7-dehydrocholesterol 
Ab antibody 
AECA anti-endothelial cell antibody 
AI ambulatory index 
AITD auto-immune thyroid disease 
ANA anti-nuclear antibody 
APC antigen presenting cell 
ARR annualized relapse rate 
ASP ankylosing spondylitis  
B “from the bone marrow” 
BAFF B-cell activating factor 
BAP bone-specific alkaline phos-
phatase 
BBB blood brain barrier 
BCG Bycobacterium bovis bacille 
Calmette-Guérin 
BD Behcet’s disease 
BFA brefeldin A 
BIC Bayesian information criteri-
on 
BLG β-lactoglobulin 
BMD bone mineral density 
BMI body mass index 
Breg regulatory B cell 
BSA bovine serum albumin 
C complement component 
calcitriol 1,25-dihydroxyvitamin D 
CBA cytometric bead array 
CCP cyclic citrullinated peptide 
CD cluster of differentiation 
cholecalciferol vitamin D3 
CI confidence interval 
CIS clinically isolated syndrome 
CL cardiolipin 
CLIA chemiluminescence immuno-
assay 
CNS central nervous system 
CpG CpG oligodeoxynucleotide 
2006 
CRP C-reactive protein 
CS casein 
CSF cerebrospinal fluid 
CSIF cytokine synthesis inhibitory 
factor 
CTx C-telopeptide 
CXCR C-X-C chemokine receptor 
CYP24A1 cytochrome P24A1 
CYP27B1 cytochrome P27B1 
d day 
DBP vitamin D binding protein 
DC dendritic cell 
DM diabetes mellitus 
DMF dimethylfumerate 
DMT disease modifying treatment 
DNA deoxyribonucleic acid 
ds double stranded  
DSS  disability status scale 
DT diphtheria toxoid 
EAE experimental auto-immune 
encephalomyelitis  
EBV Epstein Barr virus 
EDSS expanded disability status 
scale 
ELISA enzyme linked immuno-
sorbent assay 
ER endoplasmic reticulum 
ergocalciferol vitamin D2 
EX-2 exon 2 of MBP 
ex vivo “out of the living” 
F female 
FoxP3 forkhead Box P3 
FSC forward scatter 
GA glatiramer acetate 
GAD glutamic acid decarboxylase 
Gd gadolinium 
GFAP glial fibrillary acidic protein 
GM-CSF granulocyte macrophage 
colony-stimulating factor 
GWAS genome wide association 
study 
HC healthy control 
hCAP human cathelicidin antimi-
crobial peptide 
HLA-DR human leukocyte antigen 
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htTG human tissue transglutami-
nase 
ICAM intracellular adhesion mole-
cule 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
IM intra muscular 
in vitro “within the glass” 
in vivo “within the living” 
iTreg inducible regulatory T cell, 
derived peripherally 
JCV John Cunningham virus 
KIR killer immunoglobulin-like 
receptor 
LAP latency activated protein of 
TGF-β 
M male 
max maximum 
MBP myelin basic protein 
MCP monocyte chemoattractant 
protein 
MCTD mixed connective tissue 
disease 
MFI median fluorescence intensity 
MHC major histocompatibility 
complex 
min minimum 
MMP matrix metalloproteinase 
MOG myelin oligodendrocyte 
glycoprotein 
monensin-
/monensin+ 
ratio 
fraction (or MFI) of cytokine 
positive cells measured in the 
absence of monensin divided 
by the fraction (or MFI) in the 
presence of monensin 
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acid 
MS multiple sclerosis 
MSFC multiple sclerosis functional 
composite 
MSSS multiple sclerosis severity 
scale 
N number 
NAWM normal appearing white 
matter 
NK natural killer (cell) 
NK-T natural killer-like T (cell) 
NMDA N-methyl-D-aspartate 
nRNP nuclear ribonucleoprotein 
nTreg natural regulatory T cell, 
derived from the thymus 
OCB oligoclonal bands 
OPN osteopontin 
OR odds ratio 
p p-value 
PBMC peripheral blood mononucle-
ar cell 
PI proinsulin 
PDSS patient determined disability 
scale 
pERK phospho-ERK 
PHA phytohemagglutinin 
PI proinsulin 
PL phospholipid 
PLP proteolipoprotein 
PMA phorbol 12-myristate 13-
acetate 
PML progressive multifocal leu-
koencephalopathy 
PPD purified protein derivative 
PPMS primary progressive multiple 
sclerosis 
PsA psoriatic arthritis 
Q quartile 
R receptor 
RA rheumatoid arthritis 
RCT randomised controlled trial 
relapse exacerbation, period of 
neurological dysfunction 
remission (period of) recovery 
REML restricted maximum likeli-
hood 
RIA radioimmunoassay 
Ribo P ribosomal P 
RIS radiologically isolated syn-
drome 
RF rheumatoid factor 
RNA ribonucleic acid 
RNP ribonucleoprotein 
RPMS relapsing progressive multi-
ple sclerosis 
RRMS relapsing remitting multiple 
sclerosis 
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s soluble 
SCT stem cell transplantation 
SD standard deviation 
SEB staphylococcal enterotoxin B 
SI stimulation index (MTT-assay) 
SLE systemic lupus erythemato-
sus 
Sm Smith antigen 
SNRS Scripps Neurological Rating 
Scale 
SOLAR Supplementation of Vigantol 
oil versus placebo as add-on 
therapy in Rebif® (interfer-
on-beta) treated patients 
with relapsing remitting 
multiple sclerosis 
SOLARIUM SOLAR immune modulating 
effects 
SPAG sperm associated antigen 
SPMS secondary progressive multi-
ple sclerosis 
SS-A anti-Ro antibody 
SSC side scatter 
TB tuberculosis 
Tc cytotoxic T cell 
Tep trans endothelial protrusion 
TGF tumour growth factor 
Th T helper cell 
Th1 T helper cell type 1, associat-
ed with IFN-γ production 
Th2 T helper cell type 2, associat-
ed with IL-4 production 
Th17 T helper cell type 17, associ-
ated with IL-17 production 
TIMP tissue inhibitor of metallo-
proteinase 
TLR Toll like receptor 
Tm time-point measured 
TNF tumour necrosis factor 
Tr1 Type 1 regulatory T cell 
Treg regulatory T cell 
Tresp responder T cell 
TT Tetanus toxoid 
UVB ultraviolet B radiation 
VDP vitamin D binding protein 
VDR vitamin D receptor 
VDRE vitamin D response element 
WBC white blood cell count 
Wbp wet bescherming persoons-
gegevens (NL) 
WGBO wet geneeskundige behande-
lingsovereenkomst (NL) 
Y year 
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Vitamin D has gained a lot of attention in different research areas and diseases over the last 
decades. [1] Talking to people about vitamin D and vitamin D supplementation evokes a 
number of different responses. Many patients get a sense of hope and the idea of nothing 
ventured, nothing gained. It gives scientists a great deal of excitement about future pro-
spects and in most doctors it sets alight an enthusiasm to help patients in a simple and 
affordable way. Else ways, there are also physicians and researchers who have a rather scep-
tical view on vitamin D presented as the new panacea. [2] These diverse expectations bring 
together different stories, some of them based on facts, some based on big promises and 
hope. 
This thesis describes the search for some missing pieces in the understanding of the role of 
vitamin D in multiple sclerosis (MS), focusing on the clinical and immunological effects. It will 
add information on the underlying etiological mechanism of this still poorly understood 
disease, by adding knowledge on the associations between vitamin levels and long-term 
clinical outcomes, and will discuss the immunological effects of high dose vitamin D supple-
mentation as a possible add on treatment in patients with MS. 
Multiple sclerosis some time ago 
Times change and so do we. Around 1395, Lidwina, a girl of 15 years old, went skating in 
Schiedam (the Netherlands). She fell, broke a rib and since then never recovered (Figure 1). 
Till her dead in 1433 she experienced a plethora of symptoms and developed a gait disorder, 
paresis and blindness, suggested to be transient. Due to the way she accepted her illness, 
performed prayers and mental exercises and even wanted to suffer more to release spirits 
from the purgatory, made her to be canonized. She became the Saint of the city of Schiedam 
in 1890, now 125 years ago. Looking back, Lidwina is possibly the first described case of a 
person with MS. [3, 4] 
Since then, great efforts have been made to describe, understand and treat this disease 
more accurately. Among others, at the end of the 18th century, Charcot and his students 
made great contribution to the concept of MS by being the first to distinguish MS as a sepa-
rate neurological entity. They were able to correlate clinical and pathological findings and to 
describe mild and benign forms of MS. Furthermore they were the first who spoke about 
“sclerotic patches”, referring to the multifocal inflammation within the central nervous sys-
tem (CNS), forming scars and resulting in failure of neurological function. [5, 6] Halfway the 
20
th
 century, the development of an experimental auto-immune encephalitis (EAE) animal 
model [7-9], further increased the progression in the understanding of the disease and in the 
development of therapies. 
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Current insights in multiple sclerosis  
Multiple sclerosis, some general information 
Today, MS is defined as an inflammatory disease of the CNS. This disease affects approxi-
mately 16.000 people in the Netherlands and at least 1.3 million people worldwide [10, 11], 
women being at least 2 times more prone to get the disease than men [10]. The onset of the 
disease is usually between 20-40 years of age. The exact aetiology of the disease is not 
known. However, it is clear that a combination of genetics and environmental risk factors 
play a role, with a substantial overlap of these causative factors with other auto-immune 
diseases. [12] Presumably, individuals who are susceptible for a dysregulation of the immune 
system, caused by Major Histocompatibility Complex (MHC) related genotypes (especially 
DRB1*1501) [13], in combination with several genetic polymorphisms in for example the 
interleukin 7 receptor (IL-7R) gene or the IL-2R gene [14-16], and the influence of environ-
mental factors, like smoking or low vitamin D levels, will develop an auto-immune disease 
after an initiating trigger. This trigger will then easily disrupt immune homeostasis resulting 
in loss of self-tolerance. The exact origin of this initiating trigger is unknown, but an infection 
with the Epstein Barr virus (EBV) [17, 18] or endogenous factors as stress, are possible candi-
dates. 
 
 
Figure 1. Woodcut “Vita alme virginis Lijdwine” (Johannes Brugman, Otgier Pietersz. Nachtegael, 1489, 
collection Museum Catharijneconvent, Utrecht, the Netherlands).  
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A 
 
B 
 
Figure 2. The pathophysiological mechanism and clinical course in (A) RRMS and SPMS and (B) PPMS.  
The upper graphs demonstrate clinical symptoms; the lower graphs show the underlying pathophysiologi-
cal processes of inflammation and degeneration.  
In relapsing remitting multiple sclerosis (RRMS), inflammatory activity and possible thereto linked degener-
ation might precede the actual clinical symptoms. In the auto-immune hypothesis this degeneration is 
considered to be a consequence of inflammation. In the cytodegeneration hypothesis it is considered to be 
the primary cause. Over time, degeneration will (exponentially or linearly) become more prominent and the 
disease will progress between relapses entering the secondary progressive phase (SPMS). 
In primary progressive multiple sclerosis (PPMS), there is a significant degeneration without preceding 
inflammatory phases in most of the patients. Symptoms are observed from the moment compensatory 
mechanisms fail to counterbalance the degenerative effects. Therefore the onset of PPMS is usually at a 
later age.   
RRMS SPMS
Clinical threshold
Inflammation
Clinical signs
Time
Degeneration
PPMS
Inflammation
Clinical signs
Time
Degeneration
Clinical threshold
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The most common phenotypic entity of MS is the so called relapsing remitting MS (RRMS) 
subtype, characterized by periods of neurological dysfunction (relapses) followed by recov-
ery (remission). Symptoms can be diverse, but include tingling (paraesthesia) and numbness, 
cognitive dysfunction, depression, fatigue, muscle spasms, weakness, walking difficulty, 
dizziness, vision problems, pain, and bladder and bowel dysfunction. In most patients the 
recovery between relapses will be complete in the first years but usually becomes incom-
plete later on. From the moment neurological dysfunction gradually worsens between re-
lapses, the disease has entered a progressive state and is called relapsing progressive MS 
(RPMS) or secondary progressive MS (SPMS). A minority of patients has progressive disease 
from onset (without relapses), which is called primary progressive MS (PPMS). [19] (Figure 2) 
Diagnosis has long been made purely on clinical presentation based on the criteria of Schu-
macher [20] and Poser [21]. The most important principle is to establish the dissemination in 
time and space of the MS lesions. This means that for the diagnosis of RRMS at least two 
relapses have to be objectified, with involvement of different systems within the CNS, at least 
30 days apart. Magnetic resonance imaging (MRI) can nowadays be used to confirm or prove 
one of these relapses by showing gadolinium (Gd) enhancing brain or spinal cord lesions, or 
new T2 lesions. PPMS can be diagnosed after 1 year of progressive symptoms and brain 
and/or spinal cord involvement on MRI or oligoclonal bands (OCB) in the cerebrospinal fluid 
(CSF). [22-24] Apart from these MS subtypes, a clinically isolated syndrome (CIS) can be 
distinguished. This syndrome is characterized by a single attack of neurological function loss, 
suggestive of MS. Depending on the genetic background and the presence of environmental 
factors, thirty to seventy percent of CIS patients will develop MS later in life. [25] Finally, MRI 
hallmarks typical for MS without any clinical signs are described as radiologically isolated 
syndrome (RIS). [26] 
Multiple sclerosis as an auto-immune disease 
It is not clear yet whether the different subtypes of MS are presentations of the same under-
lying disease or from different diseases. What is evident is that MS symptoms are caused by 
a combination of inflammation and degeneration within the CNS. The prototypic example of 
inflammatory MS is early RRMS. Later during RRMS and in progressive disease, inflammation 
becomes less prominent and degenerative aspects are more outstanding. The pathophysio-
logical hypothesis most widely accepted is that of MS being an auto-immune disease. Auto-
immune diseases result from an error in the immune system that hampers appropriate dis-
crimination of self and non-self, resulting in a deleterious response to self-antigens. Alt-
hough the causative agent and the exact auto-antigen in MS are unknown, the auto-immune 
hypothesis supposes naïve T and B cells to be primed in the periphery with CNS antigens. 
These antigens can enter the vascular system through either leakage of CNS proteins from 
the brain or by molecular mimicry with a foreign antigen. [27] Molecular mimicry refers to a 
shared structural, functional or immunological macromolecule between two different enti-
ties, for example an infectious pathogen and its host tissue. In humans, EBV proteins have 
been shown to have overlap with human myelin associated proteins. [28, 29] After priming in 
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secondary lymphoid tissues, T and B cells enter the CNS via the blood brain barrier (BBB), 
where they re-encounter the specific antigen and become reactivated. This leads to a pro-
inflammatory environment within the CNS, an increased cytokine production and attraction 
of many other kinds of immune cells. As a consequence, myelin sheets and neurons are 
damaged, eventually resulting in demyelination, the typical hallmark of MS. The main func-
tion of myelin is to synchronize afferent nerve signal input. It is necessary for a fast and 
fluent signal transduction from the cells of the CNS into the periphery. These functions will 
be affected in MS patients and lead to the characteristic symptoms. During the disease 
course, loops of demyelination and remyelination will ultimately lead to astrocytosis and if 
the disease becomes progressive, axon degeneration will accumulate. 
 
Several lines of evidence underpin that MS is an auto-immune disease. MS is associated with 
auto-antibodies. Auto-antibodies to a whole array of myelin-associated proteins are detect-
able in MS patients, such as myelin basic protein (MBP), proteolipoprotein (PLP), and myelin 
oligodendrocyte glycoprotein (MOG), but also more recently discovered auto-antigens 
against non-myelin antigens as αB-crystalline [30], KIR4.1 [31] and SPAG16 [32]. They can be 
shown intrathecally, as OCBs in the CSF, or in the blood. The role of these auto-antibodies in 
the pathogenesis is not clear. They probably contribute to the disease process, but they are 
not single-actors inducing disease, as they can also be shown in healthy controls (HC). [33] 
The role of immunoglobulins or other serum components in the pathophysiology is also 
supported by the effectiveness of plasma exchange, when the blood plasma is replaced by 
donor plasma or replacement fluids. Furthermore, MS is considered to be a T-cell mediated 
auto-immune disease. Both T helper (Th) cells and cytotoxic T (Tc) cells are assumed to play 
a role as initiators of disease or as effectors. They can be found at the sites of inflammation, 
together with macrophages and B cells. In early RRMS, the circulating immune cell com-
partment outside the CNS is characterized by a decrease in the function of regulatory cells 
and a shift to a more pro-inflammatory immune cell profile. [34, 35] For many years, MS was 
regarded to be a T helper 1 (Th1; mainly IFN-γ producing Th cells) mediated disease. [36] 
More recently, Th17 cells, producing interleukin 17 (IL-17) [36, 37], and GM-CSF producing T 
cells [38, 39] are shown to have strong encephalitogenic capacities and are now thought to 
be the ‘pathogenic’ Th cells in MS. Regulatory T cells are important to keep pro-
inflammatory cells in control. Also genome wide association studies (GWAS) have supported 
MS to be a T cell dependent disease. [14] 
Transfer of the disease to healthy individuals or animals is one of the other criteria for an 
auto-immune disease defined in the (revised) Witebsky´s postulates. [40] However, in MS, it 
is difficult to prove this, because T cells do not efficiently cross the placenta, and therefore 
neonates of mothers with MS are not affected. Also passive immunization with auto-reactive 
T cells from humans to animals is not possible because of MHC restriction in antigen recog-
nition by T cells. [41] On the other hand, the EAE model, induced by immunization of rodents 
with CNS homogenate or (parts) of CNS proteins, can be adoptively transferred by auto-
reactive T cells to healthy syngeneic recipients. [42] Also the arguments that the disease is 
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most prevalent in young women, that the disease course is relapsing remitting and that 
immune modulating drugs have a favourable response, all give circumstantial evidence for 
MS to be an auto-immune disease. 
Alternative pathophysiological hypotheses 
Several researchers have come up with alternative hypotheses for the pathophysiology in 
MS. An interesting alternative hypothesis is that of MS being the consequence of progressive 
cytodegeneration. [43] In contrast to the auto-immune hypothesis, the basis of this hypothe-
sis is that degeneration of presumably oligodendrocytes and myelin provokes the disease 
development and becomes very quickly intertwined with a disbalanced immune system. 
Evidence from different approaches could support this hypothesis. Pathological studies have 
shown that the earliest histological changes occur at the inner layer of the myelin sheet, 
while the outer myelin wrap is still intact. Moreover, in early MS brain sections mainly mac-
rophages are abundantly present, which might indicate that the digestion of debris occurs 
before the actual activation of T and B cells. In normal appearing white matter (NAWM) in 
the CNS of MS patients, signs of myelin and axonal degeneration have been observed, with 
little evidence for involvement of an adaptive immune response. Disease modifying treat-
ments (DMT) have shown effects on the immune system, but are not able to hold the pro-
gression of demyelination, axonal degeneration and brain atrophy. This makes MS progres-
sion largely independent of inflammatory relapse activity. According to the cytodegeneration 
hypothesis, the different subtypes of MS could be explained by a difference between the 
genetic make-up of individuals in the way their immune system reacts to the initial cyto-
degeneration. Underlying mechanisms for this cytodegeneration could be an over-activation 
of the NMDA receptor (whether or not caused by a dysregulation in the copper homeosta-
sis), myelinopathy or an over-activation of other glutamate receptors. 
Another alternative hypothesis focusses more on the role of astrocytes versus microglia as 
antigen presenting cells in the CNS which induce the reactivation and pathogenicity of auto-
reactive T cells. Also different vascular components have been under investigation: MS pa-
tients have a higher risk of ischemic stroke, global cerebral hypoperfusion and a slower 
cerebral venous blood flow and this might point towards a causal component within the 
vascular system, but the exact mechanism behind this, is not completely clear yet. [44-46] 
Overall, independent of the most plausible pathophysiological hypothesis, it is clear that 
inflammation is the most important provoker of symptoms in early RRMS, while symptoms in 
later RRMS and progressive disease are the result of an outstanding degenerative compo-
nent (Figure 2). 
Within this framework, it is interesting to mention that the CNS has for a long time been 
seen as an immune privileged structure, without surveillance of immune cells in a healthy 
situation. However, it has now become clear that immune cells can cross the BBB in healthy 
and diseased individuals. [47, 48] Moreover, very recently, two papers [49, 50] have been 
published describing a lymphatic system in the CNS suggestive for a possible route for anti-
gen leakage into the cervical lymph nodes. 
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Current and upcoming treatment options in MS 
MS is as yet an incurable disease. Treatment focuses on the prevention of relapses and disa-
bility progression and is three part. [51] First, acute relapses are treated with intravenous 
corticosteroids or in severe cases with plasma exchange. Second, multidisciplinary symptom 
management is needed to promote the functional abilities, independence and the quality of 
life of the patient. Third, since the end of the 20th century, drugs that interfere with the 
disease process, the DMTs, have become available. In general, these therapies affect the 
inflammatory component of the disease and are therefore mainly applicable for CIS, RRMS 
and sometimes for SPMS patients, if still suffering from relapses. They mainly affect the 
disease activity, not so much the disability progression. The most well-known and safe DMTs 
are IFN-β and glatiramer acetate (GA). Recently, oral first-line therapies with dimethylfumer-
ate (DMF) and teriflunomide have been approved. Second line treatment consists of fin-
golimod, natalizumab or alemtuzumab. Drugs currently in development for MS treatment 
include variants of IFN-β (NU100 (NCT01464905) [52] and Bii-B017 (NCT01332019)) and 
natalizumab (firategrast [53]) and drugs with different modes of action like daclizumab [54] 
and laquinimod [55]. Also B cell depleting therapies as rituximab/ocrelizumab/ofatumumab 
[56] look very promising. Hematopoietic stem cell transplantation [57] still awaits any clinical 
breakthrough. In the future, anti-LINGO1 [58], rHigM22 (anti-oligodendrocyte IgM) [59] and 
possibly also stem cell therapies, may affect regeneration, remyelination and survival of CNS 
cells, making these drugs particularly interesting for the treatment of progressive patients. 
There is currently no evidence for combination therapies in MS. 
 
DMTs exert their disease modifying actions by affecting different steps in the immunological 
cascade of the disease process. First, some drugs (like DMF [60], teriflunomide [61], fin-
golimod [62], alemtuzumab [63] and daclizumab [54]) decrease the amount of lymphocytes 
in the circulating immune cell compartment, thereby decreasing the number of circulating 
potentially pathogenic cells. Second, the balance between pro- and anti-inflammatory cyto-
kines and cells, which is shifted to a more pro-inflammatory profile in patients with MS, can 
be rebalanced by either increasing the anti-inflammatory compartment, decreasing the pro-
inflammatory compartment or by increasing the number or function of regulatory cells (e.g. 
DMF [60, 64], GA [65]). A third mode of action is to decrease the activation of pro-
inflammatory and probable pathogenic T cells for example by decreasing antigen presenta-
tion (e.g. IFN-β [66] and rituximab [56]). Fourth, the ability of activated pro-inflammatory and 
pathogenic cells to cross the BBB can be blocked or decreased, by blocking T cell adhesion 
molecules or proteases needed for crossing (e.g. IFN-β [66], natalizumab [67]). Fifth, drugs 
may have neuroprotective effects (possibly DMF [60, 64] and fingolimod [62]). The last op-
tion is to enhance regeneration and survival of CNS cells. All DMTs have minor to even major 
and severe side effects, making patients more vulnerable to infection. The blockade of im-
mune cells entering the brain, by in particular natalizumab, but also after use of fingolimod 
and DMF, may even induce progressive multifocal leukoencephalopathy (PML), a severe and 
serious side effect, in anti-JC-virus antibody positive patients. 
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The role of vitamin D in multiple sclerosis  
Vitamin D is an essential vitamin, especially for bone metabolism. Humans obtain vitamin D 
to the largest extend (90-100%) via sun exposure. A small part is obtained from food, both 
from animal origin (cholecalciferol, e.g. fatty fish), and vegetable origin (ergocalciferol, e.g. 
mushrooms). Upon UVB light exposure, 7-dihydrocholesterol in the skin is converted to pre-
vitamin D3 and enters the blood stream. In the liver this is converted to 25-hydroxy vitamin D 
(25(OH)D), the vitamin D metabolite we measure in the blood to estimate vitamin D levels. 
25(OH)D is an inactive metabolite, but it is converted to the active metabolite 1,25-dihydroxy 
vitamin D (1,25(OH)2D) in kidneys and other tissues expressing 25(OH)D-1α hydroxylase 
(CYP27B1), like immune cells and brain tissue. This metabolite is catabolized by 1,25(OH)2D 
24-hydroxylase (CYP24A1) to 24,25-dihydroxy vitamin D. 1,25(OH)2D performs its actions via 
the activation of the intracellular vitamin D receptor (VDR) which regulates the expression of 
more than 500 genes (Figure 3).  
 
Figure 3. Schematic overview of vitamin D metabolism. 
Several metabolites of vitamin D can be found in the circulation: cholecalciferol (vitamin D3), ergocalciferol 
(vitamin D2), 25(OH)D and 1,25(OH)2D, either free or bound to the vitamin D binding protein (VDP).  
25(OH)D is the metabolite that is measured to assess the vitamin D status. 
Via the activation of the vitamin D receptor (VDR) by (25(OH)D and) 1,25(OH)2D, vitamin D can exert its biologi-
cal actions.  
DPB: Vitamin D binding protein, VDR: vitamin D receptor 
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Sufficient levels of vitamin D are needed for adequate calcium regulation and bone metabo-
lism. But also the risk of the development of auto-immune diseases as MS has been associ-
ated with insufficient sun exposure and low vitamin D levels. First of all, the geographical 
variation in the prevalence of MS, with a higher occurrence in northern latitudes and a lower 
occurrence in people living around the equator, is well proven. [68] Secondly, compared to 
the general population, an increased proportion of patients with MS was born in the months 
after the winter season [69] and vitamin D levels have been associated with MS risk in large 
prospective cohort studies. [70] Next to this, low vitamin D levels have been associated with 
disease activity in patients with MS. Low vitamin D levels are associated with an increased 
relapse risk with a decrease in the risk of 9-34% with each 10 nmol/L increase in 25(OH)D 
levels. [71-74] These findings led to the hypothesis of vitamin D3 supplementation to be 
beneficial in RRMS patients, an assumption that has already been investigated in some small 
 
Figure 4. Steps in the MS disease process and potential targets for vitamin D on the cells of the circulating 
immune compartment and/or on cells of the CNS. 
Naïve T and B cells are primed, via antigen presenting cells, with CNS antigens. They enter the CNS via the 
blood brain barrier (BBB), where they re-encounter the specific antigen and become reactivated. In the pro-
inflammatory environment that arises within the CNS, myelin sheets and neurons are damaged eventually 
resulting in demyelination, the typical hallmark of MS. 
Adapted from Smolders J., Hupperts R. and Damoiseaux J. (2016). [85] 
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high dose supplementation studies. [75-81] These studies were severely underpowered to 
detect a clinical meaningful effect, but most of them showed high dose vitamin D supple-
mentation to be safe and suggested a favourable effect of supplementation on MS disease 
activity. 
 
The underlying favourable mechanism is supposed to be the immune regulatory effect of 
vitamin D. This effect could either be in the circulating immune cell compartment or in the 
CNS itself (Figure 4). Immune cells are able to metabolize vitamin D and in vitro and in vivo 
studies show that vitamin D increases regulatory T cell (Treg) function and shifts the balance 
between pro- and anti-inflammatory immune cells. This will be described more in detail in 
chapter 1. Cells of the CNS, like neurons, microglia and astrocytes have been shown to 
express the VDR and to have functional VDR signalling. [82] Moreover, expression of the key 
proteins in vitamin D metabolism was increased in MS chronic active lesions compared to 
NAWM. [82] Vitamin D within the CNS might be beneficial by reducing the inflammatory 
profile of CNS cells, increasing neurothrophin production, modulating Ca
2+
 homeostasis or 
inhibiting nitric oxide synthase leading to a neuroprotective effect. [83, 84] The effects on 
demyelination and remyelination are, however, poorly investigated. 
Evaluating the vitamin D effects in multiple sclerosis 
The effect of vitamin D, vitamin D supplementation and other potential therapeutic strate-
gies in MS can be evaluated either with clinical outcome measures or MRI, which are im-
portant for neurologists and patients, or by assessing the effects on the immune system, to 
further unravel the underlying mechanisms.  
 
Clinical outcomes can be measured by the assessment of biological disease activity, i.e. 
relapse rate in RRMS patients. A relapse is defined as the development of new symptom(s) 
or aggravation of existing symptom(s) for at least 24 hours in a patient with stationary or 
improving disease course in the previous month. [20] The relapse rate forms one of the most 
clinical relevant aspects in RRMS patients, is easy to quantify and can be combined with 
(objective) measures as MRI. However, the relationship between relapses and long-term 
disability is still uncertain. Another outcome that may be used in very early MS is the conver-
sion from CIS (or RIS) to clinically definite MS.  
To assess disability during the disease course several measures can be used. The first meth-
od to investigate disability is the expanded disability status scale (EDSS). This is a scoring 
system from 0 till 10 with steps of 0.5 point, scoring subcategories on eight functional sys-
tems: visual (optic) functions, brainstem functions, pyramidal functions, cerebellar functions, 
sensory functions, bowel and bladder functions, cerebral functions and ambulation. The 
EDSS has two important cut-off points: below a score of 4, a patient is fully ambulatory and 
above a score of 5.5, a patient has difficulties to ambulate and needs an aid or use a wheel-
chair to do so. The EDSS is the score most often used in clinical trials, but it has the disad-
vantages that it is complicated to score, that the low end of the scale is rather subjective, 
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that it has a poor interrater and test-retest reliability and that the increment per unit on the 
scale is non-linear. [51] Researchers and clinicians have tried to improve this scoring system 
by redesigning the score and by introducing alternatives. The MS severity scale (MSSS) takes 
into account the time that a patient has a certain rate of disability, making it possible to 
estimate disability progression based on a single assessment. [86] Other less adopted op-
tions to assess patient functionality are the area under the curve or integrated DSS [87, 88], 
the Scripps neurological rating scale (SNRS) [89], the ambulatory index (AI) [90] or the MS 
functional composite (MSFC) [91]. Other alternative outcome measures could be the evalua-
tion of (grey matter) atrophy on MRI [92-95] or evoked potentials of visual, motor and/or 
somatory sensory systems, which have been implicated for objectivation of MS disease 
course and have been correlated with MS disability. [96, 97] Another way to measure disabil-
ity and disability progression is the time to conversion from RRMS to SPMS. This conversion 
is not so clearly defined in literature and has to be made in retrospect. 
Also MRI is a useful outcome measure. The first MRI of a patient with MS was published in 
1981 [66], and enormous steps have been made to improve this imaging technique in the 
following years. Nowadays, (conventional) MRI takes into account the number and volume of 
T1 and T2 lesions and new T2 gadolinium enhancing lesions. This last parameter is used as 
an indicator of recent inflammation. MRI outcomes are beyond the scope of this thesis. 
Finally, also biomarkers could give information on disease activity or disease progression and 
could therefore be used to evaluate vitamin D treatment. Biomarkers could include markers 
of inflammation, demyelination, oxidative stress, glial dysfunction, remyelination and axonal 
damage. Multiple biomarkers have been under research but only few of them may be suita-
ble to be used for the evaluation of disease prognosis or treatment. [98] Effectiveness of 
treatment could be investigated either by the use of biomarkers predicting treatment non-
response (neutralizing antibodies) or by biomarkers predicting adverse effects (like anti-JCV 
antibodies). [99]  
 
A more mechanistic evaluation of therapy can be obtained by looking at the cells in the 
circulating immune compartment. This can enhance the understanding of the underlying 
mechanism of vitamin D in MS. 
For a detailed description of immunological parameters, see chapter 1 of this thesis. In 
short, general inflammatory markers in the circulation can be assessed, like serum cytokine 
and chemokine concentrations. Furthermore auto-antibodies in serum can be determined, 
but the absence of a MS specific auto-antibody that is detectable in the majority of patients 
makes this difficult. A disadvantage of measuring serum concentrations is that the cellular 
source is uncertain and then the question remains what happens at the tissue level. There-
fore, one could also assess cytokine excretion in the supernatant of stimulated cell cultures 
(stimulated either polyclonally or antigen specific) by using ELISA/CBA or Luminex technolo-
gies. The induction of proliferation after supplementation with vitamin D can be assessed by 
labelling cells with a dye like CFSE. It is also possible to phenotypically assess cells directly ex 
vivo by isolating peripheral blood mononuclear cells (PBMC) and performing flow cytometric 
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analyses. The nature of each cell can be assessed based on the surface markers and the 
proportion of inflammatory and regulatory lymphocyte subsets can be determined. Regula-
tory T cells can be subdivided in natural Treg (nTreg) which are derived from the thymus and 
inducible Treg (iTreg) which are derived peripherally. [100]  
Vitamin D and MS anno 2016: high dose supplementation studies  
The increasing awareness of the potential role of vitamin D in MS has inspired several re-
search groups around the world to study this phenomenon in depth. A lot of research has 
been performed, investigating the role of low vitamin D levels in MS risk and disease activity. 
However, an important gap in our knowledge is the role of vitamin D in disease progression, 
which is one of the most important hallmarks of disability and has major impacts on the 
quality of life. Especially progressive patients for whom no treatments are available up to 
now, and their treating physicians, have interest in an answer to this question. Results on two 
studies on this subject are described in this thesis (chapter 2 and 3) 
The second, and maybe most apparent problem in vitamin D research, has been the ques-
tion whether low vitamin D levels in MS patients are the cause or the consequence of the 
disease, as we will elaborate on in the discussion of this thesis. The only way to answer this 
question is by performing well powered randomised placebo controlled trials (RCT). Several 
of these trials have been initiated. One of these trials initiated in the Netherlands, is the 
SOLAR trial, in which the effect of vitamin D supplementation as add on therapy in IFN-β 
treated RRMS patients is investigated. In this thesis the results of the SOLARIUM study, the 
Dutch sub study of the SOLAR trial, will be described. This study investigated the immune 
regulatory effect of the high dose vitamin D supplementation (chapter 6).  
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Aims and outline of this thesis  
The overall hypothesis of this thesis is that vitamin D acts as an immune regulator, decreas-
ing the pro-inflammatory milieu in MS, while preserving the normal immune surveillance. 
Next to this, vitamin D may also be implicated in disability progression and act directly on 
CNS tissue, thereby increasing the opportunities to regulate the inflammatory milieu in the 
CNS, as target organ of the disease, and to affect regeneration. 
In chapter 1 we give an overview of the in vivo effects of vitamin D on the immune system, 
which were shown in cross sectional and longitudinal studies and in small RCTs at the start 
of the research described in this thesis. Then, with the assumption that vitamin D not only 
acts as an immune modulator of the circulating immune cell compartment, but also could 
have local anti-inflammatory effects within the CNS, we assess the relation between vitamin 
D levels and progression of disease. In chapter 2 we investigate whether vitamin D levels 
during the disease course are associated with disability and disability progression, especially 
in progressive MS patients. In this study we use the EDSS score to assess disability. In the 
next chapter, chapter 3, we use an alternative outcome measure of disease progression and 
share our work on the relation between vitamin D levels at diagnosis and the time to conver-
sion to progressive disease in RRMS patients.  
Then we move to the mechanistic site of vitamin D actions. To answer the key question in 
the relation between vitamin D and disease activity, the SOLAR study was initiated, which is 
not in the scope of this thesis. In the SOLARIUM sub study we investigate the immune 
modulatory effects of vitamin D after high dose vitamin D supplementation. In order to use 
the most relevant outcome measures, we first had to optimize our protocols. GM-CSF, a 
recently discovered and potential pathogenic cytokine produced by T cells in EAE, was not 
investigated so far in MS patients. Therefore we first wished to increase our knowledge on 
the role of this cytokine in MS. We wanted to know whether the proportion of T cells pro-
ducing this cytokine was increased in the blood and CSF of patients with MS and whether it 
could be regulated by regulatory T cells and vitamin D. In chapter 4 we describe the results 
of this study in a cross sectional cohort of patients with MS. Furthermore, chapter 5 de-
scribes the optimisation of the protocol to detect immune cells secreting the cytokine IL-10. 
IL-10 is a prototypic anti-inflammatory cytokine that is the phenotypic hallmark of inducible 
Tregs and regulatory B cells (Breg). We were able to improve the protocol and make IL-10 
producing cells easier to detect, which is an important step forward to assess regulatory 
cells. Chapter 6 involves the most important part of this thesis describing the immune regu-
latory effect of high dose vitamin D supplementation. This thesis will close with a summary 
and general discussion.  
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Abstract  
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nerv-
ous system, characterized by an auto-reactive T cell response. High serum 25-
hydroxyvitamin D (25(OH)D) levels have been associated with a decreased risk of de-
veloping MS and less severe disease. It is hypothesized that the underlying mechanism 
behind this association is the immune modulating effect of vitamin D on the adaptive 
immune response. In vitro studies and in vivo studies in the experimental auto-
immune encephalomyelitis (EAE) animal model have consistently shown that immune 
cells are functional targets of vitamin D. However, in vivo studies in humans are lim-
ited. In this chapter, studies on the relation between vitamin D and immunological 
parameters in healthy individuals and patients with different auto-immune diseases, 
including MS, are evaluated. Correlation studies and supplementation studies per-
formed thus far are heterogeneous in many aspects and studied a diverse repertoire of 
immunological outcome measures. Overall, there seems to be a trend towards an anti-
inflammatory role of vitamin D, but this impression is not substantiated by conclusive 
data. Well-powered and controlled studies assessing disease-specific relevant immu-
nological outcomes are warranted before conclusions can be drawn. Clinical trials on 
vitamin D supplementation in MS and other diseases may provide excellent frame-
works for such studies. 
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Introduction 
Since the beginning of the 20
th
 century vitamin D has been particularly known for its func-
tion on bone and calcium metabolism. However, since the seventies, a poor exposure to 
vitamin D has also been increasingly noticed in and linked to the aetiology of multiple scle-
rosis (MS). [101, 102] Since then, a new research field developed, addressing the implications 
of vitamin D in the pathophysiology of MS in epidemiological studies, intervention studies, 
in vitro studies and animal studies. [103] Currently, almost 50 years later, first randomised 
controlled clinical trials are assessing the efficacy of vitamin D supplementation in MS. The 
view of vitamin D changed from that of a vitamin with a single role in calcium homeostasis, 
to that of an exciting steroid hormone involved in a multitude of cellular processes. One of 
these processes is the regulation of the adaptive immune response, with many in vitro and 
animal studies showing important regulatory effects of vitamin D. [104, 105] One of the 
major challenges that lies ahead is to understand if and how systemic vitamin D status inter-
feres with the human adaptive immune response in vivo. Clarification of the interaction 
between the availability of vitamin D at tissue level (target and secondary lymphoid organs) 
and the extent to which an immune response is initiated or thriven, may reveal underlying 
mechanism for associations between vitamin D status and MS. 
 
The aim of this chapter is not to give an extensive overview of the current knowledge about 
either the immune dysregulation in MS, or the association between vitamin D and MS, or the 
role of vitamin D in the immune response at a cellular level. Since these have been reviewed 
extensively by us and others, we will refer to these reviews were appropriate. In the present 
chapter, we will focus on studies exploring the in vivo relevance of the interaction between 
vitamin D and the immune response. To achieve this, we will discuss studies on correlations 
between vitamin D status and relevant immune outcome parameters, and studies on immu-
nological outcome measures in vitamin D supplementation trials, both in healthy controls as 
well as in patients with auto-immune disease including MS. We will integrate these findings 
and discuss considerations for the design of trials on the immune modulating effects of 
vitamin D in MS.  
Multiple sclerosis 
Multiple sclerosis is an inflammatory, demyelinating disease of the central nervous system 
(CNS). The prevalence is 30-100 per 100,000 individuals. [106, 107] It is twice as common in 
females as in males, with an incidence between 20-50 years, and a peak incidence at 30 years 
of age. [19, 108] MS patients have a heterogeneous disease presentation. In relapsing remit-
ting MS (RRMS), periods without neurological exacerbations are altered by periods of in-
creased neurological symptoms. These relapses can be characterised by symptoms of loss of 
motor and/or sensory function, lack of coordination, but also mental and physical fatigue 
and/ or cognitive decline. After several years, 65% of the RRMS patients becomes secondary 
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progressive (SPMS) and they experience constant neurological deterioration. A small fraction 
of the patients experience a progressive accumulation of disability from the beginning of the 
disease onwards, called primary progressive MS (PPMS). [19, 108] 
 
The exact aetiology of MS is still unknown, but one of the main hypotheses is that it is a T-
cell mediated auto-immune disease. This model for MS has been reviewed by several au-
thors. [106, 109] Shortly, it is thought that auto-reactive lymphocytes are primed with an 
unknown auto-antigen in the secondary lymphoid organs by antigen presenting cells (APC). 
Clonally expanded and activated effector T cells migrate through the blood brain barrier 
(BBB) into the perivascular space. Here, the T cells are reactivated by APCs, like perivascular 
macrophages or dendritic cells (DC), and migrate into the brain parenchyma. In the paren-
chyma, the T cells contribute to an inflammatory response in which loss of oligodendrocytes 
and myelin occurs, often followed by loss of neurons. It is a matter of debate whether MS is 
truly a classical auto-immune disease, with an auto-reactive response directed against a 
single auto-antigen. [109] Several lines of evidence suggest a general lack of control of the T 
cell response in MS. Firstly, many genetic polymorphisms associated with MS are involved in 
the maintenance of T cell homeostasis. [110] Secondly, several differences in general charac-
teristics of the circulating T cell compartment have been found between MS and control 
patients. During active disease, increased proportions of pro-inflammatory T helper type 1 
(Th1) and Th17 cells, as well as increased transcription of IL-17 mRNA have been described. 
[111-114] Most notably, the capacity of regulatory T cells (Treg) to suppress polyclonal or 
antigen-specific proliferation of effector T cells was reduced in MS. [115-117] In addition, a 
reduced transcription of Treg-related genes by peripheral blood mononuclear cells (PBMC) 
[118, 119], and a reduction of Treg-subsets with specific surface molecules as CD39 [120] 
have been described. Interestingly, these CD39
+
 Tregs are able to suppress IL-17 production 
by activated T cells. [121] Accordingly, our group found a negative correlation between the 
proportion of CD39
+
 Tregs and the proportion of Th17 cells in the circulation of RRMS pa-
tients. [122] Thirdly, the CNS tissue of MS patients is infiltrated with CD4
+
 but predominantly 
CD8
+
 T cells. [123] The clonality of these cells is diverse, and does not differ between lesions 
and normal appearing white matter (NAWM). [124] Beside T cells, B cells are also found in 
increased number in the CNS of MS patients. [123] Interestingly, oligoclonal intrathecal IgG-
production against predominantly several myelin proteins and heat shock proteins is a hall-
mark of the disease process. [125] Lastly, currently registered MS disease modulating thera-
pies interfere with either phenotypic and functional characteristics of circulating T cells [126, 
127], migration of lymphocytes into the CNS [128], or deplete B and T cells from the circula-
tion [129, 130]. 
Multiple sclerosis and vitamin D 
Several epidemiologic and genetic studies show that a poor exposure to vitamin D is a puta-
tive risk factor for developing MS, as has been reviewed elsewhere. [70, 131] In brief, genetic 
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polymorphisms within key enzymes involved in vitamin D metabolism, as well as within the 
vitamin D receptor (VDR), have been associated with the risk on developing MS [110, 132], as 
well as a poor vitamin D status prior to disease onset [133]. In established MS, a poor vitamin 
D status is associated with a high risk of relapses [71, 74, 103] and a high MS-related disabil-
ity score [73, 103]. Supplementation of high doses of vitamin D3 in MS patients did not pro-
voke hypercalcaemia and was well tolerated in several pilot studies. [75, 78, 79] A pilot study 
in MS on treatment with the biologically active metabolite of vitamin D, 1,25(OH)2D3, report-
ed the development of a hypercalcaemia in 2/15 subjects. [134] Exploratory analyses on 
clinical endpoints suggested a reduction of magnetic resonance imaging (MRI) activity in an 
uncontrolled study [78], a reduction of relapse activity in an uncontrolled [79] and controlled 
study [75], and a reduction of disability progression in a controlled study design [75]. A study 
supplementing vitamin D2, did not show clear difference on primary MRI endpoints between 
the high- and low-dose treatment arms. [81] Subsequently, first clinical trials are currently 
being performed to assess the efficacy of high dose vitamin D3 supplementation in MS. [135, 
136] Although vitamin D appears to be implicated in the disease process of MS, the underly-
ing mechanism is not known. 
Vitamin D metabolism 
Vitamin D is the precursor of an essential hormone. [137] Its natural sources are diet, both 
from vegetable origin (ergocalciferol or vitamin D2) as well as from animal origin, especially 
fatty fish (cholecalciferol or vitamin D3), and most importantly synthesis in the skin under the 
influence of ultraviolet B radiation (UVB) in sunlight (90-100%). The epidermal layer of the 
skin contains 7-dehydrocholesterol which is transformed into pre-vitamin D3 under influence 
of UVB radiation and body temperature. Subsequently, most of the vitamin D metabolites in 
the circulation are of vitamin D3 origin and only a negligible part of vitamin D2. In the circula-
tion and tissues, vitamin D is mostly present as 25-hydroxyvitamin D (25(OH)D), which is 
formed in the liver. The circulating levels of this metabolite are most useful to describe an 
individual’s vitamin D status, although 25(OH)D is not biologically active. A second hydrox-
ylation step is needed to obtain the biologically active metabolite of vitamin D, 1,25-
dihydroxyvitamin D (1,25(OH)2D). This step is catalysed by the enzyme cytochrome P27B1 
(CYP27B1 or 25(OH)D-1 hydroxylase). [138] 1,25(OH)2D in the circulation is almost exclu-
sively produced by the kidney [139], and circulating levels are regulated by the endocrine 
control of calcium homeostasis [137]. However, many other tissues can ‘activate’ 25(OH)D. 
[140] Once activated, 1,25(OH)2D behaves as a steroid hormone. It binds to the intracellular 
VDR which regulates the transcription of more than 500 genes containing the vitamin D 
response elements (VDRE). Catabolism of 1,25(OH)2D is regulated by the enzyme CYP24A1 
(1,25(OH)2D 24-hydroxylase). [141] Several cut-off points for an optimal vitamin D status 
have been proposed, mostly based on its role in the endocrine control of calcium homeosta-
sis. [141-145] Since the relevance of these cut-off values for other biological functions of 
vitamin D are uncertain, they are not very useful in research. 
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Vitamin D as an immune modulator  
All immune cells involved in the adaptive immune response have the potential to metabolize 
and to respond to vitamin D, as has been reviewed extensively. [105, 146, 147] Shortly, rest-
ing and activated myeloid cells, including monocytes, macrophages and DCs, and activated 
T- and B-lymphocytes express the VDR. [148-151] In lymphocytes, exposure to 1,25(OH)2D 
further enhances VDR expression. [148, 151] Myeloid APCs, and most notably the specialized 
DCs, lose their antigen presenting potential upon exposure to 1,25(OH)2D, and skew towards 
an immature innate profile. [152] Subsequently, they have less capability to start a T cell 
response. [153] Accordingly, 1,25(OH)2D inhibits T cell proliferation and the production of 
pro-inflammatory cytokines as IFN-γ and IL-17. [154] The synthesis of anti-inflammatory 
cytokines, such as IL-4 and IL-10, is promoted. Besides being targets of vitamin D, activated 
myeloid cells (either activated by adaptive or innate stimuli) and lymphocytes (either activat-
ed polyclonally or via antigen specific stimulation) express the activating enzyme CYP27B1, 
and subsequently synthesize 1,25(OH)2D locally. [149, 154-158] All these cells also up-
regulate the catabolic enzyme CYP24A1 upon exposure to 1,25(OH)2D. [149, 154, 156] Since 
these observations are done in vitro, it is uncertain whether these dynamics also apply to 
immune activation within tissues where the immune response becomes manifest, i.e. the 
secondary lymphoid tissues as well as the peripheral tissues affected by a disease. Neverthe-
less, studies in the experimental MS model auto-immune encephalomyelitis (EAE) showed an 
up-regulation of VDR and CYP27B1 and a down-regulation of CYP24A1, together with an 
enhanced local 1,25(OH)2D production within the inflamed CNS. [159] Accordingly, supple-
mentation of vitamin D or treatment with 1,25(OH)2D prevented development of EAE and 
ameliorated the disease course. [160, 161] Both in the circulation, lymph nodes, and CNS, 
proliferation and cytokine assays suggested a shift of the immune response towards a less 
inflammatory profile. [131] 
Vitamin D status, vitamin D supplementation and the effect on 
immune regulation in vivo  
Since an auto-reactive T cell response has been implicated in the disease process of MS, an 
immune modulating, dampening effect of vitamin D may be very relevant. [104] Although 
effects of vitamin D metabolites on immune cells in vitro have been frequently investigated, 
in vivo data are limited. The negative correlation between vitamin D status and the risk on 
developing MS was observed within the physiologically occurring ranges of vitamin D, which 
is 0–150 nmol/L. [133] Within the same range of 25(OH)D, a negative correlation between 
vitamin D status and MS relapse rate was found. [71, 74, 103] If the driving force of these 
correlations is the promotion of T cell homeostasis within the higher ranges of serum 
25(OH)D, relevant measures of immune regulation would be expected to correlate positively 
with vitamin D status in vivo.  
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We conducted a literature search to identify papers which investigated either the correlation 
of serum 25(OH)D levels with measures of immune homeostasis, or the effect of vitamin D 
supplementation on immune parameters determined in peripheral blood (correlation studies 
are summarized in Table 1, supplementation studies in Table 2). We focused on studies in 
healthy controls, patients with MS, and patients with other auto-immune diseases. Since the 
systemic metabolism of vitamin D is disturbed in kidney disease patients, we excluded stud-
ies done in this patient population. Furthermore, studies in cancer patients, HIV patients, 
allergic patients and patients with an infectious disease were excluded, because here the 
interaction of vitamin D with the immune system may be different from auto-immune dis-
eases due to distinct immunopathology. Moreover only studies in which 25(OH)D levels were 
measured and reported were included. Epidemiological studies addressed association be-
tween serum 25(OH)D levels, and the efficacy of vitamin D2/D3 supplementation (vide supra). 
Additionally, while the effect of vitamin D on the immune system is most likely mainly exe-
cuted by local activation of vitamin D, this is rather dependent on circulating 25(OH)D  than 
on 1,25(OH)2D levels. Therefore only supplementation studies in which vitamin D2 or D3 was 
supplemented and in which the effects of vitamin D supplementation could be distinguished 
from other possible co-interventions, were included. Since several approaches have been 
used to evaluate the effect of vitamin D on the immune function in vivo, we will discuss the 
different immunological outcome measures that have been used in these studies. 
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Inflammatory markers in the circulation 
First of all, several groups addressed correlations of serum 25(OH)D with serum concentra-
tions of general markers of inflammation, chemokines, and cytokines. Serum concentrations 
of C-reactive protein (CRP) did not correlate with serum 25(OH)D in most studies with con-
trols. [162-164] Supplementation of vitamin D did also not influence CRP levels in healthy, 
older or obese persons [165-167] or in patients with MS [168]. However, a negative correla-
tion between these parameters has been described in patients with systemic lupus erythe-
matosus (SLE) [169], ankylosing spondylitis (ASP) or psoriatic arthritis (PsA) [170] and 
Behcet’s disease (BD) [171, 172]. Regarding complement, a study among healthy individuals 
reported higher serum concentrations of both 25(OH)D and C3 after a long-distance holiday 
[173], and higher serum 25(OH)D levels correlated with higher serum C4 in subjects with SLE 
[174].  
Cytokines and chemokines in the circulation 
In healthy controls, multiple studies reported no association of higher serum 25(OH)D levels 
with serum concentrations of pro-inflammatory cytokines as IL-6 [162, 163], IL-12 [175], IL-17 
[175], IL-18 [164], IFN-γ [175], TNF-α [163] and the anti-inflammatory cytokine IL-10 [162]. 
Accordingly, no correlations were reported with the immune related molecules soluble 
(s)CD40L [163], sP-selectin [163], osteoprotegerin [163], sTNF-R1 [164], sTNF-R2 [163, 164], 
sICAM-1 [163] and MCP-1 [163]. Likewise, supplementation studies with vitamin D in healthy 
controls and MS patients showed no significant differences in serum IL-1β [168], IL-2 [165, 
168], IL-4 [165, 168], IL-5 [165, 168], IL-6 [166, 176], IL-10 [165, 168, 176], IL-12 [165, 168], IL-
13 [165, 168], IL-17 [165], IFN-γ [165, 168], TGF-β [176], TNF-α [168, 176], sICAM-1 [165], 
MCP-1 [165], C-telopeptide (CTx) [168], bone specific alkaline phosphatase (BAP) [168], 
kallikrein 6 [168], osteopontin (OPN) [168, 177] or B-cell activating factor (BAFF) [178]. De-
spite these negative findings, some studies reported correlations between vitamin D status 
and soluble molecules in serum. Higher serum levels of 25(OH)D have been reported to 
coincide with lower serum concentrations of TNF-α in healthy females. [162] In cord blood of 
new-borns, serum 25(OH)D levels correlated positively with levels of IL-10. [179] This correla-
tion was also observed in females with mixed connective tissue disease (MCTD) [175] and 
active BD patients [172]. Supplementation of vitamin D in patients with MS has been report-
ed to induce increased serum levels of TGF-β. [180] Conversely, in otherwise healthy obese 
females, a negative correlation of serum 25(OH)D with serum IL-5 and IL-10 was reported. 
[165] A negative correlation with IL-6 and IL-23 has been reported in females with MCTD and 
healthy controls. [163, 175] A long distance holiday induced both higher serum levels of 
25(OH)D, sCD14, and sIL-2R. [173] MCP-1 was positively correlated to 25(OH)D levels in 
obese females, but not in males. [165] Lastly, in MS patients, lower circulating concentrations 
of tissue inhibitor of metalloproteinase (TIMP)-1 and matrix metalloproteinase (MMP)-9 were 
reported after supplementation of vitamin D. [168] 
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Cytokine excretion by PBMC in supernatants 
Of course, the cellular sources of cytokines detected in serum are uncertain. To identify cells 
within the PBMC fraction producing these cytokines, several groups analysed the transcrip-
tion profile of cytokines in PBMC directly ex vivo. Supplementation of vitamin D in healthy 
subjects increased expression of cathelicidin mRNA in monocytes [181], but did not differen-
tially affect expression of TNF-α, IFN-γ, IL-2, or IL-13 mRNA in patients with MS [180]. 
Additionally, several studies measured cytokine excretion in supernatants of specific cell 
cultures. Most studies cultured PBMC stimulated either with TLR-ligands [182] or with poly-
clonal [183] or antigen specific T cell stimuli [168, 184, 185]. A higher vitamin D status corre-
lated with a reduced IL-1β and TNF-α production upon TLR-2 and TLR-4 triggering, while a 
loss of IL-6, IL-10 and IFN-γ was only found with TLR-4 triggering. [182] Upon T-cell stimuli, 
supernatant levels of IL-1β [168], IL-2 [168, 184], IL-4 [168, 184], IL-5 [168, 184], IL-10 [168, 
183, 184], IL-12 [168], IL-13 [168], IFN-γ [168, 183-186], and TNF-α [168, 183, 184], were not 
affected by supplementation of vitamin D, while TGF- [186] and IL-10 increased [186, 187] 
and IL-17 decreased [187]. The positive effect on IL-10 was mainly due to an increased pro-
duction of IL-10 by the CD4
+
 depleted PBMCs, while this cell population did not produce IL-
17 [187]. A study on polyclonal stimulation of monocyte-depleted PBMC of patients with 
Crohn’s disease reported a trend towards an increased concentration of IL-4 and IL-6 in the 
supernatants after supplementation. [183] 
Proliferation of T cells in vitro 
Another way to measure T cell responses to antigens is to measure induction of proliferation 
in vitro. A study in Crohn’s disease patients reported an increase of polyclonal T cell prolifer-
ation after supplementation of vitamin D [183], while in MS patients proliferation was de-
creased [186] or unaffected [79]. Kimball et al. tested proliferative responses of T cells 
against a large panel of antigens in MS patients. [168] After supplementation of vitamin D, 
proliferative responses against BSA, BSAp193, PI, MBP and exon 2 of MBP (EX-2) were re-
duced compared with prior to supplementation. 
Phenotyping PBMC directly ex vivo 
Several studies analysed circulating myeloid and lymphocyte subsets and phenotypes with 
flow cytometry. Two studies reported a negative correlation between serum 25(OH)D levels 
and monocyte expression levels of both TLR-2 [171, 182] and TLR-4 [171, 182]. There was 
neither a correlation with the circulating proportions of myeloid and plasmacytoid DCs, nor 
with the expression of human leukocyte antigen (HLA)-DR, CD40, or CD86 on these cells. 
[188] There was also no correlation with the proportion of CD14
+
CD16
+
 monocytes. [171] 
Vitamin D supplementation did not affect the total proportion of circulating monocytes. 
[184] 
 
Regarding lymphocytes, both B and T cell subsets have been characterized. A correlation was 
described of 25(OH)D levels with the percentages of total naïve (CXCR3
+
) and total memory 
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(CXCR
+
) CD4
+
 T cells in an MS cohort not treated with immune modulating therapies [189]. 
In patients with BD, a positive correlation between 25(OH)D and total proportions of Tregs 
was reported. [172] Such a correlation was not confirmed in patients with MS [190], and was 
even contradicted by a negative correlation in another MS population. [189] When assessing 
subsets of Tregs, lower circulating proportions of CD39
+
 Tregs correlated with higher serum 
25(OH)D levels in MS patients during disease remission. [122] Additionally, the capacity of 
Tregs to control polyclonal T cell proliferation was also improved in MS patients with higher 
serum 25(OH)D levels. [191] Supplementation of vitamin D has been reported to induce 
higher circulating proportions of Tregs in healthy individuals. [167, 192] Contrastingly, sup-
plementation of vitamin D did not result in higher proportions of naïve/memory Tregs in 
subjects with MS and Crohn’s disease [79, 183], and Treg suppressive capacity was also not 
significantly affected [79]. Regarding T helper cell subsets, a study in BD patients reported 
negative correlations between serum 25(OH)D and the circulating proportion of Th1 and 
Th17 cells, and with the Th1/Th2-ratio. [172] Although a study in MS patients could not 
detect correlations with the proportions of T helper cell subsets, the Th1/Th2 ratio correlated 
also negatively with serum 25(OH)D. [191] In a cross-sectional study among MS patients, 
serum 25(OH)D levels tended to be lower in patients with an expanded Th17 compartment. 
[122] Supplementation of vitamin D in healthy subjects resulted in a decline of Th17 cells, 
while the number of IL-10
+
 T cells did not change. [187] Supplementation of vitamin D in 
subjects with MS resulted in a decreased Th1/Th2-ratio, as well as an expanded proportion 
of IL-10
+
 T cells. [79] 
 
With respect to B cells, a study in SLE reported decreased B cell activation in subjects with 
high 25(OH)D levels. [193] However, in subjects with MS, no correlation of serum 25(OH)D 
with circulating B cell subsets, including regulatory B cells (Breg), could be found. [178] Ac-
cordingly, supplementation of vitamin D did not affect B cell subset distribution in both 
subjects with MS and healthy control donors. [178, 184] B cells are precursors to Ig-
producing plasma cells. A study in SLE and in healthy individuals on long distance holiday 
reported lower total IgG concentrations in serum with increasing 25(OH)D level [173, 174], 
which might be in line with the reduced B cell activation observed in the cross-sectional 
study [193]. IgE production seems to be affected negatively by 25(OH)D [179], while IgA 
production was increased and IgM production was not correlated [173]. On the other hand, 
other studies found no effect of vitamin D supplementation on total serum polyclonal IgG, 
IgM and IgA in healthy subjects and subjects with MS. [178, 184] However, antigen specific 
antibody-production may be more relevant than the polyclonal compartment. Indeed, sup-
plementation of vitamin D improved tetanus toxoid (TT)-specific IgG-response in TT vaccina-
tion. [184] In several SLE cohorts contrasting results have been found regarding antinuclear 
antibody (ANA) and anti-double stranded (ds)DNA antibody production. [169, 174, 193, 194] 
A negative correlation for serum 25(OH)D with anti-thyroid antibodies in thyroid disease 
patients [195], with serum anti-human tissue transglutaminase (htTG) IgA in ASP and PsA 
patients [170] and a trend towards such a correlation with anti-SS-A antibodies in SLE [193] 
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have been reported, while there was a positive correlation with serum anti-Smith antibodies 
[174]. In donors at risk for rheumatoid arthritis (RA), there was no correlation of 25(OH)D 
with either rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibodies. [196] 
In patients with MCTD, serum anti-U1-ribonucleoprotein (RNP) antibody correlated nega-
tively and serum anti-cardiolipin (CL) IgA positively with serum 25(OH)D, while no correlation 
with CL IgG/IgM and anti-endothelial cell antibodies (AECA) was found. [175] 
Discussion and conclusion 
Our literature search revealed evidently that studies done so far are heterogeneous in many 
aspects. Study populations range from healthy controls to at risk persons and patients with 
distinct auto-immune diseases. Moreover, most studies seem to be underpowered and have 
a lack of appropriate controls. Beside this, 25(OH)D status is not always properly reported. 
This is regrettable, since an effect of vitamin D on the immune system would be expected in 
the highest or higher than physiological ranges of 25(OH)D levels. [197] Without baseline 
25(OH)D levels, it is difficult to discriminate between the effects of vitamin D in individuals 
with sufficient versus insufficient vitamin D status. Besides this, 25(OH)D assays have a great 
interassay variability [198] and cut-off points used for defining 25(OH)D insufficiency and 
sufficiency are not standardized. Furthermore, correlation studies have the potential bias of 
reverse causality: vitamin D status might not be responsible for the possible improvement in 
clinical and immunological outcomes in disease, but disability itself might influence the 
vitamin D status of individuals. Supplementation studies are not subjected to reverse causali-
ty, however, these also show great diversity in the supplemented compound (either vitamin 
D2 or vitamin D3) and in the dose and duration of supplementation. The supplemented doses 
range from doses which do not affect serum 25(OH)D levels significantly to doses which lead 
to supra-physiological serum 25(OH)D levels. These factors make the individual studies 
hardly comparable, and readily explain the many contradictive results. Finally, it is also im-
portant to keep a publication bias in consideration. In general, data suggest a trend towards 
a promotion of anti-inflammatory/regulatory cytokines and cells to be present, but this is 
certainly not substantiated by conclusive data. 
 
On top of that, analyses of the studies thus far showed a diverse repertoire of immunological 
outcome measures. These outcome measures form a continuum, ranging from soluble 
markers of general inflammation which can be measured easily in large cohorts of study 
subjects, to labour-intensive, detailed assessment of specific cellular processes. We argue 
that the choice between either of these outcome measures should primarily be driven by the 
specific disease outcome that is to be studied. As described above, 1,25(OH)2D interferes in 
vitro with proliferation and cytokine secretion by activated PBMC. These in vitro models 
reflect most likely the sites in the body where antigen presentation and immune activation 
take place, which are the secondary lymphoid organs and the tissues targeted by auto-
immune diseases. In these tissues, the interaction of vitamin D with the immune response is 
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unlikely to depend on either a single cell type or cytokine, but rather on a complex interplay 
between multiple vitamin D sensitive cells of the innate and adaptive immune system. [147] 
When analysing correlations between serum 25(OH)D levels and immunological parameters 
in the blood, one has to realize that there is a mismatch in space and time related to in vitro 
experiments. Immune cells in the circulation are on the move between target sites and lym-
phoid tissue, and soluble factors are derived from both specific immune responses of inter-
est as well as from other cells. Most informative would be assessment of cells and cytokines 
in lymph nodes and target organs, but sampling of material is obviously not feasible in most 
diseases. Another issue to keep in mind is that effects of vitamin D on immune parameters, 
as described in this chapter, might be secondary to other effects of vitamin D. For instance, 
the positive correlation between 25(OH)D and C4 in SLE might be due to an immune inde-
pendent effect on disease activity; since SLE is an immune complex mediated disease associ-
ated with complement activation via the classical pathway, any reduction in disease activity 
will result in normalisation of C4 levels. Similarly, the negative association of 25(OH)D levels 
with several auto-antibodies might not be due to a direct effect of vitamin D on B cells, but 
might be mediated via an effect on auto-antigen presentation by APCs. In addition, many 
auto-immune diseases are associated with infections [195] causing inflammation and subse-
quent induction of auto-immune disease manifestations. Since vitamin D also affects the 
innate immune system via the production of beta-defensins and cathelicidins, this will re-
duce the infectious load and thereby the inflammatory response and eventually will affect 
the adaptive immune system. To substantiate an immune modulating effect of vitamin D in 
vivo, the best approach appears to be assessment of the end products of the immunological 
cascade in the circulation, which are most relevant to the disease or health outcome studied. 
For auto-immune diseases, analysis of auto-antibody titres or lymphocyte cell proliferative 
and cytokine responses against auto-antigens are more logical choices than assessment of 
polyclonal IgG levels, polyclonal T cell proliferation, or serum cytokine levels. In MS, where 
no single auto-antigen is present, studies in which immunological outcomes have been 
associated with disease in patient-control studies, or have been associated with exacerbation 
activity or remission of disease, seem most relevant. Ultimately, only well-powered, con-
trolled studies in well-defined cohorts measuring disease-specific relevant outcome 
measures will be most informative on an immune modulating potential of vitamin D. 
 
Currently, several clinical trials are investigating the efficacy of vitamin D supplementation in 
MS and other auto-immune diseases. These trials provide an excellent framework to design 
potentially conclusive studies on the immune modulating effects of vitamin D in vivo. It 
would be a missed chance not to address this issue in these studies, especially since insight 
in the working mechanism of vitamin D may reveal subgroups of patients which may benefit 
most from vitamin D supplementation. Additionally, a known working mechanism can facili-
tate hypothesis driven combination with existing treatment regimens, and may reveal a 
biomarker which allows titration of serum 25(OH)D levels to an adequate dose.
  
2      Chapter 
Vitamin D and disability progression in patients  
with multiple sclerosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published as:  Vitamin D status does not affect disability progression of multiple sclerosis 
patients over three year follow-up 
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Abstract 
The risk of developing multiple sclerosis (MS) as well as MS disease activity is associat-
ed with vitamin D (25(OH)D) status. The relationship between the main functional 
disability hallmark of MS, disability progression, and 25(OH)D status is less well estab-
lished though, especially not in MS patients with progressive disease. 
This retrospective follow-up study included 554 MS patients with a serum baseline 
25(OH)D level and expanded disability status scale (EDSS) with a minimum follow-up 
of three years. Logistic regressions were performed to assess the effect of baseline 
25(OH)D status on relapse rate. Repeated measures linear regression analyses were 
performed to assess the effect on disability and disability progression.  
Baseline deseasonalised 25(OH)D status was associated with subsequent relapse risk 
(yes/no), but only in the younger MS patients (≤ 37.5 years; OR=0.872, per 10 nmol/L 
25(OH)D, p=0.041). Baseline 25(OH)D status was not significantly associated with 
either disability or disability progression, irrespective of MS phenotype.   
Within the physiological range, 25(OH)D status is just significantly associated with the 
occurrence of relapses in younger MS patients, but is not associated with disability or 
disability progression over three years follow-up. Whether high dose supplementation 
to supra physiological 25(OH)D levels prevents disability progression in MS should 
become clear from long term follow-up of supplementation studies.  
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Introduction 
Multiple sclerosis (MS), a demyelinating disease of the central nervous system (CNS), is con-
sidered to be an inflammatory disease of auto-immune origin. [19] A low vitamin D status, 
measured as 25(OH)D, has been associated with an increased risk of developing MS [70, 131] 
and vitamin D related genes, such as CYP24A1 and CYP27B1 emerge from gene wide associ-
ation studies. [14] 
Vitamin D status has also been associated with disease activity i.e. relapse rate. Firstly, MS 
patients showed lower vitamin D status during relapse than during remission. [154, 199, 200] 
Secondly, in early relapsing remitting MS (RRMS), higher 25(OH)D levels were associated 
with an increased chance of being relapse free 24 months prior to serum sampling [103], and 
with a decrease in the relapse rate in subsequent months by 9-34% with each 10 nmol/L 
increase in 25(OH)D level. [71, 72, 74] Some, but not all, small high dose supplementation 
studies showed an increase in the proportion of relapse-free patients [75], a lower-than-
expected relapse rate [79], and a decrease in the number of gadolinium enhancing lesions 
on MRI [78, 80]. Ongoing randomised, placebo controlled trials on high-dose vitamin D 
supplementation will clarify its effect on relapse rate. [201] 
At present, it is uncertain whether vitamin D is associated with the main functional disability 
hallmark in MS, disability progression. Cross-sectional studies have shown a negative corre-
lation between 25(OH)D level and disability, yet causality is uncertain. [73, 103, 202] Higher 
sunlight exposure, being the main source of vitamin D, has been associated with a decreased 
likelihood of reaching milestones on the expanded disability status scale (EDSS) in RRMS and 
also with a decreased risk ratio of reaching milestones on the patient determined disability 
scale (PDSS) in progressive MS. [203, 204] Conversely, no correlation between 25(OH)D levels 
and the MS severity scale (MSSS) or EDSS has been found in African Americans [205] and the 
negative correlation between recent EDSS progression and 25(OH)D levels has not been 
retained after correcting for baseline EDSS in a prospective Tasmanian study [73]. Small, high 
dose vitamin D supplementation studies have revealed a reduced proportion of EDSS pro-
gressive RRMS patients [75] and a trend towards reduced disability [80]. In interferon-β (IFN-
β) treated or naive clinically isolated syndrome (CIS) patients, higher 25(OH)D levels, meas-
ured in the first months after diagnosis, predicted reduced disease activity and a slower rate 
of progression. [206] 
The reduction of relapse risk associated with higher levels of 25(OH)D in the early, inflamma-
tory course of the disease may be accompanied by a reduction of disability progression. 
[207, 208] Whether disability progression later on, may be predicted by vitamin D status is at 
present less clear. The answer to this is of great importance, since people with long standing 
MS constitute the largest proportion of patients and that number also includes the patients 
with progressive disease, who have the lowest 25(OH)D levels. [103] A low 25(OH)D status 
could be a target for intervention in these patients who have at present limited (RRMS) to no 
(progressive MS) therapeutic possibilities.  
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To elucidate further the effect of vitamin D status on disability progression, we conducted a 
retrospective, three-year follow-up study in which we assessed the predictive value of base-
line 25(OH)D levels on relapse risk, EDSS disability, and EDSS progression in 554 MS patients. 
We show that 25(OH)D status, within the physiological range, is just significantly associated 
with the occurrence of relapses in younger MS patients, but is not associated with disability 
or disability progression over the three years follow-up. 
Methods 
Patients and study outcome measurements 
All patients with MS according to the original or 2005 revised McDonald criteria [22, 24] 
were eligible for inclusion in the cohort. They all visited the Academic MS Centre Limburg, 
the Netherlands in the period 2005 to 2013. This centre was based at the Maastricht Univer-
sity Medical Centre, Maastricht and is currently at the Zuyderland Medical Centre, Sittard. 
Both cities are located in the south of the Netherlands at 51° latitude north. All patients 
visited the outpatient clinic for normal clinical care and were included when they had had a 
three year follow-up in EDSS [209] by the end of 2013, after a baseline serum 25(OH)D level 
measurement with corresponding EDSS within 6 months. During the visits to the outpatient 
clinic, relevant events regarding MS activity and progression were routinely registered. Clini-
cal characteristics were recorded in all subjects according to the Dutch law on Medical 
Treatment Act (WGBO), the Personal Data Protection Act (Wbp) and the Code of Conduct for 
Health Research (Federa). [210] Data included age, sex, MS debut (date), MS phenotype [211] 
(RRMS, SPMS, PPMS; RRMS and SPMS patients were classified as RRMS-onset), date of MS 
diagnosis, start of progressive disease (date) if applicable, relapses (number and date), base-
line serum 25(OH)D levels (nmol/L), baseline EDSS, at least 1 follow-up EDSS more than 3 
years after inclusion, information on 25(OH)D supplementation and disease modifying 
treatments (DMT). EDSS and the occurrence of relapses (defined as the development of new 
symptom(s) or aggravation of existing symptom(s) for at least 24 hours in a patient with 
stationary or improving disease course in the previous month [20]), were assessed by an 
experienced neurologist. Only EDSS during periods of remission (defined as having relapse 
free disease at least in the three months prior and half a month after measurement) were 
included. Patients who were included in high dose vitamin D supplementation (>800 IU, 
equal to >20μg) studies were excluded from the current study. Patients who were classified 
as having progressive relapsing MS were assigned to the SPMS group. The use of DMTs was 
highly variable between and within patients, because of treatment choices based on clinical 
patient care. Therefore, we were not able to include these data as an independent variable in 
our analysis. 
Based on the inclusion criteria, 793 patients were deemed to be potential study subjects and 
their patient files were studied in detail. Eventually, 554 MS patients were included in the 
study (Figure S1). 
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25(OH)D measurement 
During the study period, serum 25(OH)D levels were measured by routine clinical analysis. 
Before 2008 (n=196 samples), both a chemiluminescence immunoassay (CLIA) (Nichols 
Institute Diagnostics, California, USA) and a radioimmunoassay (Immunodiagnostics Systems, 
Boldon, UK) were used, due to a change in clinical diagnostic operating procedures. Both 
methods had a good inter-assay correlation. [103] After 2008 (n=358 samples), a CLIA (LIAI-
SON® 25 OH Vitamin D TOTAL Assay, Diasorin, Saluggia, Italy) was used. 
In accordance with other studies, 25(OH)D data were deseasonalised to correct for seasonal 
variation of 25(OH)D levels. [73, 212, 213] The total of all consecutive 25(OH)D levels from all 
patients were used to model seasonal variation in our cohort according to the sinusoidal 
model described by van der Mei et al. [73] yt = β0 + β1sin(2πt/365)+ β2cos(2πt/365), where 
yt denotes serum 25(OH)D concentration, t denotes the day of the year when the sample 
was collected, and βj (j = 0,1,2) are estimated regression coefficients. The adjusted 25(OH)D 
value was calculated by applying the deviation of an individual from the population mean at 
a time-point measured, on the population mean at T=0. The seasonal corrected 25(OH)D 
levels are referred to as vitamin D status. 
Statistical analysis 
SPSS software (SPSS Inc., version 20.0, Chicago, USA) was used to analyse the effect of the 
deseasonalised 25(OH)D status at baseline as the primary predictor of relapses during the 
three year follow-up period in RRMS-onset patients. This association was assessed by using 
either a logistic (yes/no) or ordinal logistic regressions (0,1,2,3 or more relapses over follow-
up). Covariates included in these models were age at baseline (years), sex (M/F), disease 
duration (years), MS-phenotype (RRMS, SPMS), number of relapses in the three years prior 
to baseline, and EDSS at baseline. To answer the question whether the effects were MS-
phenotype dependent the second order interaction baseline deseasonalised 25(OH)D*MS-
phenotype, was investigated. Furthermore, potential relevant interactions with the primary 
outcome measure relapse rate, that were investigated were sex*age, sex*disease duration, 
age at baseline*baseline deseasonalised 25(OH)D, baseline deseasonalised 25(OH)D*baseline 
EDSS and the interactions with pre-study relapse rate. Interactions that were not significantly 
relevant for the model and did not investigate our primary research question were omitted 
from the final analyses using stepwise backward modelling. 
Repeated measures linear regression analyses were performed to investigate the role of 
baseline deseasonalised 25(OH)D in EDSS progression and to account for the correlation 
between repeated measurements within the same patients. Based on the best fit of the 
model to our data (-2LL (REML) and BIC), a model with Toeplitz covariance structure was 
used to model these correlations. The robustness of the final model was verified by applying 
different covariance structures. The outcome measure EDSS was analysed as a continuous 
variable [214] and was measured over equal spaces in time (trimesters). All EDSS data be-
tween baseline and three year follow-up were included in the analyses. Besides baseline 
deseasonalised 25(OH)D status, other covariates of potential interest that were included in 
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the model were follow-up time (trimesters), age at baseline (years), sex (M/F), disease dura-
tion (years), baseline EDSS, and MS-phenotype (RRMS, SPMS, PPMS). To look at the effects 
on EDSS change, all first order interactions with time were investigated. Other relevant inter-
actions that may affect the role of deseasonalised 25(OH)D levels on disease progression, 
were included: disease duration*sex, baseline deseasonalised 25(OH)D*disease duration, 
baseline deseasonalised 25(OH)D*MS-phenotype, baseline EDSS*relapse rate pre-baseline, 
age at baseline*relapse rate pre study, disease duration*relapse rate pre study, sex*relapse 
rate pre-baseline and baseline EDSS*sex. Finally we also included the three way interaction 
baseline deseasonalised 25(OH)D*time*MS-phenotype, to investigate the MS-phenotype 
dependent effects of vitamin D on EDSS change. Interactions that were not significantly 
relevant for the model and did not investigate the relation between 25(OH)D and EDSS or 
EDSS progression were omitted from the analyses. 
All of our tests were hypothesis driven. Three main outcome variables were tested: the rela-
tion of 25(OH)D status with relapse rate in three years follow-up, the relation with EDSS and 
with EDSS progression. Therefore the number of tests was minimal and correction for multi-
ple testing was not applicable. A p-value of <0.05 was considered statistically significant. 
Results 
Patient characteristics and deseasonalisation of 25(OH)D levels 
The total study cohort comprised 554 patients. Patient characteristics are shown in Table 1. 
The characteristics of this selected study population did not differ from the total MS popula-
tion at the Academic MS Centre Limburg with respect to age at diagnosis, female/male ratio 
and MS-phenotype distribution (age at diagnosis 39.3±10.9 year; 71.6% female, 28.4% male; 
distribution of MS phenotype 51.8% RRMS, 34.1% SPMS and 14.0% PPMS). The model of the 
seasonal fluctuation of the 25(OH)D levels of the whole population had a mean of 59.2 
nmol/L and an average fluctuation between 50.6 nmol/L and 67.9 nmol/L. Based on this 
data, the following formula was used for the deseasonalisation of all individual 25(OH)D 
data: deseasonalised 25(OH)D = crude 25(OH)D -(-4.168*sin(2πt/365))-7.546*cos(2πt/365)) 
(Figure 1). 
Table 1. Characteristics of the selected study population of MS patients of the Academic MS Centre Limburg.  
Population Number Percentage 
Number of  patients 554  
Age (years) 46.7 (11.6)   
Sex (F/M) 395/158   71%/29%  
MS phenotype   
  RRMS 340 61.4%  
  SPMS 152 27.4%  
  PPMS 62 11.2%  
Disease duration (years)   
 Vitamin D and disability progression in MS 53 
 
Data are provided as mean (SD) and as #median (Q1-Q3) in case of skewed distributions. 
25(OH)D: 25-hydroxyvitamin D; EDSS: expanded disability status scale; F: female; M: male; PPMS: primary 
progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive 
multiple sclerosis 
 since onset 12.5 (10.1) 
#9.7 (4.2-18.8) 
 
 since diagnosis 7.2 (7.7) 
#4.2 (0.9-11.3) 
 
Age (years)   
 at onset 34.2 (10.4)  
 at diagnosis 39.6 (10.8)  
Number of  pre-baseline relapses (in 3 years)     
 0 196 35.4% 
 1 147 26.5 % 
 2 104 18.8% 
 3 or more 107 19.3% 
Baseline EDSS  4.0 (2.0-6.0)  
 ≤3.5 274 49.5% 
 4.0-5.5 129 23.2% 
 ≥6.0 151 27.3% 
EDSS after 3 years follow-up 4.0 (2.5-6.5)  
 ≤3.5 228 41.2% 
 4.0-5.5 140 25.3% 
 ≥6.0 186 33.6% 
Number of patients with EDSS progression after 3 years follow-up   
 <1 357 64.4% 
 ≥1 197 35.6% 
Baseline 25(OH)D (nmol/L)   
 crude 57.5 (28.4)  
 deseasonalised 56.7 (28.0)  
Disease modifying treatment used most frequently during follow-up   
 none 225 40.6% 
 first line treatment (interferon, glatiramer acetate) 193 34.8% 
 second line treatment (natalizumab,  fingolimod) 40 7.2% 
 third line treatment (methotrexate, immunoglobulins, 
mitoxantrone) 
75 13.5% 
 Other 6 1.0% 
 Unknown 15 2.7% 
Number of relapses during three year follow-up   
 0 288 52.0% 
 1 130 23.5% 
 2 67 12.1% 
 3 or more 69 12.5% 
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Figure 1. Seasonal fluctuation in 25(OH)D levels measured in the total Academic MS Centre Limburg MS 
population (n=4294 25(OH)D measurements). 
Each dot represents a 25(OH)D measurement of an MS patient. Formula of curve: 25(OH)D = 59.23 -
4.168*sin(2πt/365)) - 7.546*cos(2πt/365)). 
25(OH)D: 25-hydroxyvitamin D 
Vitamin D status predicts the risk of relapses during three-year follow-up in younger 
RRMS-onset patients 
In the RRMS-onset cohort (n=490, characteristics in Table S1), we studied the effect of base-
line 25(OH)D level on relapse rate. Baseline deseasonalised 25(OH)D did not have an overall 
effect on the risk of getting relapses (yes/no) (OR=0.96, CI OR=0.89-1.03, p=0.21, Table 2A) 
or the number of relapses (Table S2) in the follow-up period of three years. However, the 
effect of 25(OH)D status on the risk of getting relapses was age dependent (OR =1.007, CI 
OR=1.000-1.015, p=0.047, Table 2B), showing a low significant beneficial effect of deseason-
alised baseline 25(OH)D status on relapses (yes/no) in RRMS-onset patients in the lowest 
age at baseline quartile ≤37.5 year (OR=0.872, CI OR=0.765-0.994, p=0.041 in the most 
extensive model, Table 2C), no effect in MS patients aged between 37.5 and 54 year, and a 
disadvantageous effect in the MS patients aged ≥54 year at baseline which was also just 
significant (OR=1.430, CI OR=1.003-2.040 p=0.048, Table 2C). Other predictors of relapses 
were age at baseline per se, EDSS at baseline and relapse rate pre-baseline, the last factor 
being disease duration dependent.  
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Table 2. Association of vitamin D status and relapses (yes/no) during three year follow-up in RRMS-onset 
patients. 
A Model 1: main variables  
Vitamin D and relapse risk in RRMS-onset population (logistic regression) 
Parameter B Odds 
Ratio 
95% CI OR p-value 
Relapses (ref.= no)     
Baseline 25(OH)D (per 10 nmol/L) deseasonalised -0.045 0.956 0.892-1.025 0.206 
SPMS (ref. = RRMS) -0.642 0.526 0.275-1.008 0.053 
Age at baseline (years) -0.036 0.964 0.944-0.985 0.001* 
Duration of disease (years) 0.024 1.024 0.994-1.055 0.112 
Sex (ref. = female) -0.183 0.833 0.538-1.290 0.413 
EDSS baseline 0.138 1.148 1.003-1.313 0.045* 
EDSS baseline2 (centred around mean of 3.8) -0.093 0.912 0.869-0.956 <0.001* 
Relapse rate 3 years pre-baseline 0.243 1.275 1.107-1.467 0.001* 
See for characteristics of the RRMS-onset study population Table S1  
* significant independent variable at p<0.05; 25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; EDSS: 
expanded disability status scale; OR: odds ratio; ref.: reference category; RRMS: relapsing remitting multiple 
sclerosis; SPMS: secondary progressive multiple sclerosis 
 
 
B Model 2: model 1 plus interaction terms 
Vitamin D and relapse risk in RRMS-onset population (logistic regression) 
Parameter B Odds 
Ratio 
95% CI OR p-value 
Relapses (ref. = no)     
Baseline 25(OH)D (per 10 nmol/L) deseasonalised -0.333 0.717 0.530-0.970 0.031* 
SPMS (ref. = RRMS)*Baseline 25(OH)D  
(per 10 nmol/L) deseasonalised 
-0.090 0.914 0.764-1.094 0.327 
Age at baseline (years)*Baseline 25(OH)D 
(per 10 nmol/L) deseasonalised 
0.007 1.007 
 
1.000-1.0145 
 
0.047* 
SPMS (ref. = RRMS) -0.222 0.801 0.248-2.592 0.712 
Age at baseline (years) -0.077 0.926 0.884-0.970 0.001* 
Duration of disease (years) -0.010 0.990 0.951-1.030 0.610 
Sex (ref. = female) -0.217 0.805 0.516-1.257 0.340 
EDSS baseline 0.149 1.160 1.013-1.329 0.032* 
EDSS baseline2 (centred around mean of 3.8) -0.093 0.911 0.868-0.957 <0.001* 
Relapse rate 3 years pre-baseline 0.032 1.033 0.843-1.265 0.757 
Corrected for “duration of disease (years)*relapse rate 3 years pre-baseline” B 0.029, OR 1.030, p=0.012 
See for characteristics of the RRMS-onset study population Table S1 
* significant independent variable at p<0.05; 25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; EDSS: 
expanded disability status scale; ref.: reference category; OR: odds ratio; RRMS: relapsing remitting multiple 
sclerosis; SPMS: secondary progressive multiple sclerosis 
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C Effect of vitamin D on relapses (yes/no) in different age categories (n=123 per quartile) at baseline 
Vitamin D and relapse risk in RRMS-onset population (logistic regression) 
Effect of baseline 25(OH)D (per 10 nmol/L) deseasonalised 
Age category B Odds Ratio 95% CI OR p-value 
Q1: <37.5 year     
 Simple model -0.109 0.897 0.797-1.009 0.069* 
 Model 1  -0.120 0.890 0.786-1.007 0.065* 
 Model 2 (adjusted) -0.137 0.872 0.765-0.994 0.041* 
Q2: 37.5-46.2 year     
 Simple model -0.065 0.937 0.824-1.066 0.323 
  Model 1  -0.040 0.961 0.835-1.106 0.581 
 Model 2 (adjusted) -0.024 0.977 0.834-1.144 0.770 
Q3: 46.2-54.0 year     
 Simple model -0.056 0.946 0.836-1.070 0.376 
  Model 1  -0.075 0.928 0.806-1.068 0.296 
 Model 2 (adjusted) 0.013 1.013 0.855-1.200 0.883 
Q4: >54.0 year     
 Simple model 0.203 1.226 1.030-1.460 0.022* 
 Model 1  0.140 1.151 0.943-1.404 0.166 
 Model 2 (adjusted) 0.358 1.430 1.003-2.040 0.048* 
See for characteristics of the RRMS-onset study population Table S1 
Simple model includes only baseline 25(OH)D deseasonalised as covariate. 
Model 1 includes baseline 25(OH)D deseasonalised, MS phenotype, age at baseline, duration of disease, sex, 
EDSS baseline, relapse rate three years pre-baseline, and EDSS baseline2 (centred) as covariates. 
Model 2 (adjusted) same as Model 1 but including MS phenotype*baseline 25(OH)D deseasonalised, and 
duration of disease*pre-baseline relapse rate as covariates and excluding age at baseline*baseline 25(OH)D 
deseasonalised 
* significant effect of baseline 25(OH)D deseasonalised at p<0.05; 25(OH)D: 25-hydroxyvitamin D; CI: confi-
dence interval; OR: odds ratio; RRMS: relapsing remitting multiple sclerosis; Q: quartile 
 
Vitamin D status does not predict disability and disability progression in multiple scle-
rosis patients over three year follow-up 
Baseline deseasonalised 25(OH)D status did not have any overall effect on EDSS (β=-0.003, 
p=0.615 (Table S3A)) or EDSS change over three year follow up (β=-0.002, p=0.790 (Table 
3A) in the simple model and β=-0.011, p=0.113 in the more extensive model (table 3B)). Also 
after correction for MS-phenotype, 25(OH)D did not predict EDSS change over time 
(β=0.021, p=0.198 for SPMS and β=0.013, p=0.621 for PPMS with RRMS as reference, table 
S3B) which was confirmed by an MS phenotype subgroup analyses (data not shown). MS 
phenotype at baseline, age at baseline, EDSS at baseline and relapse rate three years pre-
baseline were the most important predictors in the model for EDSS change over time (table 
3B). In addition, whether patients had stable or progressive disease (≥1 EDSS increase over 
three year follow-up) was not dependent on baseline 25(OH)D status in a logistic regression 
model (OR=1.021, CI OR=0.952-1.095, p=0.560). 
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Table 3. Effect of vitamin D status on EDSS over 3 year follow-up according to repeated measures linear re-
gression analyses with Toeplitz covariance structure.  
A Model 1: main variables  
Repeated measures linear regression analyses of longitudinal EDSS data with Toeplitz covari-
ance structure 
Parameter .β 95% CI β p-value 
Baseline 25(OH)D (per 10 nmol/L) deseasonalised  -0.002 -0.014-0.0100 0.733 
Baseline 25 (OH)D deseasonalised*time since baseline  
(per 10 nmol/L per year) 
-0.002 -0.016 - 0.012 0.790 
MS phenotype at baseline (ref. = RRMS)    
 SPMS 0.049 -0.054-0.152 0.353 
 PPMS 0.070 -0.039-0.180 0.208 
Time since baseline (years)  0.156 0.072-0.244 <0.001* 
Age at baseline (years) 0.002 -0.001-0.006 0.148 
Duration of disease (years) 0.001 -0.004-0.006 0.809 
Sex (ref. = female) 0.015 -0.053-0.082 0.670 
EDSS baseline 0.962 0.941-0.983 <0.001* 
EDSS baseline2 (centred around mean of 3.8) 0.010 0.002-0.017 0.012* 
Relapse rate 3 years pre-baseline 0.005 -0.017-0.026 0.679 
* significant independent variable at p<0.05; 25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; EDSS: 
expanded disability status scale; PPMS: primary progressive multiple sclerosis; ref.: reference category; RRMS: 
relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis 
 
B Model 2: Model 1 plus two way interaction terms 
Repeated measures linear regression analyses of longitudinal EDSS data with Toeplitz covari-
ance structure 
Parameter .β 95% CI β p-value 
Baseline 25(OH)D (per 10 nmol/L) deseasonalised  -0.0037 -0.017-0.010 0.595 
Baseline 25(OH)D deseasonalised*time since baseline  
(per 10 nmol/L*year) 
-0.011 -0.024-0.003 0.113 
MS phenotype at baseline (ref. = RRMS)*baseline 25(OH)D 
(per 10 nmol/L) deseasonalised 
   
 SPMS 0.017 -0.008-0.043 0.175 
 PPMS 0.014 -0.025-0.053 0.479 
MS phenotype at baseline (ref. = RRMS)    
 SPMS -0.132 -0.307-0.043 0.139 
 PPMS -0.087 -0.330-0.155 0.480 
Time since baseline (years)  0.415 0.208-0.623 <0.001* 
Age at baseline (years) 0.0004 -0.0031-
0.0039 
0.831 
Duration of disease (years) 0.003 -0.002-0.008 0.285 
Sex (ref. = female) 0.092 0.001-0.183 0.048* 
EDSS baseline 1.012 0.989-1.035 <0.001* 
EDSS baseline2 (centred around mean of 3.8)  0.011 0.003-0.018 0.004* 
Relapse rate 3 years pre-baseline 0.016 -0.007-0.040 0.173 
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MS phenotype at baseline (ref. = RRMS)*time since base-
line (years) 
   
 SPMS 0.237 0.119-0.355 <0.001* 
 PPMS 0.170 0.043-0.297 0.009* 
Age at baseline (years)*time since baseline (years) 0.005 0.002-0.009 0.006* 
EDSS baseline*time since baseline (years) -0.130 -0.154--0.106 <0.001* 
Relapse rate 3 years pre-baseline*time since baseline 
(trimesters) 
-0.031 -0.058--0.004 0.023* 
Corrected for duration of disease (years)*sex B -0.010, p=0.029 
* significant independent variable at p<0.05; 25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; EDSS: 
expanded disability status scale; PPMS: primary progressive multiple sclerosis; ref.: reference category; RRMS: 
relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis 
Discussion  
In this study, we retrospectively assessed the relation between baseline 25(OH)D status and 
EDSS progression over three year in an unselected, real life, clinical MS population. Disease 
disability per se, as expressed by EDSS, was not affected by baseline 25(OH)D levels and also 
the accumulation of disability over time was not correlated with baseline 25(OH)D status. In 
our population there was a strong trend towards 25(OH)D status predicting the occurrence 
of relapses, but only in MS patients in the youngest and the oldest age groups. 
There are several mechanisms which support the hypothesis that a higher vitamin D status 
may reduce disability progression both in early MS patients with inflammatory disease and 
later on in established or progressive MS. First of all by the proposed immunomodulatory 
effects of vitamin D [147], which could prevent relapses in RRMS-onset patients, thereby 
preventing accumulation of tissue damage. It has been shown that recovery, post relapse, 
will be incomplete in a substantial proportion of about 50% of the patients, leading to an 
increased EDSS. [207] In the present study, we indeed showed that vitamin D status most 
probably can predict the occurrence of relapses in younger MS patients. Furthermore, vita-
min D could have a direct beneficial effect on the brain in late MS, by either neuroprotective 
effects, maintaining the blood brain barrier integrity, decreasing axonal damage or improv-
ing remyelination. [82-84] Additionally, the vitamin D responsiveness of the CNS may be 
increased due to neuroinflammation. [82] Our data do not support these hypotheses, 
though. However, they do confirm the results found by van der Mei et al. [73] and Løken-
Amsrud et al. [215] who were also unable to detect a significant association of vitamin D 
status with EDSS progression, whether corrected for baseline EDSS or not. Soilu-Hanninen et 
al. [80] found (a trend towards) a relation between 25(OH)D levels and EDSS in their supple-
mentation study in which patients with supplementation had a mean 25(OH)D level of 110 
(67-163) nmol/L after 12 months. However, our patient population did not receive high-dose 
supplementation, was larger, and the follow up was longer. Furthermore, while most vitamin 
D association studies in MS were performed in selected patient cohorts, we deliberately have 
chosen for an unselected, real life MS population, in order to obtain robust results that can 
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be used in clinical practice. In contrast to what we found in our unselected, clinical MS pa-
tient population, Ascherio et al. [206] showed that in CIS patients a 50 nmol/L increase in 
25(OH)D levels was associated with a reduction of 0.16 EDSS points per year. This change 
was lower in the highest vitamin D ranges. Altogether this may indicate that vitamin D in-
deed plays a role in the onset and disease activity in young, early MS patients with inflam-
matory disease, but not at a later stage in the progression of disability. It has been suggest-
ed that once a clinical threshold of 4 EDSS points is reached, relapses no longer have any 
effect on the progression of disability. [208, 216] This might explain why the 25(OH)D status 
in young MS patients is related to the occurrence of relapses but did not show any overall 
association with disability progression. 
Although we could not demonstrate any effect of vitamin D status on EDSS progression, also 
established and often used treatments in MS do not have an immense effect on EDSS pro-
gression. First line medication, such as IFN-β, has been shown to decrease EDSS in RRMS by 
0.7 points in high dose and by 0.1 points in low doses in 24 months. [217] The pooled effect 
size in a meta-analysis was non-significant over 24 months and IFN-β was also not associat-
ed with a change in disability progression in a big retrospective cohort study with a mini-
mum follow-up of 4 years. [218, 219] Also in SPMS, no significant differences on the EDSS 
change were found between low dose IFN-β1a and high dose IFN-β1a. [220] Glatiramer 
acetate was associated with an EDSS change of 0.6 (±2.0) over 15 years while withdrawn 
patients had a mean change of 1.0 (±1.7). [221] With natalizumab the mean EDSS-change 
was comparable for those patients who had ongoing treatment and the patients who with-
drew (mean change 0.05 vs. 0.07). Over nearly 5 years, mean EDSS remained stable in both 
groups, while the difference between placebo and natalizumab remained significant (3.15 vs. 
2.79). [222] 
There are certain limitations in this study. First of all, this was a retrospective study and base-
line 25(OH)D levels and EDSS were measured in a clinical setting, unrelated in timing to 
disease onset or diagnosis and not fixed to study visits. Second, it investigated the effect of 
25(OH)D status in a, although clinically relevant and unselected, heterogeneous population, 
which might have led to a biased estimate of the true effect size. Third, the follow-up in this 
study was limited to a three year follow-up. Fourth, a majority of patients took low dose 
vitamin D supplementation (400/800 IU/day, equal to 10-20μg/day), which might have un-
derestimated the outcomes. Vitamin D status showed a regression to the mean over three 
year follow up (data not shown), which has also been described earlier. [206, 223] Other than 
the effect of supplementation, this regression to the mean might be due to lifestyle changes 
of the MS patients. Other important co-factors such as BMI, smoking habits and the use of 
DMTs could not be included. The fact that 25(OH)D levels were measured by different assays 
before and after 2008, did not change the vitamin D effect on disease activity and disease 
progression as was tested by adding this factor as a covariate to the models. Finally, EDSS as 
an outcome measure is not the ultimate measure with significant intra- and interrater differ-
ences and a non-linear course. However, it is the only frequently used measure available to 
monitor disability.  
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While it was not possible to detect any effect of vitamin D status on disability progression, it 
might still be possible that (high dose) vitamin D supplementation is beneficial in MS pa-
tients with long standing and progressive disease. We examined 25(OH)D levels in the phys-
iological range in patients taking only low doses of vitamin D supplementation. This might 
have underestimated the effect of 25(OH)D status on EDSS (progression), but it might also 
be that high dose supplementation is needed to exert its effects on the immune system and 
the brain. Secondly, supplementation might be beneficial particularly in patients with the 
lowest 25(OH)D status. Finally, we were not able to take into account all the treatments 
patients received and, therefore, could not investigate the possible add-on or synergistic 
effects that vitamin D might have, as has been suggested for IFN-β and fingolimod. [223-
226] Noticeably, this presumed interaction between vitamin D and IFN-β could not be re-
produced by others. [215, 227] 
To date, evidence that vitamin D status affects disability progression in MS patients could 
not be found. So far, the small effects of vitamin D on disease activity and disability in MS 
seem to be mainly visible in well selected homogeneous subgroups of MS patients, which 
makes translation to the MS population in the daily clinical practice difficult. Long term 
follow-up studies of high-dose vitamin D supplementation have to confirm these results. 
Before these data are available, though, it might be worthwhile considering preventive vita-
min D supplementation in young (CIS and early) MS patients. 
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Supporting information 
 
Figure S1. Flow chart inclusion of study patients.  
25(OH)D: 25-hydroxyvitamin D; EDSS: expanded disability status scale; MS: multiple sclerosis; n=number 
 
All patients Academic MS Centre Limburg
Screening based on inclusion criteria
• Diagnosis of MS (original or 2005 
revised McDonald criteria)
• Baseline 25(OH)D level 
measurement with corresponding 
EDSS (≤ 6 months)
• 3 year follow-up of EDSS & clinical 
characteristics by the end of 2013
• No participation in high dose 
25(OH)D supplementation studies
Detailed study of patient files and 
exclusion of patients that did not fit 
inclusion criteria 
Potential study subjects 
n=793
Study population
n=554
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Table S1. Characteristics of the RRMS-onset study population of MS patients of the Academic MS Centre 
Limburg.  
Data are provided as mean (SD) and as #median (Q1-Q3) in case of skewed distributions. 
25(OH)D: 25-hydroxyvitamin D; EDSS: expanded disability status scale; F: female; M: male; PPMS: primary 
progressive multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive 
multiple sclerosis 
 
 
 
 
 
Study Population                                                               Number Percentage 
Number of  patients 492  
Age (years) 45.9 (11.6)  
Sex (F/M) 362/129 73.6%/26.2% 
MS phenotype   
  RRMS 340 69.1% 
  SPMS 152 30.9% 
Disease duration (years)   
 since onset 12.7 (10.2) 
#10.2 (4.2-19.2) 
 
 since diagnosis 7.5 (7.8) 
#4.5 (1.1-11.8) 
 
Age (years)   
 at onset 33.2 (10.0)  
 at diagnosis 38.4 (10.5)  
Number of pre-baseline relapses during three year   
 0 151 30.7% 
 1 138 28.0% 
 2 97 19.7% 
 3 or more 106 21.5% 
Baseline EDSS   
 ≤3.5 254 51.6% 
 4.0-5.5 108 22.0%  
 ≥6.0 130 26.4% 
Baseline 25(OH)D (nmol/L)   
 crude 58.0 (28.9)  
 deseasonalised 57.4 (28.5)  
Number of post baseline relapses during three year   
 0 232 47.3% 
 1 124 25.3% 
 2 67 13.7% 
 3 or more 67 13.7% 
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Table S2. Association of vitamin D status and relapses (0, 1, 2, 3 or more) during three year follow-up in RRMS-
onset patients. 
A  Model 1: main variables  
Vitamin D and relapse risk in RRMS-onset population (ordinal logistic regression) 
Parameter .β Odds 
Ratio 
95% CI OR p-value 
Baseline 25(OH)D (per 10 nmol/L) deseasonalised -0.050 0.952 0.895-1.012 0.117 
SPMS (ref. = RRMS) -0.728 0.483 0.269-0.867 0.015* 
Age at baseline (years) -0.035 0.966 0.948-0.984 <0.001* 
Duration of disease (years) 0.017 1.017 0.991-1.045 0.201 
Sex (ref. = female) -0.137 0.872 0.586-1.296 0.499 
EDSS baseline 0.152 1.164 1.034-1.310 0.012* 
EDSS baseline2 (centred around mean of 3.8) -0.078 0.925 0.886-0.967 0.001* 
Relapse rate 3 years pre-baseline 0.252 1.287 1.142-1.450 <0.001* 
Test of parallel lines: p=0.964 
See for characteristics of the RRMS-onset study population Table S1 
* significant independent variable at p<0.05; 25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; EDSS: 
expanded disability status scale; OR: odds ratio; ref.: reference category; RRMS: relapsing remitting multiple 
sclerosis; SPMS: secondary progressive multiple sclerosis 
 
B Model 2: Model 1 plus interaction terms  
Vitamin D and relapse risk in RRMS-onset population (ordinal logistic regression) 
Parameter .β Odds 
Ratio 
95% CI OR p-value 
Baseline 25(OH)D (per 10 nmol/L) deseasonalised -0.041 0.960 0.895-1.029 0.249 
SPMS (ref. = RRMS)*Baseline 25(OH)D (per 10 
nmol/L) deseasonalised 
-0.022
  
0.998 0.983-1.013 0.770 
SPMS (ref. = RRMS) -0.725 0.484 0.184-1.273 0.142 
Age at baseline (years) -0.034 0.966 0.948-0.985 <0.001* 
Duration of disease (years) -0.012 0.988 0.954-1.024 0.519 
Sex (ref. = female) -0.136 0.872 0.586-1.300 0.502 
EDSS baseline 0.164 1.178 1.046-1.327 0.007* 
EDSS baseline2 (centred around mean of 3.8) -0.076 0.927 0.887-0.969 0.001* 
Relapse rate 3 years pre-baseline 0.093 1.097 0.924-1.304 0.290 
Test of parallel lines: p=0.925 
Corrected for duration of disease (years)*relapse rate 3 years pre-baseline B 0.020, OR 1.020, p=0.017 
See for characteristics of the RRMS-onset study population Table S1  
* significant independent variable at p<0.05; 25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; EDSS: 
expanded disability status scale; OR: odds ratio; ref.: reference category; RRMS: relapsing remitting multiple 
sclerosis; SPMS: secondary progressive multiple sclerosis 
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Table S3. Additional analyses of the effect of vitamin D status on EDSS over 3 year follow-up according to 
repeated measures linear regression analyses with Toeplitz covariance structure.  
A Effect on EDSS independent of time 
Repeated measures linear regression analyses of longitudinal EDSS data with Toeplitz covari-
ance structure 
Parameter .β 95% CI β p-value 
Baseline 25(OH)D (per 10 nmol/L) deseasonalised  -0.003 -0.014-0.008 0.615 
MS phenotype at baseline (ref. = RRMS)    
 SPMS 0.049 -0.054-0.152 0.353 
 PPMS 0.070 -0.039-0.180 0.208 
Time since baseline (years)  0.147 0.109-0.185 <0.001* 
Age at baseline (years) 0.002 -0.001-0.006 0.148 
Duration of disease (years) 0.001 -0.004-0.006 0.810 
Sex (ref. = female) 0.015 -0.055-0.082 0.671 
EDSS baseline 0.962 0.941-0.983 <0.001* 
EDSS baseline2 (centred around mean of 3.8) 0.097 0.002-0.017 0.012* 
Relapse rate 3 years pre-baseline 0.005 -0.017-0.026 0.677 
* significant independent variable at p<0.05; 25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; EDSS: 
expanded disability status scale; PPMS: primary progressive multiple sclerosis; ref.: reference category; RRMS: 
relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis 
 
B Model 3: Model 2 (see Table 3B) plus three way interaction terms 
Repeated measures linear regression analyses of longitudinal EDSS data with Toeplitz covari-
ance structure 
Parameter .β 95% CI β p-value 
Baseline 25(OH)D (per 10 nmol/L) deseasonalised  -0.001 -0.016-0.013 0.849 
Baseline 25 (OH)D deseasonalised*time since baseline  
(per 10 nmol/L per year)   
-0.004 -0.008--0.000 0.041* 
Baseline 25 (OH)D deseasonalised*MS phenotype at baseline 
(ref. = RRMS) (per 10 nmol/L)   
0   
 SPMS 0.009 -0.035-0.053 0.532 
 PPMS 0.009 -0.035-0.053 0.689 
Baseline 25 (OH)D deseasonalised*MS phenotype at baseline 
(ref. = RRMS)*time since baseline (per 10 nmol/L per year)   
   
 SPMS 0.021 -0.011-0.001 0.198 
 PPMS 0.013 -0.039-0.066 0.621 
MS phenotype at baseline (ref. = RRMS)    
 SPMS -0.087 -0.274-0.101 0.363 
 PPMS -0.059 -0.323-0.206 0.664 
Time since baseline (years)  0.448 0.235-0.661 <0.001* 
Age at baseline (years) 0.000 -0.0031-0.0038 0.838 
Duration of disease (years) 0.003 -0.002-0.008 0.288 
Sex (ref. = female) 0.092 0.001-0.183 0.046* 
EDSS baseline 1.012 0.989-1.035 <0.001* 
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EDSS baseline2 (centred around mean of 3.8) 0.011 0.003-0.018 0.004* 
Relapse rate 3 years pre-baseline 0.016 -0.008-0.040 0.186 
MS phenotype at baseline (ref. = RRMS)*time since baseline 
(years) 
   
 SPMS 0.128 -0.076-0.331 0.218 
 PPMS 0.098 -0.210-0.405 0.534 
Age at baseline (years)*time since baseline (years) 0.005 0.002-0.009 0.006* 
EDSS baseline*time since baseline (years) -0.130 -0.154--0.105 <0.001* 
Relapse rate 3 years pre-baseline*time since baseline (years) -0.030 -0.057--0.003 0.029* 
Corrected for duration of disease (years)*sex B -0.010, p=0.027 
* significant independent variable at p<0.05; 25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; EDSS: 
expanded disability status scale; PPMS: primary progressive multiple sclerosis; ref.: reference category; RRMS: 
relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis 
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Abstract 
Low circulating 25-hydroxyvitamin D (25(OH)D) levels have been associated with an 
increased risk of relapses in relapsing remitting multiple sclerosis (RRMS), but an asso-
ciation with disability progression is uncertain. Lower 25(OH)D levels are found in 
secondary progressive MS (SPMS) when compared to RRMS. We hypothesized that a 
poor vitamin D status in RRMS is associated with an increased risk of conversion to 
SPMS. 
In a retrospective longitudinal study we measured 25(OH)D levels at the start of a 3-
year follow-up, and analysed whether these levels predict the risk of RRMS to SPMS 
conversion.  
In 338 RRMS patients, vitamin D status did not predict the 3-year risk of conversion to 
SPMS (n=51; OR 0.970; p=0.65). However, in diagnostic blood samples of SPMS pa-
tients with a relatively short RRMS duration (n=19) 25(OH)D levels were significantly 
lower (38 nmol/L; Q1-Q3: 24-50) than in diagnostic samples of matched RRMS patients 
with no progression to SPMS (n=38; 55 nmol/L; Q1-Q3: 40-70; p<0.01).  
These data indicate an association between a low vitamin D status at the start of RRMS 
and the early conversion to SPMS. Therefore, time to SPMS conversion is of interest as 
clinical measure in (follow-up of) clinical vitamin D supplementation studies. 
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Introduction 
One of the major concerns amongst patients with multiple sclerosis (MS) and their clinicians 
is progressive neurological disability, which is inevitable in most cases. Neurological deficits 
in this inflammatory disorder are the result of demyelinating lesions in the central nervous 
system. In its most prevalent phenotypic entity MS starts with a relapsing remitting (RR) 
phase. [19] In this phase sub-acute episodes of neurological deterioration, called relapses, 
usually recover. However, in the majority of RRMS patients, recovery between relapses will 
become incomplete after several years, and there will be progressive worsening between 
relapses or without any new relapses. [228, 229] In either case, patients have entered the 
secondary progressive (SP)MS phase. [211, 228] The pace at which disability accumulates in 
the RRMS phase is variable, and some patients never convert to SPMS during their disease 
course. [229-231] The use of disease modifying treatments (DMT) prevents relapses and 
postpones the accumulation of disability in the RRMS phase. [232] However, currently regis-
tered DMTs still cannot protect against disability progression in the SPMS phase. [233] 
Likewise, vitamin D status is predominantly associated with the disease course in the RR 
phase of MS. A high vitamin D status has been associated with a lower risk of relapses in 
RRMS [74], which may be true particularly for patients at the start of their disease or for 
younger patients [103, 206]. Although negative correlations between disability and vitamin D 
status have been described in MS cohorts [73, 103], an effect of vitamin D status on disability 
progression was not found in longitudinal [234, 235] and cross-sectional data [73]. Only at 
the start of disease, in clinically isolated syndrome (CIS) patients, a higher vitamin D status 
predicts less disability progression. [206] Interestingly, we observed lower 25(OH)D levels in 
SPMS when compared to RRMS patients [103], which could indicate an increased vulnerabil-
ity to develop SPMS in RRMS patients with a poor vitamin D status. 
A delay in the onset of the SP phase in RRMS patients is highly relevant, since this could 
delay the accumulation of disability and prolong the window of opportunity for treatment 
with DMTs. Therefore, we assessed whether the vitamin D status in RRMS patients is associ-
ated with the time to conversion to SPMS.  
Material and methods 
Patients 
In this retrospective longitudinal study subjects with MS were selected from a longitudinal 
vitamin D study cohort of the Academic MS Centre Limburg (Zuyderland Medical Centre, 
Sittard, the Netherlands), which consists of all patients with MS according to the original or 
2005 revised McDonald criteria [22, 24] who visited the centre in the period 2005 to 2013 
and of whom vitamin D data were available. To assess whether the vitamin D status in estab-
lished RRMS predicts a 3-year risk of conversion to SPMS, all RRMS patients with vitamin D 
assessment at the start of a 3-year follow-up were included. To assess whether vitamin D 
status at diagnosis is associated with conversion to SPMS, index subjects with SPMS were 
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selected, when both 25-hydroxyvitamin D (25(OH)D) levels or blood samples at diagnosis (± 
1 year) and reported dates of conversion to SPMS were available. Those SPMS patients were 
matched in a 1:2 ratio with RRMS control patients, based on their sex, year of birth and year 
of MS diagnosis. Therefore, compared to the SPMS index patients, the RRMS control patients 
by definition had a longer RRMS duration, with also several years of progression-free follow-
up. By matching for year of birth and year of diagnosis, SPMS index and RRMS control pa-
tients were diagnosed and treated with MS therapies within the same timeframe. 
Endpoint definition and 25(OH)D measurement 
No clear clinical criteria are available to define the transition point from RRMS to SPMS, and 
the diagnosis of SPMS is mostly made retrospectively. [228] Nevertheless, clinicians have to 
determine this point to make treatment decisions in daily practice. In this study, the transi-
tion point was determined by the treating physician (RH), defined as the visit after which the 
RRMS patient starts to accumulate sustained disability. To describe disability in MS the most 
widely accepted clinimetrical scale is the expanded disability status scale (EDSS). [209] SPMS 
was defined as an increased EDSS-score independent of relapses, but not necessarily without 
relapses. This definition has also been used in other studies. [231] 
Serum 25(OH)D levels were measured to assess vitamin D status. The samples of the 3-year 
follow-up sub-study were analysed as part of routine patient care. Before 2008, first a radio-
immunoassay (RIA; Immunodiagnostics Systems, Boldon, UK), and later a chemiluminescence 
immunoassay (CLIA; Nichols Institute Diagnostics, California, USA) were used for 25(OH)D 
measurement, due to changed procedures in the clinical setting. For later samples, 25(OH)D 
levels were determined with a CLIA (LIAISON® 25 OH Vitamin D TOTAL, Diasorin, Saluggia, 
Italy). 
For the diagnostic samples, 25(OH)D levels at diagnosis (± 1 year) were available from rou-
tine patient care for 19 index and control patients. Seven of them were measured before 
2008 (RIA or CLIA (Nichols Institute Diagnostics)). For the remaining 38 patients, stored  
(-80˚C) blood samples (± 1 year from diagnosis) were collected and 25(OH)D levels were 
measured using the CLIA (LIAISON® 25 OH Vitamin D TOTAL, Diasorin).  
To correct for seasonal variation the 25(OH)D levels were deseasonalised, according to the 
sinusoidal model described by van der Mei et al. [73]. Hereto the total of all consecutive 
25(OH)D levels from all patients of the longitudinal vitamin D cohort were used to model 
seasonal variation. The adjusted 25(OH)D value was calculated by applying the deviation of 
an individual from the population mean at a time-point measured (Tm), on the population 
mean at T=0. 
Statistics 
All statistical analyses were performed using SPSS software (SPSS Inc., version 20.0, Chicago, 
USA). Differences in 25(OH)D levels between RRMS and SPMS patients were analysed with a 
Mann-Whitney U test. A linear regression model was used to assess which patient character-
istics were associated with the vitamin D status in SPMS. The factors entered in this model, 
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which were linked to the vitamin D assessment date, were sex, age, EDSS score, relapse rate 
in the previous 3 years, disease duration, and RRMS duration. 
To assess whether the vitamin D status contributes to the risk of conversion to SPMS during 
a 3-year follow-up (yes/no), logistic regression models were used. Several covariates, linked 
to the vitamin D assessment date, were included in these models: sex, age, EDSS score, dis-
ease duration, relapse rate in the previous 3 years, and the deseasonalised 25(OH)D level. 
Also potential relevant interactions between these covariates were included in the analysis 
and omitted from the analysis when not statistically relevant using stepwise backward mod-
elling. 
To compare 25(OH)D levels at MS diagnosis between SPMS index and the matched RRMS 
control patients, a Mann-Whitney U test was used. Group differences after matching were 
analysed by chi-square tests for binomial data, or student’s T tests or Mann-Whitney U tests 
for continuous data. Year of birth and year of MS diagnosis were compared by using the age 
and disease duration calculated at the day of statistical analysis, respectively. Odds ratios 
were calculated using simple logistic regression. 
A p-value <0.05 was considered statistically significant. 
Results 
25(OH)D levels are lower in SPMS than in RRMS patients 
First, we confirmed that SPMS patients have lower 25(OH)D levels than RRMS patients. In our 
longitudinal vitamin D study cohort, the median 25(OH)D level of SPMS patients (n=118) was 
43 nmol/L (Q1-Q3: 29-60), which was lower than the median 25(OH)D levels of RRMS pa-
tients (n=338; 58 nmol/L; Q1-Q3: 39-77) (p=<0.01). Patient characteristics are shown in Table 
1. Then, we explored which factors could be related to the lower vitamin D status in SPMS 
patients, and found that RRMS duration was positively associated with vitamin D status. The 
fit of the model, with 25(OH)D level as dependent variable, improved significantly by adding 
the combined effect of RRMS duration and RRMS duration
2
 (p=0.01). 
Table 1. Patient characteristics of the RRMS and SPMS patients of the longitudinal vitamin D cohort.  
 RRMS (n=338) SPMS (n=118) 
M/F ratio (n) 73/265 47/71 
Age (years) (mean (±SD)) 42.0 (±10.0) 53.8 (±10.1) 
Disease duration from diagnosis (years) (mean (±SD)) 5.0 (±6.3) 13.9 (±7.8) 
Relapses in previous 3 years (n) (median (Q1-Q3)) 1 (0-2) 0 (0-1) 
EDSS-score (median (Q1-Q3)) 2.0 (1.5-4.0) 6.5 (5.9-7.0) 
RRMS: relapsing remitting multiple sclerosis, SPMS: secondary progressive multiple sclerosis, M: male, F: female, 
EDSS: expanded disability status scale, Q1-Q3: 25th-75th quartile 
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Table 2. Effect of vitamin D status on the SPMS conversion risk. 
 B OR 95% CI OR p-value 
Simple model -0.105 0.900 0.804-1.008 0.07 
Model 1 -0.048 0.953 0.842-1.078 0.44 
Model 2 -0.034 0.966 0.852-1.096 0.59 
Model 3 -0.030 0.970 0.853-1.104 0.65 
Effect of deseasonalised 25(OH)D (per 10 nmol/L) on conversion to SPMS (yes/no) during a 3-year follow-up in 
RRMS patients (n=338) in a logistic regression model. 51 patients converted from RRMS to SPMS.  
 
Simple model includes only deseasonalised 25(OH)D level as a covariate. 
Model 1 includes deseasonalised 25(OH)D level, age, disease duration, sex, EDSS and relapse rate in the previ-
ous 3 years as covariates 
Model 2 includes deseasonalised 25(OH)D level, age, disease duration, sex, EDSS, relapse rate in the previous 3 
years, and relapse rate in the previous 3 years2 (centred) as covariates. 
Model 3 includes deseasonalised 25(OH)D level, age, disease duration, sex, EDSS, relapse rate in the previous 3 
years, and relapse rate in the previous 3 years2(centred), disease duration*sex and age*relapse rate in the 
previous 3 years as covariates. 
* significant effect of deseasonalised baseline 25(OH)D at p<0.05; CI: confidence interval; OR: odds ratio 
 
 
 
Figure 1. Deseasonalised 25(OH)D levels of SPMS and RRMS patients at MS diagnosis.  
Bold lines indicate medians, and the fine lines indicate interquartile ranges.  
25(OH)D: 25-hydroxyvitamin D; SPMS: secondary progressive multiple sclerosis; RRMS: relapsing remitting 
multiple sclerosis; CLIA: chemiluminescence immunoassay; RIA: radioimmunoassay 
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Table 3. Patient characteristics of the SPMS index patients and the matched RRMS control patients.  
 SPMS (n=19) RRMS (n=38) p-value 
M/F ratio (n) 6/13 12/26 1.00 
Age (years) (mean (±SD)) 55.1 (±8.4) 53.1 (±7.4) 0.38 
Disease duration from diagnosis (years)  
(median (Q1-Q3)) 
9.7 (6.6-12.0) 7.7 (6.3-10.0) 0.08 
RRMS duration (years) (median (Q1-Q3)) 3.5 (1.0-5.7) 7.7 (6.3-10.0) <0.01* 
Age at diagnosis (years) (mean (±SD)) 45.4 (±8.7) 45.3 (±8.2) 0.96 
EDSS-score (median (Q1-Q3)) 3.0 (2-4) 2.0 (1.5-2.8) 0.08 
* significant independent variable at p<0.05; SD: standard deviation; SPMS: secondary progressive multiple 
sclerosis, RRMS: relapsing remitting multiple sclerosis, M: male, F: female, Q1-Q3: 25th - 75th quartile. 
25(OH)D levels in RRMS do not predict the 3-year risk of conversion to SPMS  
To assess whether 25(OH)D levels in the RRMS phase predict the risk of conversion to SPMS, 
we longitudinally analysed 338 RRMS patients. The cohort was characterized as indicated in 
Table 1. During the 3-year follow-up, 51 (15%) patients converted to SPMS. Vitamin D status 
was not a significant predictor of risk of conversion to SPMS, neither in the simple nor in the 
more advanced regression models (Table 2). Factors that did predict the risk to SPMS con-
version were a higher age (model 2: OR 1.054; p=0.01) and EDSS score (model 2: OR 1.828; 
p<0.01) at vitamin D assessment. 
Diagnostic 25(OH)D levels are lower in SPMS patients with a short RRMS duration than 
in matched RRMS patients 
We did not find an association between vitamin D status and the 3-year risk of conversion to 
SPMS, but 25(OH)D levels very early in the disease course of RRMS may be more relevant to 
predict conversion to SPMS. To investigate this hypothesis, 19 SPMS index patients with a 
relatively short RRMS duration were matched with 38 RRMS control patients who had not 
(yet) converted to SPMS. After matching, no statistically significant differences were found in 
the distribution of sex, age, disease duration, age and EDSS at MS diagnosis (Table 3). The 
median disease duration of RRMS patients (7.7; Q1-Q3: 6.3-10.0) was significantly longer 
than the RRMS duration of the SPMS patients (3.5; Q1-Q3: 1.0-5.7; p<0.01). The SPMS pa-
tients had significantly lower 25(OH)D levels (38 nmol/L; Q1-Q3: 24-50) than the RRMS pa-
tients (55 nmol/L; Q1-Q3: 40-70; p<0.01) (Figure 1). Alternatively expressed, MS patients 
within the lowest tertile of diagnostic 25(OH)D levels  (4-36 nmol/L) had a 5.9-times (95% CI: 
1.3-27.3) increased risk of being in the SPMS cohort, when compared to the highest tertile 
(58-129 nmol/L) (p=0.02).  
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Discussion 
In our retrospective, longitudinal sub-study, we confirmed the presence of lower 25(OH)D 
levels in SPMS when compared to RRMS patients. We found no effect of deseasonalised 
25(OH)D levels in established RRMS on the risk of conversion to SPMS within a 3-year fol-
low-up. In our second sub-study, however, vitamin D status at the time of MS diagnosis was 
significantly lower in SPMS patients, with a relatively short RRMS duration, compared to 
RRMS patients who had not converted to SPMS (yet). These data suggest that a low vitamin 
D status at the start of the RRMS disease course is a risk factor for early conversion to SPMS.  
In our current longitudinal study a higher age and a higher EDSS-score were positive predic-
tors of conversion to SPMS during a 3-year follow-up. These are factors known to be associ-
ated with progressive disease in natural history studies. [230, 231, 236] Vitamin D status, 
however, was not associated with short-term conversion to SPMS. This is in line with the 
pathophysiological concept that neurodegeneration in SPMS is a process which commences 
many years before the actual SPMS diagnosis. [19] Therefore, an effect of vitamin D status on 
SPMS conversion might not be expected in a later stage of RRMS, where this neurodegener-
ation process is already ongoing. Alternatively, we cannot exclude that the sample size is too 
small, or the follow-up duration too short to detect an effect.  
Interestingly, diagnostic 25(OH)D levels were lower in the RRMS patients with an early con-
version to SPMS, compared to those of RRMS patients remaining longer in an RRMS pheno-
type. This is consistent with accumulating data pointing to the very early RRMS/CIS phase in 
which a relationship between vitamin D status and clinical disease activity is most eminent. In 
a cross-sectional design, we found higher 25(OH)D levels in relapse-free patients with a 
disease duration shorter than 5 years. [103] In a longitudinal analysis, higher 25(OH)D levels 
predicted a reduced risk of relapses only in the younger RRMS patients in our cohort. [235] 
In the study by Simpson et al., higher 25(OH)D levels were associated with a lower hazard of 
relapses in an RRMS cohort with a mean disease duration of 6.8 years. [74] In the study by 
Ascherio et al., reporting a faster rate of EDSS progression in subjects with low 25(OH)D 
levels, only CIS patients were included. [206] These studies and the present data point to the 
early phase of MS, which may provide a window of opportunity for intervention studies with 
vitamin D. This is in accordance with established MS therapies. For example, in CIS patients, a 
long-term effect of interferon-beta therapy on disease progression was found when treat-
ment was instantly initiated. [237] 
Regarding the diagnostic 25(OH)D levels found in these SPMS index patients, it is noticeable 
that these were markedly lower than we reported earlier in our RRMS population. [103] This 
finding is in line with the generally higher 25(OH)D levels reported in other RRMS [73, 74] or 
CIS populations [206]. Furthermore, the SPMS index patients in our diagnostic sample cohort 
had a very short RRMS duration, with the 75th percentile at 5.7 years; it is estimated that 
only 10% of the RRMS patients convert to SPMS within the first 5 years of disease. [229] It 
seems that SPMS patients with a very short RRMS duration represent a sub-group of MS 
patients with lower 25(OH) levels at diagnosis. Strikingly, Ascherio et al. argue that CIS pa-
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tients with such low 25(OH)D levels have more cerebral lesion accumulation, more brain loss 
(atrophy) and a higher annual EDSS increase over time. [206] These observations fit the idea 
of a shorter progression-free RRMS duration in case of low 25(OH)D levels at the start of 
disease. This view is supported by experimental data. Zastepa et al. observed that SPMS 
patients with a short RRMS phase have an increased gene expression of the vitamin D recep-
tor (VDR) in naïve CD4
+
 T (helper) cells [238], which may be a correlate of insufficient expo-
sure to vitamin D. For interpretation of our results, however, we must take into account the 
rather small sample size. Furthermore, we noticed a trend towards higher EDSS-scores at MS 
diagnosis in the SPMS index patients. Therefore, reversed causation cannot be ruled out. 
However, since EDSS-scores at diagnosis were probably influenced by relapses, it might be 
as well that the SPMS index patients experienced more severe and/or more multifocal re-
lapses at time of diagnosis compared to the RRMS control patients. 
 
Altogether, our data suggest that low 25(OH)D levels at the diagnosis of RRMS may be 
associated with an early conversion to SPMS. Whether the associations between vitamin D 
and MS activity at MS onset are driven by a disease modulating effect of vitamin D on MS 
should become eminent from clinical supplementation trials. Time to SPMS conversion can 
be an interesting clinical measure for long-term follow-up in these trials. 
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Abstract 
Data from animal models of multiple sclerosis suggest that GM-CSF+ CD4+ T cells are 
pathogenic cells. Therefore, GM-CSF production by CD4+ T cells of MS patients and 
their susceptibility to regulatory mechanisms were investigated. 
Intracellular flow cytometry was performed to determine the GM-CSF+ CD4+ T cell 
fraction in PBMC and CSF of MS patients and controls. The effect of regulatory T cells 
(Treg) on GM-CSF production by CD4+ T cells was studied in MS patients using a pro-
liferation-suppression assay. Finally, GM-CSF+ CD4+ T cell fraction and GM-CSF protein 
levels in supernatant were assessed in anti-CD3-stimulated CD4+ T cell cultures derived 
from healthy controls and MS patients, in the presence or absence of the active vita-
min D metabolite calcitriol. 
The GM-CSF+ CD4+ T cell fraction in the peripheral blood did not differ between con-
trols and MS patients. This T cell population could also be detected in the CSF of both 
subjects with MS as well as subjects with another diagnosis. In the CSF, it comprised a 
significant fraction of the T cell population. Upon in vitro stimulation of PBMC with 
anti-CD3 antibody, no differences were observed in GM-CSF+ CD4+ T cell frequencies. 
GM-CSF secretion was susceptible to regulation by Tregs and vitamin D. Suppression 
of GM-CSF secretion by vitamin D was reduced in MS patients. 
Our study showed no elevation in GM-CSF+ CD4+ T cell fractions in MS patients com-
pared to controls. Furthermore, GM-CSF secretion was prone to regulation by Tregs 
and vitamin D, the latter being less effective in MS patients.  
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Introduction 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system of auto-
immune origin, in which auto-reactive T cells are critically involved. For many years, MS was 
regarded to be a T helper 1 (Th1) mediated disease. More recently, Th17 cells are believed to 
be the main pathogenic T cells in MS. In the animal model of MS, both Th1 and Th17 cells 
are able to adoptively transfer experimental auto-immune encephalomyelitis (EAE). However, 
knockout models of IFN-γ and IL-17A, i.e. Th1 and Th17 cell signature cytokines, are still 
susceptible to EAE. [38, 239-241] Interestingly, mice with a knockout of either the IL-23 sub-
unit (p19 or p40) have been shown to be protected from EAE development. [242, 243] This 
cytokine is not only important in the development of pathogenic Th17 cells [244, 245], but 
also in inducing production of granulocyte macrophage colony-stimulating factor (GM-CSF) 
by T cells [244]. 
GM-CSF is a hematopoietic growth factor that is produced by many cell types, including T 
cells. This cytokine has been described to promote the activation and differentiation of anti-
gen presenting cells and increase the survival of monocytes, macrophages, neutrophils, 
eosinophils and basophils. [246] It exerts pro-inﬂammatory functions by increasing antigen 
presentation and release of inflammatory cytokines. Studies in EAE have demonstrated a 
critical role for GM-CSF in the disease process, since GM-CSF
-/-
 mice were resistant to EAE 
development. [38, 247] Furthermore, infusion of anti-GM-CSF antibodies before disease 
onset could prevent EAE induction. Also, complete recovery from EAE was demonstrated 
when mice were treated with an anti-GM-CSF antibody after onset of the disease. [247] GM-
CSF marks a highly pathogenic Th cell population. In contrast to any other known helper T 
cell cytokine, GM-CSF positive CD4
+
 T cells exert a non-redundant function in neuro-auto-
immune pathogenicity in vivo. [38, 248] From these studies it can be concluded that GM-CSF 
producing T cells have strong encephalitogenic capacity in EAE.  
Regulation of potentially pathogenic T cells is important and in healthy individuals this is 
effectively achieved. One of the most important regulators of effector T cells is the regulato-
ry T cell (Treg), which has been shown functionally defective in MS patients. [115-117] An-
other important immune regulator is vitamin D, which has also been found to inhibit effector 
T cells directly and enhances numbers and/or function of Tregs (reviewed in [147]). Both 
Tregs and vitamin D might be critical for GM-CSF
+ 
CD4
+
 T cell regulation. 
Because of the potential pathogenic role of GM-CSF producing Th cells, we investigated the 
expression and secretion of GM-CSF by CD4
+
 T cells from MS patients and controls and 
explored the susceptibility of GM-CSF producing T cells to regulation by Tregs and vitamin 
D. 
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Table 1. Population characteristics. 
A. Cross-sectional study cohort; subjects used for the ex vivo experiments (Figure 1B) 
HC: healthy control; RRMS: relapsing remitting multiple sclerosis; EDSS: expanded disability status scale; IFN: 
interferon; GA: glatiramer acetate; min: minimum; max: maximum; No: no treatment 
B. In vitro tests study cohort; subjects used for the in vitro experiments (Figure 2&4) 
 HC RRMS Remission 
 Number (%)/ median (min-max) 
Treatment - No 
Number of subjects 9 8 
Gender   
 Male  3 (33.3) 3 (37.5) 
 Female 6 (66.7) 5 (62.5) 
Age (years) 29.8 (22.8-56.8) 30.0 (23.5-53.3) 
Disease duration (years) - 0.0 (0.0-4.2) 
Relapse rate (relapse/year) - 1.0 (0.0-3.0) 
EDSS - 1.0 (0.0-2.0) 
HC: healthy control; RRMS: relapsing remitting multiple sclerosis; EDSS: expanded disability status scale; min: 
minimum; max: maximum; No: no treatment  
  
 HC  RRMS Remission 
 Number (%)/ median (min-max) 
Treatment - No IFN-β GA Total 
Number of subjects 13 10 5 7 22 
Gender      
 Male 3 (23.1) 3 (30.0) 2 (40.0) 2 (28.6) 7 (31.8) 
 Female 10 (76.9) 7 (70.0) 3 (60.0) 5 (71.4) 15 (68.2) 
Age (years) 29.2  
(22.8-56.8) 
29.9  
(23.2-53.3) 
45.1  
(43.7-51.0) 
40.9  
(34.4-49.0) 
40.7  
(23.2-53.3) 
Disease duration (yrs) - 0.3 (0.0-4.2) 0.5 (0.4-2.7) 2.6 (1.0-4.4) 1.4 (0.0-4.4) 
Relapse rate  
(relapse/year) 
- 1.0 (0.0-2.0) 1 .0 (1.0-2.0) 0.0 (0.0-0.0) 1.0 (0.0-2.00) 
EDSS - 1.0 (0.0-2.0) 2.0 (2.0-2.0) 2.0 (1.0-6.0) 1.5 (0.0-6.0) 
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Methods 
Patients and blood samples 
This study consists of 3 parts, each being based on distinct (partially overlapping) patient 
populations. RRMS patients were recruited from the Academic MS Centre Limburg, Orbis 
Medical Centre (Sittard, the Netherlands) or the MS Centre of Amphia Hospital (Breda, The 
Netherlands). Written informed consent was obtained from each study subject for blood 
sampling (heparinized blood). RRMS was defined by the revised McDonald criteria. [23] All 
RRMS patients had a disease duration <6 years and were in remission >6 weeks at the time 
of inclusion. The study was approved by the regional ethical committee ‘Atrium-Orbis-Zuyd’ 
and ‘the medical ethical committee of Amphia’ of Amphia Hospital. 
The ex vivo assays (part 1) were performed on peripheral blood of 22 RRMS patients receiv-
ing either no, IFN-β or GA treatment, and 13 healthy controls (HC). Population characteristics 
are given in Table 1A. In addition, for ex vivo assays performed on material derived from 
paired blood or cerebrospinal fluid (CSF) samples, 8 subjects, suspected of MS at the Aca-
demic MS Centre Limburg at Orbis Medical Centre, were included (not included in table 1). 
Four of these subjects were subsequently diagnosed with MS of which 2 had clinical isolated 
syndrome, 1 subject had primary progressive MS (PPMS) and 1 subject had clinical definite 
MS. Three of these MS patients were sampled during remission, and one during active dis-
ease. The other four subjects were diagnosed with either a cerebro vascular accident, mi-
graine, systemic lupus erythematosus (SLE) or two-sided opticopathy and were classified as 
having ‘other diagnosis’. 
For in vitro assays (part 2) to assess GM-CSF expression by T helper cells after stimulation 
and the effect of calcitriol on this, 8 treatment naïve RRMS patients and 9 HC were included. 
Population characteristics of HC and RRMS patients are given in Table 1B.  
To assess the effect of Tregs on GM-CSF production by CD4
+
 T cells in MS patients (part 3), 
baseline culture supernatants obtained from functional Treg assays performed in a previous 
study were available. [79] Culture supernatants of 13 RRMS patients in remission and on IFN-
β therapy were included in the current study.  
Cell isolation  
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll (Histopaque; Sigma-
Aldrich, Zwijndrecht, the Netherlands) density gradient centrifugation and cells within the 
CSF were collected by centrifugation of the CSF at 4°C. In a series of in vitro experiments, 
purified CD4
+
 T cells were used. These CD4
+
 T cells were isolated from heparinized peripher-
al blood via negative selection using RosetteSep (STEMCELL technologies, Grenoble, France) 
followed by a Ficoll density gradient centrifugation step. Purity of the isolated CD4
+
 cells 
within the T cell population usually is between 97.8%-99.4%. 
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Intracellular cytokine detection 
The CD4
+ 
T cell cytokine profile in peripheral blood and CSF was determined by flow cy-
tometry by assessing the expression of cytokines within the CD3
+
CD8
-
 lymphocytes, i.e. CD4
+
 
T cells, as described before. [79] Shortly, cells were stimulated for 4 or 5h with 1 μg/mL 
ionomycin and 50 ng/mL PMA (both from Sigma-Aldrich) in the presence of monensin (BD 
Biosciences, Breda, the Netherlands) to block cytokine secretion. Surface staining was per-
formed with anti-CD3-Horizon V450 and anti-CD8-APC-H7 (both BD Biosciences), and anti-
GM-CSF-PE (Biolegend, Uithoorn, the Netherlands) was used for the intracellular staining. 
Regulation by Tregs and vitamin D 
All cells were cultured in RPMI medium (Gibco Invitrogen, Breda, the Netherlands) supple-
mented with 10% foetal bovine serum (Greiner Bio-One, Alphen aan de Rijn, the Nether-
lands), 1% non-essential amino acids (Gibco Invitrogen), 1 mM sodium pyruvate (Gibco 
Invitrogen) and 2% penicillin-streptomycin (Gibco Invitrogen). 
To evaluate the ability of FACS-sorted Tregs to suppress GM-CSF secretion by CD4
+
 T cells, 
culture supernatants from a previously performed Treg suppression assay [79] were analysed 
for GM-CSF protein content. Shortly, Treg (CD25
high
CD127
- 
CD4
+
 T cells) and Tresp (CD25
- 
CD4
+
 T cells) were activated with anti-CD3 antibody and either cultured alone or in a 1:1 
coculture. After 4-5 days, culture supernatants were harvested and stored at -20°C until 
analysis. 
To test the effect of calcitriol (1,25(OH)2D; the active form of vitamin D) on the expression of 
GM-CSF by CD4
+
 T cells, 1*10
5
 CD4
+
 T cells were plated in a flat bottom 96-well plate (Corn-
ing Incorporation, Amsterdam, the Netherlands) precoated with anti-CD3 antibody (clone 
2G3, kind gift from Biomedical Research Institute (Biomed), Diepenbeek, Belgium). The cells 
were cultured in the absence or presence of 10
-8 
M calcitriol (Sigma-Aldrich). After 5 days, 
culture supernatants were collected and stored at -20°C until further analysis. In addition, the 
GM-CSF
+
 cell fraction was assessed by intracellular flow cytometry as described above. Bre-
feldin A (5 μg/mL; Sigma-Aldrich) was used to block cytokine secretion. 
Quantification of GM-CSF protein levels 
GM-CSF protein levels in the culture supernatants were detected by means of cytometric 
bead array (CBA) flex set technology (BD Biosciences). The beads were prepared as described 
by the manufacturer. Culture supernatant (50 μL) was incubated with GM-CSF capture beads. 
After 1h the GM-CSF PE detection reagent was added and incubated for 2h. After washing, 
data acquisition was performed on a FACS Canto II flow cytometer and data were analysed 
with FACS Diva software. 
Statistics 
Statistical analysis was performed with Statistical Package for Social Sciences version 17.0 
software (SPSS inc., Chicago IL, USA). Results are given as median with corresponding range 
(minimum-maximum) for continues variables. The Mann-Whitney U test was performed to 
assess differences between groups and the Wilcoxon signed-rank test was performed to test 
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the difference between paired samples in the absence or presence of calcitriol or Tregs. The 
percentage inhibition in T cell frequencies or protein levels by calcitriol was calculated using 
the formula: (1-[condition with calcitriol]/[condition without calcitriol])x100%. Spearman 
correlation was used to test correlations. A p-value <0.05 was considered statistically signifi-
cant. 
Results 
GM-CSF positive CD4+ T cell frequencies in blood and CSF are not different in MS pa-
tients 
We assessed the percentage GM-CSF
+
 cells within the CD4
+
 T cell population (GM-CSF
+ 
CD4
+
 T cells) in the peripheral blood of HC (n=13) and RRMS patients in disease remission 
(n=22). For this, PBMC were shortly stimulated ex vivo with PMA and ionomycin in the pres-
ence of monensin. Subject characteristics are given in Table 1A. A representative density plot 
of GM-CSF expression in CD4
+ 
T cells for both HC and MS patients is shown in Figure 1A. 
The percentage of this CD4
+
 T cell subset in the peripheral blood was not increased in RRMS 
patients in remission compared to HC (7.9% (2.1-20.1) and 11.2% (5.7-23.6), p=0.162; Figure 
1B). Group sizes are, however, too small to statistically test differences between treated and 
untreated RRMS patients. 
In order to assess whether GM-CSF
+ 
CD4
+
 T cells are also present in closer proximity to the 
CNS, as proof of principle, we examined the relative presence of these cells in paired CSF 
and PBMC samples of MS patients (n=4) and patients with other diagnoses (n=4) (Figure 
1C). Interestingly, these T cell frequencies were 6.8 times (1.5-11.7) higher in CSF versus 
blood (39.2% (14.1-59.3) and 6.4% (3.0-17.8), respectively, p=0.008) for the total cohort. 
Moreover, the percentage GM-CSF
+ 
CD4
+
 T cells in CSF of MS patients did not differ from 
patients with other diagnosis within this limited sample size (p=0.386). 
In vitro GM-CSF expression and secretion by CD4+ T cells is not elevated in RRMS pa-
tients 
To investigate in vitro GM-CSF expression and cytokine secretion, CD4+ T cells of treatment 
naïve RRMS patients (n=8) and HC (n=9) were stimulated for 5 days with anti-CD3 antibody. 
Subject characteristics are given in Table 1B. After 5 days of culture, the percentage GM-CSF
+ 
CD4
+
 T cells was similar for HC and RRMS patients (35.8% (19.9-49.9) and 32.1% (16.3-42.7), 
respectively, p=0.386, Figure 2A). GM-CSF protein levels in the supernatant of stimulated 
CD4
+
 T cells were not significantly different between HC and RRMS patients (5887 pg/mL 
(4816-8861) and 5067 pg/mL (3618-6937), respectively, p=0.083, Figure 2B). 
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Figure 1. GM-CSF+ CD4+ T cell frequencies in blood and CSF. 
GM-CSF+ CD4+ T cell frequencies in peripheral blood and CSF of MS patients and controls. Total PBMC or cells 
from the CSF were stimulated with PMA and ionomycin for 5 hours in the presence of monensin. A) Density 
plots of GM-CSF positive cells in CD4+ T cells of a representative RRMS patient (right) and control subject (left). 
B) GM-CSF+ CD4+ T cell frequencies in peripheral blood of HC (n=13) and RRMS patients (n=22), C) GM-CSF+ 
CD4+ T cell frequencies in paired CSF and blood samples of subjects with other diagnosis (n=4) and MS pa-
tients (n=4). Differences between groups were assessed by the Mann-Whitney U test (B), and differences 
between paired samples were assessed with the Wilcoxon sign-rank test (C). A p-value <0.05 was considered 
statistically significant. In B) closed squares represent RRMS patients not on immune modulatory therapy; open 
triangles represent RRMS patients on interferon-beta and inversed closed triangles represent RRMS patients on 
glatiramer acetate. In C) closed squares represent MS patients, while open squares represent subjects with 
other diagnosis. 
CD: cluster of differentiation; CSF: cerebrospinal fluid; FSC: forward scatter; GM-CSF: granulocyte-macrophage-
colony-stimulating factor; HC: healthy control; MS: multiple sclerosis 
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Figure 2. GM-CSF expression and secretion by in vitro cultured CD4+ T cells.  
CD4+ T cells from healthy controls (HC) and treatment-naïve RRMS patients (MS) were stimulated in vitro with 
plate bound anti-CD3 antibody for 5 days. A) GM-CSF+ CD4+ T cell frequencies and B) GM-CSF protein levels in 
the culture supernatant of CD4+ T cells in HC (n=9) and MS patients (n=8). Differences between groups were 
assessed with Mann-Whitney U test and a p-value <0.05 was considered statistically significant. 
CD: cluster of differentiation; GM-CSF: granulocyte macrophage colony-stimulating factor; HC: healthy control; 
MS: multiple sclerosis 
 
Autologous Tregs are able to regulate GM-CSF secretion by CD4+ T cells of RRMS pa-
tients 
Tregs have been shown to be able to regulate pathogenic T cell responses and therefore 
might also be able to suppress GM-CSF secretion by CD4
+
 T cells. GM-CSF protein levels 
were determined in the stored culture supernatants of a historically performed functional 
Treg assay from 13 RRMS patients. [79] Tresp and Treg were either cultured separately or 
together for 4 to 5 days. Upon stimulation with anti-CD3 antibody, Tresp were found to 
secrete considerable amounts of GM-CSF (118.2 pg/mL (64.9-224.6)) while Tregs secreted 
only minimal amounts of GM-CSF (4.7 pg/mL (0.0-25.3), p=0.001, Figure 3). In the co- cul-
tures of Tresp and Treg, we found that GM-CSF protein levels were significantly lower (7.4 
pg/mL (0.0-20.4)) as compared to Tresp mono-cultures (p=0.001, Figure 3). 
Since Tregs appear to inhibit GM-CSF secretion by CD4
+
 T cells, there might be an associa-
tion between Tregs and GM-CSF
+ 
CD4
+
 T cell frequencies in vivo. However, our data revealed 
no association between these two cell subsets in the different cohorts (data not shown). 
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Figure 3. Regulation of GM-CSF producing CD4+ T cells by regulatory T cells. 
GM-CSF protein levels in the culture supernatant of anti-CD3 antibody activated T responder cells (Tresp, CD25- 
CD4+ T cells), Tregs (CD25highCD127- CD4+ T cells) or a 1:1 coculture of Tresp cells and Tregs from 13 RRMS 
patients on interferon-beta therapy. The boxes represent the 25th and the 75th percentile with the dark horizon-
tal lines inside the boxes representing the median. The whiskers represent the minimum and maximum values. 
Statistical differences between conditions were tested with the Wilcoxon signed-rank test. A p-value <0.05 was 
considered statistically significant. 
CD: cluster of differentiation; GM-CSF: granulocyte macrophage colony-stimulating factor; Treg; regulatory T 
cell, Tresp: responder T cell 
 
Calcitriol-mediated suppression of GM-CSF secretion by CD4+ T cells is impaired in 
RRMS patients 
Calcitriol has been described to be a potent immune modulator that can reduce pathogenic 
T cell responses. Therefore, we assessed the effect of calcitriol on GM-CSF producing CD4
+
 T 
cells in vitro. GM-CSF+ CD4+ T cell frequencies were equally reduced by calcitriol in HC (n=9) 
and RRMS (n=8) patients (inhibition: 82.7% (49.0-91.1) and 76.8% (31.6-87.8), respectively, 
p=0.773, Figure 4A-B). Interestingly, the reduction in GM-CSF protein levels in the culture 
supernatant in the presence of calcitriol was more pronounced in the samples from HC 
compared to RRMS patients (inhibition: 80.9% (63.5-89.8) and 64.9% (-15.5-76.8), respective-
ly, p=0.021, Figure 4C-D). 
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Figure 4. Regulation of GM-CSF expression and secretion of CD4+ T cell by calcitriol.  
CD4+ T cells from peripheral blood of healthy controls (HC, n=9) and treatment-naïve RRMS patients (RRMS, 
n=8) were cultured in vitro and activated with plate bound anti-CD3 antibody for 5 days in the absence (-) or 
presence (+) of calcitriol. A) Frequencies of GM-CSF+ CD4+ T cells after culture in the absence or presence of 
calcitriol, B) the percentage of inhibition of GM-CSF+ CD4+ T cell frequencies by calcitriol relative to the condi-
tion without calcitriol, C) GM-CSF protein levels in the culture supernatant of CD4+ T cells in the absence or 
presence of calcitriol and D) the percentage inhibition of GM-CSF protein levels by calcitriol relative to the 
condition without calcitriol. Horizontal bars represent the median. Differences between groups were assessed 
with Mann-Whitney U test and a p-value <0.05 was considered statistically significant. 
CD: cluster of differentiation; GM-CSF: granulocyte macrophage colony-stimulating factor; HC: healthy control; 
RRMS: relapsing remitting multiple sclerosis 
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Discussion 
In the present study, we showed that the frequency of GM-CSF
+ 
CD4
+
 T cells in the circula-
tion of RRMS patients in remission is not elevated compared to healthy controls. Interesting-
ly, GM-CSF
+ 
CD4
+
 T cells frequencies were enriched in CSF as compared to blood. Further-
more, we showed that Tregs from RRMS patients are capable to strongly reduce GM-CSF 
secretion by CD4
+
 T cells. Finally, calcitriol appeared to be able to reduce the fraction of GM-
CSF
+ 
CD4
+
 T cells in RRMS patients and HC, but suppression of GM-CSF secretion by calcitri-
ol was significantly reduced in RRMS patients compared to HC. 
A pathogenic role of GM-CSF has been described in experimental models of arthritis, auto-
immune myocarditis and multiple sclerosis. [247, 249, 250] More recently, GM-CSF express-
ing CD4
+
 T cells have been identified as the dominant pathogenic cells in EAE. [38] Expres-
sion of GM-CSF mRNA has been shown in CNS tissue of mice 7–8 days after EAE induction. 
[248, 251] Dependent on the study, GM-CSF mRNA was already decreasing at day 15 or 21 
after induction. The results from Ponomarev et al. indicate that this GM-CSF was derived 
from the T cells, since there was only a low expression of GM-CSF in the spinal cord of mice 
that were induced with EAE by MBP-TCR GM-CSF
−
/
−
 T cells compared to WT MBP-TCR T 
cells. [248] Moreover, they showed that mice receiving WT MBP-TCR T cells had 7.8% GM-
CSF expressing cells within T cells derived from CNS tissue at the peak of disease (day 14). 
The exact mechanism of action for CD4
+
 T cell derived GM-CSF in EAE is unknown. It is pos-
tulated, however, that its effects on the myeloid cell compartment, i.e., microglial activation 
and/or myeloid cell recruitment to CNS, is of utmost importance. [38, 248] Moreover, GM-
CSF has been shown to stimulate IL-6 production by dendritic cells, which is required for 
Th17 cell differentiation and also appears to be important for survival of activated T cells. 
[250] In contrast, studies performed in experimental mice models of auto-immune thyroidi-
tis, myasthenia gravis and type I diabetes showed a beneﬁ cial effect of GM-CSF infusion. 
[252] Furthermore, they showed that GM-CSF enhances the proliferation of functional Tregs. 
[253] However, these studies did not focus on GM-CSF
+ 
CD4
+
 T cells. Moreover, it can be 
expected that GM-CSF expressing CD4
+
 T cells can play variable roles in different target 
organs. 
Since GM-CSF
+ 
CD4
+
 T cells are critical in EAE, we expected an increased frequency of this 
cell subset in the peripheral blood of RRMS patients compared to HC. Yet, our data did not 
show an augmented GM-CSF
+ 
CD4
+
 T cell population in RRMS patients in remission. Moreo-
ver, Noster et al., recently did not find any increase in these cells in MS patients with active 
disease. [39] In contrast, Hartmann et al. showed that RRMS patients have an increased 
percentage of GM-CSF
+ 
CD4
+ 
T cells compared to patients with other non-inflammatory 
neurological diseases (OND). [254] However, in their validation cohort this difference is only 
borderline significant. Moreover, they show that medication reduces GM-CSF
+ 
CD4
+ 
T cell 
frequencies in RRMS patients. Inclusion in our study of patients on first-line MS medication 
therefore may have obscured a possible difference. Distinct outcomes may also be related to 
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differences in the patient cohorts, the control cohorts, and the work-up of the blood sam-
ples.  
The fact that we did not observe a difference in GM-CSF
+ 
CD4
+
 T cell population in the pre-
sent study might also be due to the possibility that the GM-CSF
+ 
CD4
+
 T cell population 
represents a heterogeneous pool of pathogenic and non-pathogenic cells similar to the 
Th17 cell subset. [244, 245] This might be in line with the observation that GM-CSF produc-
tion by CD4
+
 T cells can only be inhibited by IL-27 in cells that do not co-express IL-17. [255] 
However, in our current study, also GM-CSF
+
IL17
+ 
CD4
+
 T cell frequencies did not differ 
between HC and RRMS patients (data not shown).  
Presence of GM-CSF
+ 
CD4
+
 T cells in the CSF might be more relevant for MS than the pres-
ence of these cells in the peripheral blood. Our results show that GM-CSF
+ 
CD4
+
 T cells can 
indeed be detected in the CSF and there they make up a significant fraction of the T cell 
population. This observation might indicate that these cells are importantly involved in brain 
immune pathology. This is in line with the results observed in the study of Noster et al.. 
Although, earlier studies showed no differences in GM-CSF protein levels in CSF of MS pa-
tients in remission compared to controls [256, 257], Noster et al. showed that the GM-CSF+ 
CD4
+
 T cell population is increased in the CSF of MS patients with active disease versus non-
MS patients [39]. To make a definitive statement on an enriched fraction of GM-CSF express-
ing Th cells in the CSF of MS patients, a larger population of MS patients (both during remis-
sion and relapse) and controls should be investigated. 
Cell frequencies as such do not reflect quantitative cytokine production. Therefore, GM-CSF 
protein levels were measured in the culture supernatants of activated CD4
+
 T cells. Also, GM-
CSF protein levels were not elevated in culture supernatant of cells derived from RRMS pa-
tients in remission compared to HC. Similar results have been found by Vrethem et al. in 
supernatants of stimulated PBMC. [257] Altogether, the presence of GM-CSF
+ 
CD4
+
 T cells 
and/or GM-CSF production was not increased in MS patients compared to controls. Future 
studies employing stimulation with possible auto-antigens, like myelin oligodendrocyte 
glycoprotein (MOG) and/or myelin basic protein (MBP), might be able to reveal an elevated 
antigen specific response in MS patients and provide more insight in the relevance of GM-
CSF
+ 
CD4
+
 T cells in MS pathogenesis. However, the auto-antigens in MS are still unknown. 
In addition, T cells reactive to the classical antigens, MOG, MBP and/or proteolipoprotein 
(PLP), believed to be involved in MS are also observed in healthy individuals. [258] The more 
recently identified antigens, as detected by auto-antibodies such as SPAG16 and KIR4.1, are 
only found in a fraction of the MS patients. [31, 32] The relatively high prevalence of anti-
KIR4.1 positive patients, however, could not be reproduced in an independent study. [259] 
Our results show that T cell derived GM-CSF is mainly attributable to the non-Treg popula-
tion. This is in concordance with a study using mice Tregs. [260] Moreover, our data show 
that Tregs can efficiently inhibit GM-CSF secretion by non-Treg CD4
+
 T cells from RRMS 
patients. Although, all patients were on IFN-β therapy and therefore, a possible effect of this 
therapy on Treg function cannot be excluded, our data are in line with the results observed 
by Hartmann et al. revealing that Tregs can reduce GM-CSF+ CD4+ T cell frequencies. [254] 
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Since culture supernatants were obtained from a previous study and HC were not included in 
the respective study design [116], comparison with HC was not possible. However, the 
Tresp/Treg cocultures of MS patients used in our study already strongly suppressed the GM-
CSF protein levels and therefore might have prevented to find a potential defect in suppres-
sion. Possibly, different Tresp/Treg ratios may unravel such an effect in future studies. Romio 
et al. showed that a possible mechanism of action of Tregs on GM-CSF secretion by Tresp 
might be exerted through the adenosine axis. [260] Adenosine can be converted from ATP 
by CD39 together with CD73, which are expressed on a Treg subset. [120, 121, 261, 262] This 
Treg subset seems to be functionally defective in MS patients [121, 122] and might, there-
fore, also be impaired in regulating GM-CSF
+ 
CD4
+
 T cells. 
An important immune modulator that seems to be associated with MS disease susceptibility 
and severity is vitamin D. [70, 147] Vitamin D might be critically involved in local regulation 
of T cell responses within the CNS, since calcitriol, the biological active vitamin D metabolite, 
can be generated locally by activated immune cells. [84] Additionally, infiltrating and peri-
vascular T cells in MS lesions stained positive for the vitamin D receptor. [82] Our results 
show that calcitriol is able to inhibit GM-CSF
 
expression and secretion by CD4
+
 T cells. This is 
in line with another study showing calcitriol dependent reduction of GM-CSF mRNA levels in 
a T cell line. [263] Although calcitriol equally reduces the fraction of GM-CSF positive CD4
+
 T 
cells in RRMS patients and HC, the reduction in GM-CSF protein levels is less effective in the 
RRMS patients as compared to HC. Since calcitriol has been known to inhibit T cell prolifera-
tion, the effects of calcitriol on GM-CSF might be linked to suppression of the activation or 
proliferation of the T helper cells (reviewed in [147]). However, a non-classical vitamin D 
receptor (VDR) response element has been observed in the promoter region of GM-CSF in a 
T cell line [263], suggesting a direct effect of calcitriol on GM-CSF transcription. It might be 
of interest to investigate possible (epi)genetic changes in this region in MS patients. 
In conclusion, MS patients included in our study do not have an augmented GM-CSF
+ 
CD4
+
 
T cell fraction in the circulation, but these cells can be detected in the CSF. Both Tregs and 
vitamin D seem to be able to down-regulate GM-CSF producing CD4
+
 T cells. The regulation 
of GM-CSF protein expression by calcitriol seems to be less efficient in RRMS patients as 
compared to controls. 
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Abstract 
In the past two decades, interleukin-10 (IL-10) has gained much attention as an im-
portant regulatory cytokine involved in self-tolerance. Functional assessment of IL-10 
producing immune cells is traditionally done by stimulation and measurement of cyto-
kine production by flow cytometry. Thereby a protein transport inhibitor like 
monensin is used to accumulate the cytokine of interest intracellularly. In this study we 
elaborated on the monensin effect on cytokine detection and focused on IL-10 detec-
tion in human T cells. 
Peripheral blood mononuclear cells (PBMC) of 32 study subjects were isolated and 
stimulated with PMA/ionomycin, in the absence and presence of monensin, and 
stained intracellularly for IFN-γ, IL-4, IL-10 and IL-17A. 
Our results re-established that detection of IFN-γ+ and IL-4+ T cells benefited from the 
presence of monensin during stimulation. However, stimulation in the presence of 
monensin yielded lower proportions of IL-10+ T cells (0.45% (0.28-0.80) versus 0.80% 
(0.50-1.50) of CD4+ T cells, p<0.01), although monensin addition did result in an in-
creased MFI (2431 (1273-4959) vs. 1928 (1147-3760), p<0.01). Detectable fractions of 
IL-17A+ CD4+ T cells were not affected by monensin. A shorter incubation time, but 
not lower monensin concentrations, was effective in improving the detection of IL-10+ 
T cells. We found a strong correlation between the fraction of IL-10+ CD4+ T cells in the 
presence and absence of monensin (R=0.80, p<0.01). Next to this, also the detection 
of IL-10+ NK-T cells and IL-10+ monocytes, but not IL-10+ B cells, is impaired in the 
presence of monensin. 
This study shows that the effect of monensin on cytokine accumulation is time and 
cytokine dependent. Due to the use of monensin, previous research may have underes-
timated the number of IL-10+ leukocytes or may even have not been able to detect 
them at all. It is important to consider this for future research or when interpreting 
historical IL-10 data. 
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Introduction 
Interleukin-10 (IL-10) was first discovered in 1989 as a cytokine synthesis inhibitory factor 
(CSIF) produced by T helper 2 (Th2) cells. [264, 265] Nowadays, a variety of IL-10 producing 
leukocytes are identified, including subsets of T cells, B cells, mast cells and phagocytic cells 
like eosinophils, monocytes/macrophages, and dendritic cells. IL-10 regulates the immune 
response by inhibiting the pro-inflammatory function of various innate and adaptive im-
mune cells and of endothelial cells. [266, 267] In particular, the discovery of regulatory T cells 
(Treg) has further boosted the scientific interest in IL-10. Tregs are IL-10 producers, and 
there is some evidence that Tregs fail to develop or function in the absence of IL-10. [268] 
Furthermore, IL-10 can induce differentiation and trigger the suppressive function of the 
regulatory Tr1 subset. [266, 269-271] More recently, also IL-10 producing regulatory B cells 
and IL-10 producing regulatory natural killer (NK) cells have been discovered. [272-274] On 
the other hand, IL-10 has been described as a growth factor for activated B cells and there-
fore an increased production of this cytokine can play an important role in the onset of 
clinical manifestations of antibody-mediated auto-immune diseases such as systemic lupus 
erythematosus and myasthenia gravis. [275, 276] All together, this brought IL-10 to the 
attention as an important regulator in the process of inflammation and as a crucial player in 
the control of self-tolerance and auto-immunity. [266, 270] 
 
Cytokine production can be assessed by multiple approaches. [277, 278] Since IL-10 can be 
produced by many different cell types it is desirable to appropriately identify the cellular 
source. Detection of IL-10 production at the single cell level by flow cytometry is a relatively 
rapid, highly sensitive and specific method to evaluate a large population of cells. [279, 280] 
Traditionally a protein transport inhibitor, such as monensin or brefeldin A (BFA), is used to 
prevent excretion, resulting in the accumulation of the cytokine of interest intracellularly. 
Monensin leads to anatomical disorganisation and non-specific disturbance of Golgi func-
tion and mainly affects the distal part of the Golgi complex, while BFA affects the pre-Golgi 
apparatus secretory pathway. [281-284] The use of a protein transport inhibitor in combina-
tion with intracellular staining makes it possible to identify subtypes of cytokine producing 
cells. Importantly, by using this method it is also possible to detect weakly expressed cyto-
kines. [279] However, efficacy of cytokine detection can be time, activator and cytokine 
dependent, and is also dependent on the chosen protein transport inhibitor. In general 
monensin is more toxic than BFA. [285] However, with respect to the detection of IL-10, 
monensin has been advocated to be more effective than BFA in inducing IL-10 accumulation 
in T cells. 
The use of protein transport inhibitors and especially monensin was traditionally tested and 
optimized for cytokines like IL-2, IL-4 and interferon-gamma (IFN-γ). In these experiments 
monensin enhanced fluorescence intensity, increased the number of detectable cells and 
delayed the peak of cytokine production. [279, 285, 286] We noticed that monensin may 
actually hamper IL-10 detection. Therefore, we studied in detail the effects of monensin on 
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cytokine detection, in particular detection of IL-10 in T-cells, and investigated whether we 
could improve detection of human IL-10
 
producing immune cells by lowering monensin 
concentrations or shortening monensin incubation time. 
Material and methods 
Subjects 
We included 32 study subjects. Nineteen of them were female (59.4%), 13 were male (40.6%) 
and the median age of the whole population was 34.5 years (range from 22-73 years). In-
formed consent was acquired from all subjects. 
Isolation of PBMCs 
Peripheral blood samples from study subjects were collected in a 10 mL sodium heparin 
blood sampling tube (BD Bioscience, Breda, the Netherlands). Peripheral blood mononuclear 
cells (PBMC) were isolated using Ficoll-density gradient (Histopaque; Sigma Aldrich, 
Zwijndrecht, the Netherlands) and centrifugation, performed as described before. [191] The 
isolated PBMCs were kept in RPMI glutamax medium (Gibco Invitrogen, Breda, the Nether-
lands) supplemented with 10% foetal calf serum (Greiner Bio-One, Alphen a/d Rijn, the 
Netherlands), 1% non-essential amino acids (Gibco Invitrogen), 1% sodium pyruvate (Gibco 
Invitrogen) and 2% penicillin-streptomycin (Gibco Invitrogen). 
Stimulation of PBMC with PMA/ionomycin in the absence or presence of monensin 
PBMCs were stimulated for 5 hours with PMA (50 ng/mL, Sigma Aldrich) and ionomycin (1 
μg/mL, Sigma Aldrich) in the absence or presence of monensin (BD Biosciences) or BFA 
(Sigma Aldrich) and placed in a 37°C incubator with a humidified atmosphere containing 
95% air and 5% CO2. Monensin was used in the recommended concentration of 1.25 μg/mL 
or was further diluted to concentrations ranging from 0 μg/mL to 1.25 μg/mL as indicated in 
the figures. BFA was used in a concentration of 5 μg/mL. 
Intracellular staining  
PBMCs were stained with anti-CD3-horizon450 (BD Biosciences), anti-CD8-APC-H7 (BD 
Biosciences) and anti-CD19-FITC (BD Biosciences) to distinguish CD3
+
CD8
- 
lymphocytes 
(CD4
+
 T cells), CD3
+
CD8
+ 
lymphocytes (CD8
+
 T cells)
 
and CD19
+
CD3
-
 lymphocytes (B-cells). 
Monocytes were identified based on the FSC/SSC scatter and absence of CD3 staining. 
CD3
+
CD56
+
 lymphocytes (natural killer-like T cells (NK-T cells)) were stained using anti-CD3-
horizon 450 and anti-CD56-PE (BD Biosciences). PBMCs were fixed and permeabilised (Cy-
tofix/Cytoperm, BD Biosciences) and stained intracellularly with anti-IL-4-PE (Biolegend, 
Uithoorn, the Netherlands), anti-IFN-γ-FITC (BD Biosciences), anti-IFN-γ-PE (BD Biosciences), 
anti-IL-17A-PerCP-Cy5.5 (Biolegend) and anti-IL-10-APC (Biolegend). The activation status of 
cells was assessed by anti-CD69-PE-Cy7 (Biolegend). Samples were analysed on a FACS 
Canto II flow cytometer (BD Biosciences). 
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Statistical analysis 
GraphPad Prism 5 (GraphPad Software Inc., La Jolla CA, USA) was used to construct figures 
and perform statistics. Of continuous variables, the median value and corresponding range 
(min–max) are provided. Differences between two related samples were assessed using the 
Wilcoxon signed-rank test. Correlations were assessed with the Spearman correlation coeffi-
cient. A p-value <0.05 was considered statistically significant. 
Results 
Monensin impairs the detectable amount of IL-10+ CD4+ and IL-10+ CD8+ T cells 
As is evident from Figure 1A, monensin positively affects both the relative amount as well as 
the median fluorescence intensity (MFI) of IFN-γ producing cells, whereas the relative 
amount of IL-10 producing cells is reduced. Indeed, BFA is comparable to monensin in the 
detection of IFN-γ
+ 
CD4
+ 
T cells, but negatively influences the detectable relative amount of 
IL-10
+
 CD4
+ 
T cells. Following these observations we studied the effect of monensin addition 
on the detection of IFN-γ, IL-4 (the prototype cytokines for Th1 and Th2 cells, respectively), 
IL-10 and IL-17A producing cells by intracellular flow cytometry. The fraction of cytokine 
producing cells and MFI was highly variable between donors (Table 1). To evaluate the effect 
of monensin, we divided the fraction (or MFI) of cytokine positive cells measured in the 
absence of monensin by the fraction (or MFI) in the presence of monensin, for each cytokine 
and each donor. Calculated monensin
-
/monensin
+
 ratios were below 1 for both IFN-γ and IL-
4: 0.53 and 0.79 (both p<0.01), respectively (Figure 1B), implying that both IFN-γ and IL-4 
producing T cells are better detectable in the presence of monensin. Also the ratio of 
Th1/Th2 cells, defined as the IFN-γ
+
/IL-4
+ 
T cell ratio, was significantly higher (p<0.01) when 
measured in the presence of monensin (median=3.75), as compared to the ratio in the ab-
sence of monensin (median=2.78). This implies that IFN-γ detection benefits more from 
monensin addition than IL-4 detection. Interestingly, the median monensin
-
/monensin
+
 ratio 
of the fraction of IL10
+ 
CD4
+ 
T-cells was 1.75 (p<0.01) (Figure 1B). Detection of IL-17A
+ 
CD4
+ 
T cells was not affected by the addition of monensin, the median monensin
-
/monensin
+
 ratio 
was 1.00. Furthermore, the monensin
-
/monensin
+
 ratio’s for IFN-γ, IL-4, IL-10 and IL-17A 
were significantly different (p<0.01) from each other, indicating that the consequences of 
monensin addition on the detectable fraction of cytokine producing CD4
+
 T cells are highly 
cytokine dependent. The difference in vulnerability to monensin of different T-cell subsets 
could not be attributed to differential activation status, since all T–cell subsets expressed 
similar levels of CD69, after activation (data not shown). Furthermore, these results were 
independent of the monensin batch used, or the general status of the sample (data not 
shown). Similar findings were obtained in the CD8
+ 
T cell population (data not shown).  
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Figure 1. Effects of monensin or BFA on cytokine production and MFI in human CD4+ T cells. 
A) Representative dot plots of IL-10 and IFN-γ production by human CD4+ T cells in absence and presence of 
monensin or BFA B) monensin-/monensin+ ratio of fraction of cytokine producing CD4+ T cells (n=32) C) 
monensin-/monensin+ ratio of MFI of cytokine producing CD4+ T cells (n=32) 
* p<0.05, ** p<0.01; monensin- compared to monensin+ condition; CD; cluster of differentiation; IFN; interferon; 
IL; interleukin; MFI: median fluorescence intensity; monensin-/monensin+ ratio: fraction (or MFI) of cytokine 
positive cells measured in the absence of monensin divided by the fraction (or MFI) in the presence of 
monensin 
 
In addition, we could confirm that monensin increases the MFI of IFN-γ and IL-4 producing 
CD4
+
 T cells: this is expressed in a monensin
-
/monensin
+
 ratio of 0.37 and 0.70 (both p<0.01) 
for IFN-γ
+
 CD4
+
 T cells and IL-4
+
 CD4
+
 T cells, respectively (Figure 1C). Also the MFI of IL-10
+
  
CD4
+
 T cells and IL-17A
+ 
CD4
+
 T cells was decreased in the absence of monensin with a 
monensin
-
/monensin
+
 ratio of 0.77 and 0.62 (both p<0.01), respectively (Figure 1C). 
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Table 1. Fraction and MFI of cytokine producing CD4+ T cells in the presence (monensin+) and absence of 
monensin (monensin-) (n=32). 
 Fraction MFI 
Cytokine Monensin - Monensin +  Monensin - Monensin +  
IFN-γ 5.05%   
(1.00-40.10) 
8.90%  
(4.10-78.18)  
** 1441  
(1008-4395) 
4054  
(1867-10102)  
** 
IL-4 2.32%  
(0.73-7.80) 
2.57%  
(1.10-9.90)  
** 1766  
(1010-5108) 
2587  
(1058-5376)  
** 
IL-10 0.80%  
(0.08-3.80) 
0.45%  
(0.05-2.10)  
** 1928  
(1147-3760) 
2431  
(1273-4959)  
** 
IL-17A
  
0.50%  
(0.13-2.90) 
0.50%  
(0.15-2.70) 
 6537  
(417-21197) 
10359  
(1777-36010) 
** 
** p<0.01; monensin- compared to monensin+ condition; IFN: interferon; IL: interleukin; MFI: median fluores-
cence intensity 
Monensin inhibits detection of IL-10 producing T cells at low concentrations 
Next, we investigated whether we could enhance the sensitivity of detection of IL-10
+
 CD4
+
 T 
cells, without losing sensitivity for IFN-γ
+
 CD4
+
 T cell detection, by lowering the monensin 
concentration. For evaluation we normalised all fractions to the detected fraction of cytokine 
producing cells in the recommended monensin concentration of 1.25 μg/mL. This was done 
for each cytokine and for each donor separately. 
For IFN-γ, we observed a monensin concentration dependent loss of sensitivity (Figure 2A): 
the higher the monensin concentration, the higher the fraction of detectable IFN-γ
+
 CD4
+ 
T 
cells, although these differences were not statistically different. The detectable fraction of IL-
10 producing CD4
+
 T cells was comparable in the different monensin concentrations tested 
(Figure 2B). These data show that lowering the monensin concentration did not enhance the 
sensitivity of the detection of IL-10 producing CD4
+
 T cells without affecting the detection of 
IFN-γ producing CD4
+ 
T cells. 
Monensin is most effective in detecting IL-10 producing CD4+ T cells after 1 or 2 hours 
of incubation 
Another option to circumvent the negative effects of monensin could be to use a shorter 
monensin incubation time. PBMCs were stimulated for 5 hours with PMA/ionomycin, and 
monensin (1.25 µg/mL) was present during stimulation for 0 to 5 hours. For evaluation we 
normalised all obtained fractions (or MFI) to the fraction (or MFI) of cytokine producing 
CD4
+
 T cells in the 5 hours monensin incubation protocol. This was done for each cytokine 
and for each donor separately (Figure 3). 
Detection of IFN-γ
+ 
CD4
+ 
T cells was optimal when monensin was added for 3 to 5 hours. 
With shorter incubation times, the fraction of IFN-γ
+ 
CD4
+ 
T cells decreased to a median ratio 
of 0.75 at 1 hour of incubation (p<0.05) (Figure 3A). The detection of IL-4
+
 CD4
+ 
T cells  
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A 
 
 
B 
 
Figure 2. Effect of monensin concentration on detection of cytokine producing CD4+ T cells.  
Normalised fractions of A) IFN-γ producing CD4+ T cells B) IL-10 producing CD4+ T cells; in the various 
monensin concentrations tested (n=6). The recommended monensin concentration (1.25 mg/mL) was used 
to normalise detected fractions measured in the various monensin concentrations tested.  
* p<0.05; detected fraction in tested monensin incubation time compared to detected fraction with 5 hours 
of monensin incubation; IFN: interferon; IL: interleukin 
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showed a trend towards an optimum at a monensin incubation period of 2 to 5 hours (Fig-
ure 3B). In general, the relative amount of IL-10 producing CD4
+
 T cells increased with a 
decrease in monensin incubation time. The fraction of IL-10
+
 CD4
+
 T cells at 1 hour of incu-
bation versus 5 hours of incubation was 2.91 (p<0.05) (Figure 3C). The percentage of IL-17A 
producing cells was not influenced by the monensin incubation time with a normalised 
fraction of IL-17A
+ 
CD4
+
 T cells of about 1 for all conditions (Figure 3D). We have shown 
before (Figure 1C) that although the fraction of IL-10
+ 
CD4
+ 
T cells increased in the absence 
of monensin, this was at the expense of the MFI. Therefore, we assessed whether this reduc-
tion in MFI was influenced by the monensin incubation time. The MFI of IFN-γ
+ 
CD4
+ 
T cells 
was comparable when monensin was added for 3 to 5 hours. A monensin incubation time of 
2 hours or shorter affected the MFI of IFN-γ
+
 CD4
+
 T cells significantly (Figure 3A). This was 
also the case for the MFI of IL-4
+
 CD4
+ 
T cells which decreased time dependently when 
monensin was present for 3 hours or less (p<0.05) (Figure 3B). For IL-10 producing CD4
+ 
T 
cells the MFI also decreased with shorter incubation times (p<0.05 for 1 and 2 hours incuba-
tion time) (Figure 3C). The MFI of IL-17A producing CD4
+
 T cells was not affected by the 
addition of monensin (Figure 3D). 
 
The fraction of IL-10+ CD4+ T cells detected in the absence of monensin is strongly correlat-
ed with the fraction of IL-10+ CD4+ T cells in the presence of monensin 
Since most studies on intracellular IL-10 detection in CD4
+
 T cells were done in the presence 
of monensin, we investigated the relationship between the IL-10 CD4
+
 T cell fraction meas-
ured in the absence and presence of monensin. As is shown in Figure 4, the fraction of IL-10
+
 
CD4
+
 T cells detected in the absence of monensin was strongly correlated with the fraction 
of IL-10
+
 CD4
+
 T cells detected in the presence of monensin (Spearman R 0.80, p< 0.01). Also 
the fractions of other cytokine producing CD4
+ 
T cells detected in the absence of monensin 
were correlated with the fraction detected in the presence of monensin: Spearman R of 0.78 
(p<0.01), 0.91 (p<0.01) and 0.94 (p<0.01) for IFN-γ, IL-4 and IL-17A respectively. Also the 
Th1/Th2 ratio’s in the absence and presence of monensin were significantly correlated (R 
0.80, p<0.01). 
Detection of IL-10+ monocytes and IL-10+ NK-T cells, but not IL-10+ B cells, seem to be 
affected by monensin 
To investigate whether the monensin effect on IL-10 production was T cell specific, we addi-
tionally studied other IL-10 producing leukocytes directly ex vivo. To evaluate the effect of 
monensin addition, we divided the fraction (or MFI) of IL-10 positive cells measured in the 
absence of monensin by the fraction (or MFI) in the presence of monensin, for each donor. 
Besides the negative effects on IL-10 detection in T cells (p<0.01), monensin has detrimental 
effects on the detection of IL-10
+
 NK-T cells, and IL-10
+
 monocytes (median monensin
-
/monensin
+ 
ratios of 1.69 (p<0.01) and 1.38 (p<0.01), respectively). B cells, however, seemed 
to benefit from the addition of a protein transport inhibitor: the median monensin
-
/monensin
+ 
ratio was 0.60 (p<0.01). (Figure 5) 
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Figure 4. Correlation between fraction of IL-10+ CD4+ T cells in the presence and absence of monensin. 
Fractions of IL-10+ CD4+ T cells in the absence of monensin are plotted against the fraction of IL-10+ CD4+ T cells 
in the presence of monensin (n=32). Monensin was used in the recommended concentration (1.25 μg/mL) and 
the standard incubation time of 5 hours. 
CD: cluster of differentiation; IL: interleukin 
 
 
Figure 5. Effect of monensin on IL-10 producing leukocytes. 
Monensin-/monensin+ ratios of fraction of IL-10 producing cells in presence or absence of monensin (n=18). 
Directly ex vivo, T cells are defined as CD3+ lymphocytes, NK-T cells as CD3+CD56+ lymphocytes, B cells as 
CD19+ lymphocytes and monocytes were identified based on the FSC/SSC scatter and absence of CD3 stain-
ing  
* p<0.05 **p<0.01; monensin- compared to monensin+ condition; IL: interleukin; NK: natural killer  
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Discussion and Conclusion 
In this study, we show that the effect of monensin on cytokine accumulation is time and 
cytokine dependent. In contrast to the known improvement of cytokine detection for IFN-γ 
and IL-4 [279, 285, 286], monensin impairs the detectable fraction of IL-10
+
 T cells, whereas 
detection of IL-17A producing T cells is not affected. Monensin, though, increases the IL-10 
per cell (expressed by an increased MFI), as is the case for other cytokines. Apparently, 
monensin has a highly cytokine dependent effect on the different subsets of cytokine pro-
ducing cells, and this is confirmed by significant differences between the monensin
-
/monensin
+
 ratios of the detectable fraction of IFN-γ, IL-4, IL-10 and IL-17A producing CD4
+
 
T cells. 
Monensin impaired detection of IL-10
+ 
CD4
+
 T cells in 27 of the 32 studied subjects. Howev-
er, we observed a high donor-to-donor variation in the effect monensin had on the detec-
tion of IL-10. The extent of the monensin effect on cytokine detection did not correlate 
between the different cytokines within the same sample. Moreover, the inter-individual 
variation was not caused by differences in the general status of the sample or the size of the 
IL-10
+ 
CD4
+
 T cell population. 
To circumvent the drop in IL-10 detection without affecting the detection of other intracellu-
lar cytokines we tested either the use of lower monensin concentrations or a shorter 
monensin incubation time. A 25-fold lower monensin concentration had detrimental effects 
on IFN-γ detection but did not improve IL-10 detection in CD4
+
 T cells. Incubation with 
monensin for a shorter time period, e.g. 2 hours, resulted in improved detection of IL-10
 
 
producing T cells (p<0.05). This might be a good alternative for the simultaneous detection 
of IFN-γ, IL-4, IL-10 and IL-17A producing cells in one tube. A possible disadvantage of this 
approach is that distinguishability of cytokine positive cells, expressed in MFI, might be 
worse. Otherwise, when only the IL-10
+
 T cell is of interest, absence of monensin in the intra-
cellular FACS protocol should be considered. An extra advantage then is that quantification 
of excreted cytokines into the supernatant by for example ELISA will be possible. Besides, 
there are also other ways to detect IL-10 producing cells like the recently described single 
cell secretion analysis, which is based on droplet based micro fluidic platforms. [287] Finally, 
although these lymphocyte subsets are usually stimulated by more cell specific stimuli and 
excretion of cytokines is prevented by using BFA instead of monensin, we showed that the 
effect of monensin is immune cell specific: monensin seems to impair detection of IL-10
+ 
T 
cells, IL-10
+
 NK-T cells, and IL-10
+
 monocytes, but not of IL-10
+
 B cells. 
The mechanism behind this impaired detection of IL-10 producing T cells is at present un-
clear. Monensin is known to inhibit the secretion of cytokines, which are then accumulated 
intracellularly. This is in agreement with our data which show an increased MFI upon 
monensin usage for all cytokines tested. Monensin is known to be toxic, probably due to the 
block in Golgi function. [285, 286, 288, 289] Recently, monensin was shown to induce a Golgi 
stress response, which is manifested by remodelling of the expression of genes involved in 
lipid synthesis, extension of Golgi capacity and apoptosis. [288, 290] In addition, there is 
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conflicting evidence for the (direct or indirect) effects of monensin on the endoplasmic retic-
ulum (ER). [290, 291] The ER stress response and related unfolded protein response have 
been shown to induce an increase in pro-inflammatory cytokine production. [292] We pro-
pose that monensin triggers, directly via the Golgi stress response or indirectly via the ER 
stress response, a pro-inflammatory cytokine shift, which could explain the increase in the 
detection of pro-inflammatory cytokines and the decrease in the detection of IL-10
+
 T cells 
in the presence of monensin. The incubation-time experiments may underline this hypothe-
sis, since a 2 hours monensin incubation time may be too short to affect gene expression 
and translation. On the cellular level, different cell types may be variably vulnerable to the 
induction of stress responses by monensin, for example by expression of microRNAs, and 
the same stress responses may result in a different outcome. In IL-10 positive T cells, these 
stress responses may preferentially result in apoptosis. However, in PBMCs, the fraction of IL-
10 producing T cells is too low to specifically test toxic effects of monensin in these cells. 
Alternatively, monensin was shown to delay cytokine production in the cell. [279] It can be 
speculated that IL-10 production is more delayed than IFN-γ production. However, our data 
do not support this explanation for the impaired IL-10 detection in T cells. 
Future research into IL-10 production by leukocytes should take into account that monensin 
reduces the proportion of IL-10
+
 cells detected with intracellular flow cytometry, or even 
makes them undetectable. Due to the use of monensin, previous research may have under-
estimated the number of IL-10
+ 
leukocytes. It is important to consider this when interpreting 
historical IL-10 data.  
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Abstract 
Multiple sclerosis (MS) is characterized by a disturbed homeostasis of the circulating 
immune cell compartment and low serum levels of vitamin D are associated with an 
increased disease activity. Vitamin D has been hypothesized to promote the mainte-
nance of immune homeostasis. High dose vitamin D3 supplementation could therefore 
be of benefit to patients with MS. The SOLAR study investigated the effects of high 
dose vitamin D3 supplementation on clinical outcomes in a randomised controlled 
trial. Here we present the immune regulatory effects, investigated in the SOLARIUM 
sub-study. 
Peripheral blood mononuclear cells (PBMC) were isolated from 53 Dutch relapsing 
remitting (RR)MS patients treated with IFN-β-1a, who participated in the SOLAR study. 
Thirty of them received high dose vitamin D3 supplementation and 23 received placebo 
during a follow-up period of 48 weeks. Lymphocytes were phenotypically character-
ized by flow cytometry and in vitro pro- and anti-inflammatory cytokine secretion in 
culture supernatant was assessed in the presence or absence of 1,25(OH)2D3 using 
Luminex technology. Changes in immune regulatory parameters were determined 
within subjects as well as between treatment groups. 
First, the number of cells in the regulatory immune cell compartment (including nTreg, 
iTreg and Breg) was not altered upon high dose vitamin D3 supplementation. Second, 
proportions of T helper subsets were not affected by vitamin D3, except for the pro-
portion of IL-4+ Th cells, which decreased in the placebo but not in the vitamin D3 
group. T cell cytokine secretion increased, most pronounced for IL-5 and latency acti-
vated protein of TGF-β, in the placebo group but not in the vitamin D3 group. Lym-
phocytes remained equally reactive to in vitro 1,25(OH)2D3 addition after 48 weeks of 
follow-up. 
In conclusion, high dose vitamin D3 supplementation did not result in a relative in-
crease in lymphocytes with a regulatory phenotype. However, this study supports the 
hypothesis that vitamin D contributes to the maintenance of immune homeostasis by 
preventing a further disturbance of the T cell compartment taking place during the 
early disease course in MS. Clinical studies will eventually indicate if the subtle differ-
ences between the treatment groups in this study, also result in improved clinical out-
come.   
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Introduction 
Main challenges in multiple sclerosis (MS) research are to further unravel the underlying 
pathogenic mechanisms of this still poorly-understood disease and to make treatments 
more effective while minimising the associated serious side effects. Genetic [14], epidemio-
logical [71, 74], clinical [72, 75, 199, 200] and immunological [131, 154] data have pointed 
towards a beneficial role of vitamin D in MS risk, and disease activity. Since most MS patients 
have low vitamin D levels, vitamin D supplementation may be an effective and safe (add-on) 
treatment option in MS. The SOLAR study assessed the efficacy of high dose vitamin D3 as 
add-on therapy to interferon-beta-1a (IFN-β-1a) on clinical outcome, i.e. disease activity free 
status, in 232 patients with early relapsing remitting MS (RRMS) in 11 countries in Europe 
(NCT01285401). [136] In this paper we present the results on the immune modulating effects 
of high dose vitamin D3 supplementation investigated in the Dutch sub-study SOLARIUM 
(SOLAR ImmUne Modulating effects). 
MS is a devastating inflammatory disease of the central nervous system (CNS). In its most 
prevalent phenotypic entity, called RRMS, the disease course is characterized by periods of 
neurological deterioration (relapses), followed by periods of recovery (remissions). In particu-
lar, this subtype is considered to be of auto-immune origin, but neither the target nor the 
exact aetiology has been unravelled to date. The immunopathological hypothesis currently 
most widely accepted is that auto-reactive lymphocytes become activated in the secondary 
lymphoid tissues and, after entering the CNS, become reactivated. Via a positive feedback 
loop, a pro-inflammatory environment arises, resulting in an attack by the immune system 
that damages myelin and neurons, eventually leading to loss of neurological function. [105, 
109, 293] For many years, MS was regarded to be a T helper 1 (Th1; mainly IFN-γ producing 
Th cells) mediated disease. [36] More recently, Th17 cells, producing interleukin 17 (IL-17) 
[36, 37], and GM-CSF producing Th cells [38, 39] are held responsible for the encephalito-
genic reaction. Outside the CNS, in the circulating immune system, MS is characterized by a 
disturbed lymphocyte homeostasis, with a diminished function of regulatory T cells (Treg) 
[117, 294], a decrease in the number of regulatory B cells (Breg) [117, 295] and a disruption 
in the equilibrium between pro- and anti-inflammatory immune cells resulting in disturbed 
cytokine networks [34, 35]. 
The function of vitamin D as an immune regulator most probably explains its proposed 
disease modulating effects. [296] It is well established that immune cells are able to react to 
and even to metabolize vitamin D. [105, 147, 197] In vivo association studies with vitamin D, 
measured as serum 25-hydroxyvitamin D (25(OH)D), suggest that vitamin D can help to 
maintain or restore the immune homeostasis in auto-immune diseases by promoting the 
number and/or suppressive function of Tregs. [296] Directly or indirectly via the modulation 
of the regulatory lymphocytes, vitamin D may inhibit T cell proliferation, affect cytokine 
production by T cells, and change the balance between T cell subsets. [296] In MS patients, 
lower pro-inflammatory cytokine levels, including IFN-γ levels, produced by peripheral blood 
mononuclear cells (PBMC) and T cells, were associated with higher serum 25(OH)D levels, 
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while anti-inflammatory cytokine production, such as IL-4 and IL-10, was positively associat-
ed with serum 25(OH)D levels. [191] Patients with lower serum 25(OH)D levels tended to 
have a higher proportion of  IL-17
+ 
Th cells, but 25(OH)D levels did not correlate with the 
proportion of Bregs. [122, 191, 295] GM-CSF production by Th cells was differentially inhibit-
ed by vitamin D in an in vitro study in MS patients and healthy controls (HC). [297] In HC, in 
vivo high dose vitamin D3 supplementation studies (most of them uncontrolled and with a 
maximum follow-up of 12 weeks) have shown a significant increase in the numbers of Tregs 
without any effect on the function of these Tregs or on other immune cells. [296, 298] Others 
showed that vitamin D3 supplementation in HC resulted in a reduced frequency of IL-17
+
 Th 
cells and an increase in the production of the regulatory cytokine IL-10 by non-T cells after 3 
days of stimulation with PHA. [187] In MS patients, vitamin D3 supplementation resulted in a 
shift in the balance between the proportions of IFN-γ
+
 and IL-4
+
 Th cells and an increase in 
the amount of inducible Tregs (iTreg) as proportion of total Th cells, whereas the number 
and function of natural Tregs (nTreg) was not affected. [79] In general, data on vitamin D and 
the immune system are not consistent and studies were often under-powered, but they do 
suggest that vitamin D promotes anti-inflammatory/regulatory immune parameters and 
reduces pro-inflammatory immune parameters. 
In this randomised placebo-controlled trial (RCT) in patients with RRMS, we assess the ef-
fects of vitamin D3 supplementation as add-on therapy to IFN-β treatment on the circulating 
lymphocyte compartment. In line with our hypothesis, i.e. vitamin D being an important 
player in the immune regulation and Th cells being the most relevant cells of the immuno-
logical cascade in the immune cell compartment of patients with MS [14], we first report on 
the vitamin D3 effects on regulatory lymphocytes. Thereafter, the effects on inflammatory 
cytokine production by PBMC and Th cells are described.  
Methods 
Patients  
In- and exclusion criteria and the study design of the SOLAR study are described elsewhere. 
[136] In short, study participants, aged between 18 and 55 years, had a diagnosis of RRMS 
(according to McDonald criteria 2005) which was confirmed by typical MS findings on brain 
or spinal MRI. They had a first clinical event within 5 years prior to screening and active 
disease in the prior 18 months, but no relapse 30 days before inclusion. Patients were ex-
cluded if they took more than 1000 IU (25μg) of vitamin D supplements. All patients received 
IFN-β-1a (Rebif®, Merck Serono S.A., Darmstadt, Germany), 44 μg three times weekly s.c. for 
a minimum of 90 days and not longer than 18 months. After being randomised, patients 
received either IFN-β-1a and placebo or IFN-β-1a  and vitamin D3 (cholecalciferol, Vigantol® 
Oil, Merck KGaA, Darmstadt, Germany) 7000 IU daily for 4 weeks, followed by 14000 IU daily 
up to week 48. 
Patients for the SOLARIUM sub-study were recruited in four of the five participating centres 
in the Netherlands (Zuyderland Medical Centre (Sittard), Maasstad Hospital (Rotterdam), 
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Groene Hart Hospital (Gouda) and St. Antonius Hospital (Nieuwegein)), without additional 
inclusion or exclusion criteria. They were eligible when they agreed with participation in this 
sub-study. The study protocol was approved by the Medical Ethical Committee Zuyderland 
Zuyd (Heerlen, the Netherlands). Researchers performing the immunological analyses were 
blinded for treatment and patient details. 
PBMC isolation 
Peripheral blood samples from study subjects were collected at baseline (wk0) and after 48 
weeks (wk48) of treatment (placebo or vitamin D3). Blood was collected in a 10 mL sodium 
heparin blood sampling tube (BD Bioscience, Breda, the Netherlands) and kept at room 
temperature during transportation to Maastricht University Medical Centre, the Netherlands. 
PBMC were isolated within 24 hours using a Ficoll-density gradient (Histopaque; Sigma 
Aldrich, Zwijndrecht, the Netherlands) and centrifugation, performed as described before. 
The freshly isolated PBMC were kept in culture medium. [191] 
Staining for detection of T and B cell subtypes 
Directly after isolation, PBMC were stained with a cocktail of monoclonal antibodies to iden-
tify nTreg according to the following definitions CD25
+
CD127
- 
CD4
+
 T cells (CD25
+
CD127
- 
nTreg), CD25
+
FoxP3
+
 CD4
+
 T cells (CD25
+
FoxP3
+ 
nTreg) and CD25
+
CD127
-
FoxP3
+
 CD4
+
 T 
cells (CD25
+
CD127
-
FoxP3
+ 
nTreg), as described before [79, 122] (Figure 1A). Within the 
CD25
+
CD127
- 
nTregs, subsets were defined based on expression of CD45RA (naïve/memory 
nTreg) and CD39 (CD39
+
 nTreg, which are the Tregs associated with the suppression of the 
encephalitogenic IL-17
+
 Th cells [121]).  
Cytokine expression of IL-4, IFN-γ, IL-17, IL-22, GM-CSF and TNF-α by CD3
+
CD8
-
 T lympho-
cytes, which are further referred to as Th cells [79], was assessed after a 5 hours in vitro 
activation with phorbol 12-myristate 13-acetate (PMA) (50 ng/mL, Sigma Aldrich) and iono-
mycin (1 μg/mL, Sigma Aldrich) in the presence of monensin (1.25 μg/mL, BD Biosciences). 
Expression of IL-10, which was used to define IL-10
+
 Th cells/ iTreg, was assessed after simi-
lar activation, but without the addition of monensin. [299] Cells were intracellularly stained 
after fixation and permeabilisation (Cytofix/Cytoperm, BD Biosciences). Antibodies used, are 
described before [79, 297], except for IL-22 (anti-IL-22-efluor-660 (eBioscience, Vienna, 
Austria)) and TNF-α (anti-TNF-α-PE-Cy7 (eBioscience)). Gating strategies are shown in Figure 
1B. 
To identify Breg, PBMC were stimulated with CpG oligodeoxynucleotide 2006 (0.1 μM, Invi-
vogen, Toulouse, France) for 66 hours in a 24-wells plate. Subsequently, PBMC were restimu-
lated for six hours with PMA (10 ng/mL), ionomycin (1 μg/mL) and brefeldin A (BFA) (Sigma 
Aldrich, 1 μg/mL) and then stained to distinguish IL-10
+
 7AAD
-
 CD19
+
CD3
- 
cells (IL-10
+
 B 
cells/Breg), as described before [295] (Figure 1B). Furthermore, to identify CD24
high
CD38
high
 
CD19
+ 
B cells directly ex vivo, anti-CD19-PerCP-Cy5.5 (BD Bioscience), anti-CD24-PE (Bio-
legend, Uithoorn, the Netherlands) and anti-CD38-APC (BD Bioscience) were used.  
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        iTreg Breg 
 Figure 1. continued. 
B.   Gating strategy of cytokine production by lymphocyte subsets 
IL-10+ Th cells/ iTreg were measured as IL-10+ CD8- T cells after 5 hours of stimulation with PMA/ionomycin in 
the absence of monensin. IL-4+, IFN-γ+, IL-17+, GM-CSF+, IL-22+ and TNF-α+ Th cells were measured after 5 
hours of stimulation with PMA/ionomycin in the presence of monensin. Cytokine producing T cells were gated 
from the CD3+ cells within the lymphogate 
IL-10+ B cells/ Breg were measured as IL-10+ CD19+CD3- B cells within the lymphogate after stimulation for 72 
hours with CpG and restimulation for the last 6 hours with PMA/ionomycin/BFA. 
BFA: brefeldin A; Breg: regulatory B cell; CD: cluster of differentiation; GM-CSF: granulocyte macrophage colo-
ny-stimulating factor; IFN: interferon; IL: interleukin; iTreg: inducible regulatory T cell; PMA: phorbol 12-
myristate 13-acetate 
 
After (re)stimulation for intracellular staining, the activation status of cells was assessed by 
staining cells with anti-CD69-PE-Cy7 (Biolegend). Samples were measured on a FACS Canto 
II flow cytometer and analysed with FACS Diva software 8.01 (both BD Biosciences). 
Cytokine secretion upon T cell activation using Luminex technology 
To investigate the effects of in vivo high dose vitamin D3 supplementation on cytokine pro-
duction, PBMC were stimulated in vitro for 72 hours with soluble anti-CD3 (WT32, 4 ng/mL, 
kindly provided by Dr. W. Tax, Nijmegen, the Netherlands) in a 96-wells plate. In addition, we 
assessed the reactivity of immune cells to vitamin D at wk0 and wk48 in vitro. Hereto the 
active vitamin D metabolite 1,25(OH)2D3 (10
-8
 M, Sigma Aldrich) was added to the anti-CD3-
stimulated PBMC. All conditions were cultured in duplo. After 72 hours, culture plates were 
centrifuged and culture supernatant was collected and stored until further analyses. At the 
end of the study, an in-house developed and validated multiplex immunoassay (Laboratory 
of Translational Immunology, University Medical Centre Utrecht, the Netherlands) based on 
Luminex technology (xMAP, Luminex, Austin TX, USA) [300] was used to assess the amount 
of produced cytokines (IL-4, IL-5, IL-10, IL-17, IL-22, TNF-α, IFN-γ, LAP, GM-CSF) in each 
culture supernatant. Data were analysed using Bio-Plex Manager software, version 6.1.1 
(Biorad laboratories, Hercules, CA, USA). 
iTreg Breg
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Figure 2. Schematic overview of SOLARIUM study participants’ inclusion and analysis. 
IFN: interferon; n=number 
  
n=64
Dutch IFN-β treated patients with RRMS included in the SOLAR trial 
n=58 
informed consent for participation in SOLARIUM substudy
n=58
randomised
n=25
placebo
n=33
vitamin D3
n=2 
lost to follow up before wk48
 n=1 serious adverse event
 n=1 consent withdrawal
n=3 
lost to follow up before wk48
 n=1 did not fulfill
inclusion criteria anymore
 n=2 consent withdrawal
n=23
analysed
n=30
analysed
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Additional laboratory parameters 
Analyses of additional laboratory parameters were done by Covance (Princeton, NJ, USA) as 
part of the SOLAR trial. Serum 25(OH)D (with an upper limit of 250 nmol/L) and 1,25(OH)2D 
levels (upper limit 442 nmol/L) were measured (radioimmunoassay, Packard Cobra II Gamma 
Counter (GMI, Ramsey, MN, USA)). The white blood cell count (WBC) and proportion of 
lymphocytes were used to calculate the absolute number of T and B cells. 
Statistical analyses  
SPSS software (SPSS Inc., version 20.0, Chicago, IL, USA) was used to assess the effect of 
vitamin D3 supplementation on immunological outcome measures. Normality of data was 
assessed by visual inspection of histograms with normal curves, skewness and kurtosis and 
normality tests (Kolmogorov-Smirnov and Shapiro-Wilk). For normal distributed populations, 
means and standard deviations are shown. For non-normal distributed populations, median 
and range (Q1-Q3) are shown. To test for statistical significant differences between follow-up 
measurements within each group, a paired T test or Wilcoxon rank test was used as appro-
priate. 
10
log ratios (wk48/wk0) were calculated to investigate the treatment effect between 
groups corrected for baseline measurements and T tests or Mann-Whitney U tests were 
performed accordingly. 
A p-value of <0.05 was considered statistically significant. 
Results 
Patient characteristics 
Between March 2011 and February 2014, 64 patients were included in the SOLAR trial in the 
Netherlands. A flow diagram of the patient inclusion is shown in Figure 2. Fifty-eight of those 
patients gave informed consent for the SOLARIUM sub-study. Twenty-five of them were 
allocated to the placebo group, and 33 to the vitamin D3 group. Two patients in the placebo 
group and 3 in the vitamin D3 group were lost-to-follow-up (see Table 1 for patient charac-
teristics). Details on supplementation regimen, treatment effects and side effects will be 
presented in the definitive SOLAR study report. Paired (before and after) samples of 23 and 
30 patients were analysed in the placebo group and in the vitamin D3 group, respectively. 
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Table 1. Baseline characteristics of analysed study participants. 
 Placebo Vitamin D3 
Number of patients with RRMS 23 30 
Sex (F/M) 14/9 (60.9%/39.1%) 21/9 (70%/30%) 
Age (years) 37.2 (±9.6) 37.7 (± 7.2) 
Disease duration (months) 7.3 (4.1-12.3) 7.3 (5.0-11.9) 
BMI ≥25 kg/m2 13/23 (56.5%) 16/30 (53.3%) 
EDSS at wk0   
 ≤3.5 22 (95.7%) 28 (93.3%) 
 4.0-5.5 1 (4.3%) 2 (6.6%) 
Number of attacks during past 2 years at wk0 1.26 (±0.62) 1.67 (±0.88) 
 1 19 (82.6%) 15 (50.0%) 
 2 2 (8.7%) 12 (40.0%) 
 ≥ 3 2 (8.7%) 3 (10.0%) 
Duration since last attack at wk0 (months)  8.0 (±3.1) 7.4 (±3.9) 
IFN-β duration (in months) 4.9 (±2.5) 6.0 (±3.0) 
Patients of Caucasian origin 23 28 
BMI: body mass index; EDSS: expanded disability status scale; F: female, IFN: interferon; M: male; RRMS: relaps-
ing remitting multiple sclerosis  
Serum 25(OH)D and 1,25(OH)2D levels are increased in the vitamin D3 supplemented 
group 
Serum 25(OH)D levels in the placebo group were rather stable (54 (43-63) nmol/L at wk0 and 
60 (36-85) nmol/L at wk48, p=0.38), while they increased significantly from 60 (38-85) 
nmol/L at wk0 to 231 (162-250) nmol/L at wk48 in the vitamin D3 group (p<0.001). These 
differences were significant between the groups (p<0.001) (Figure 3). Also 1,25(OH)2D levels 
increased significantly in the vitamin D3 group while they were stable over the follow-up 
time in the placebo treated patients (data not shown).  
Vitamin D3 supplementation does not affect the total amount of lymphocytes (subsets) 
We first assessed the total amount of lymphocytes, which were similar between wk0 and 
wk48 for both groups (total white blood cells count from 5.9*10
9 
(±2.1*10
9
) 
 
cells/L to 5.8*10
9 
(±2.4*10
9
) cells/L in the placebo group and from 5.1*10
9 
(±1.8*10
9
) cells/L to 5.1*10
9 
(±1.7*10
9
) cells/L in the vitamin D3 group; T cells from 1.1*10
9 
(±0.6*10
9
) cells/L to 0.9*10
9 
(±0.6*10
9
) cells/L in the placebo group and from 0.9*10
9 
(±0.4*10
9
) cells/L to 1.0*10
9 
(±0.6*10
9
) cells/L in the vitamin D3 group and B cells from 0.2*10
9 
(±0.1*10
9
) cells/L to 
0.2*10
9 
(±0.1*10
9
) cells/L in the placebo group and from 0.2*10
9 
(±0.1*10
9
) cells/L to 0.2*10
9 
(±0.2*10
9
) cells/L in the vitamin D3 group). 
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Vitamin D3 supplementation does not affect the fraction of Tregs and Bregs 
Next we measured the fraction of Tregs as proportion of CD4
+
 T cells within the lymphocyte 
compartment before and after supplementation with placebo or vitamin D3. Data are provid-
ed in Table 2A and Figure 4. The proportion of nTregs either defined as CD25
+
CD27
-
 nTreg, 
CD25
+
FoxP3
+
 nTreg or CD25
+
CD27
-
FoxP3
+
 nTreg did not change in the placebo group, or in 
the vitamin D3 group. As described previously [79], the different methods to phenotypically 
characterize nTreg were highly correlated (data not shown). Also the proportion of memory 
nTregs and CD39
+
 nTregs within the CD25
+
CD127
-
 nTregs, did not change upon vitamin D3 
treatment. The proportion of iTregs, defined as IL-10
+ 
Th cells, was not affected by high dose 
vitamin D3 supplementation and there was no significant difference in the effect between 
both groups (p=0.46). 
Besides Tregs, Bregs may be important for the maintenance of immunological homeostasis 
and self-tolerance. Also the change in Breg proportions over the follow-up time was not 
statistically different between the supplementation groups (p=0.08, Table 2A and Figure 4). 
In addition to IL-10 expression in B cells upon in vitro stimulation with CpG, we also used 
surface markers to identify Breg subsets directly ex vivo. Blair et al. showed that IL-10+ Bregs 
are enriched in the CD24
hi
CD38
hi
 CD19
+ 
B cell subset and that these cells have immune 
regulatory capacities. [301] We measured these surface markers directly ex vivo in the sam-
ples collected at wk48 follow-up. The mean proportion of CD24
high
CD38
high
 CD19
+
 B cells 
was 5.2% (±4.1) in the placebo group and 5.7% (±2.9) in the vitamin D3 group and these 
proportions did not differ significantly from each other (p=0.62). 
Vitamin D3 supplementation may balance the T cell compartment in patients with 
RRMS and prevent a decrease in the fraction of anti-inflammatory cytokine producing 
Th cells 
Although we did not find any effect of high dose vitamin D3 supplementation on the regula-
tory compartment of the adaptive immune system in RRMS patients, the balance in Th cell 
subsets may be affected by alternative pathways. Cytokine producing CD4
+
 T cells can be 
distinguished in pro-inflammatory (IFN-γ, IL-17, IL-22, GM-CSF, TNF-α) and anti-
inflammatory (IL-4) Th cells. There was no difference in the proportions of pro-inflammatory 
and potential MS-pathogenic Th cells over the follow-up period of 48 weeks neither in the 
placebo group, nor in the vitamin D3 group (Table 2B and Figure 4). The only difference that 
was observed was a decreased proportion of anti-inflammatory IL-4
+
 Th cells over the fol-
low-up period in the placebo group (3.8±1.6% to 2.9±1.7%, p=0.04), while the proportion of 
IL-4
+
 Th cells was stable over the follow-up time in the vitamin D3 group (4.1 ±2.4% to 
4.1±2.2%, p=0.92). Comparing the effect between both groups revealed a significant differ-
ence (p=0.05) (Table 2B and Figure 4). However, the ratio IFN-γ
+
 Th cells/IL-4
+
 Th cells was 
not influenced by vitamin D3 supplementation (2.5 ±0.9 to 2.5±1.0 (p=0.96) in the placebo 
group and 2.5±1.3 to 2.3±1.0 (p=0.56) in the vitamin D3 group, without a significant differ-
ence in effect size between the groups (p=0.95)). 
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Vitamin D3 supplementation prevents an imbalance in cytokine production upon T cell 
activation but does not change the reactivity to in vitro 1,25(OH)2D3 
Since we only found minor effects of vitamin D3 supplementation on the composition of the 
T helper cell compartment directly ex vivo, we assessed whether a functional effect on the T 
cell compartment could be observed. To this end, T cells within PBMC were activated in vitro 
with anti-CD3 and levels of various cytokines were measured in the culture supernatants. 
Overall, T cell cytokine secretion increased in the placebo group but not in the vitamin D3 
group. A significant increase was shown for the anti-inflammatory cytokines IL-5 and latency 
activated protein of TGF-β (LAP) in the placebo group (Table 3A). This was also reflected in a 
decreased IFN-γ/IL-5 ratio in the placebo group. Likewise, in the placebo group, there was a 
trend towards increased production of IL-10, IL-17 and GM-CSF over time, which was not 
seen in the vitamin D3 group. TNF-α levels increased in both groups over time. LAP was the 
only cytokine that significantly increased more in the placebo group then in the vitamin D3 
group (p<0.01). 
To assess whether vitamin D3 supplementation also has implications for the responsiveness 
of lymphocytes to vitamin D, we assessed the response of anti-CD3 stimulated PBMC cul-
tures to addition of 1,25(OH)2D3. 1,25(OH)2D3 decreased the amount of the pro-
inflammatory cytokines IFN-γ, IL-17, IL-22, GM-CSF and TNF-α and increased the anti-CD3 
induced amount of the anti-inflammatory cytokines IL-4, IL-5 and LAP in both treatment 
groups at both time points to the same extent (Table 3B and data not shown). Again, this 
was also reflected in a decreased IFN-γ/IL-5 ratio in both groups over the follow-up time. For 
IL-10 the results were less clear-cut, but there was no difference in effect size between the 
groups (p=0.16). This indicates that in vitro responsiveness to 1,25(OH)2D3 is preserved in 
lymphocytes after in vivo high dose vitamin D3 supplementation. 
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Discussion 
In the last decade, the interest in vitamin D research with respect to several (auto-immune) 
diseases has increased markedly. In MS, in vitro and in vivo studies have suggested that high 
dose vitamin D supplementation may be beneficial on clinical and immunological outcome 
parameters. We investigated the effects of high dose vitamin D3 supplementation in a place-
bo controlled randomised study on relevant immunological parameters in a homogenous 
patient group with early RRMS that was treated with IFN-β. The proportion of lymphocytes 
with a regulatory phenotype did not change over the follow-up after vitamin D3 supplemen-
tation and there was no difference between the placebo and vitamin D3 group. There was 
also no change in the proportion of Th cells producing pro-inflammatory and pathogenic 
cytokines at the end of the supplementation period, nor between randomization groups. 
Although the proportion of Th cells expressing the anti-inflammatory cytokine IL-4 de-
creased in the placebo group and was stable in the vitamin D3 group, this was not reflected 
in a shift in the ratio of IFN-γ
+
 Th cells/IL-4
+
 Th cells within and between groups.  
Despite this minor phenotypic change, functional studies with anti-CD3-stimulated PBMC 
cultures showed a general trend towards increased levels of cytokines in supernatant over 
time in the placebo group, most marked of the anti-inflammatory cytokines IL-5 and LAP, 
while these levels were unaffected in the vitamin D3 group. Furthermore, we have shown that 
the PBMC were still reactive to 1,25(OH)2D3 in vitro, independent of in vivo vitamin D3 sup-
plementation. Overall, this study showed that high dose vitamin D3 supplementation does 
not have the proposed effect on the peripheral T cell- and B cell-mediated immune regula-
tion, as has been suggested by the results of previous studies. As a matter of fact, changes 
are typically observed only in the placebo group. Therefore, it is tempting to speculate that 
the disturbances in the immune system in the placebo group may reflect disturbances in the 
adaptive (T cell) immune response as a possible consequence of ongoing disease activity 
early in the disease course of RRMS. The enhanced T cell cytokine release is most prominent 
in the anti-inflammatory immune compartment and this may imply subsequent compensato-
ry mechanisms in early MS. The absence of such disturbances in the vitamin D3 group might 
indicate that vitamin D3 can suppress these inflammatory fluctuations by maintaining im-
mune homeostasis and possibly may also be able to suppress subsequent clinical disease 
activity. Confirmation of this explanation should come from the clinical outcome analyses of 
high dose vitamin D3 supplementation studies, such as the SOLAR trial. 
As said, vitamin D research in MS is a hot topic and several RCTs have been performed or are 
ongoing at this moment, all with different supplementation regimes. Some of the published 
RCTs analysed immunological parameters. These did not show any effect on serum cytokines 
in MS, including IL-10 [302-305] and IFN-γ [303-305]. The only parameter that increased 
significantly in the vitamin D3 group was circulating LAP/TGF-β protein, but whether the 
effect size was significantly different between the supplemented and the placebo group was 
not reported. [180, 303] Conflicting and incomplete results have been reported on IL-17. 
[303, 304, 306] The change in circulating PBMC mRNA of TNF-α, IFN-γ, IL-13 and IL-2 did not 
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differ between the placebo and vitamin D3 group. [180] In supernatant of PHA stimulated 
PBMC, IFN-γ levels were unaffected whereas TGF-β and IL-10 increased and the proliferative 
response in PBMC of vitamin D3 supplemented patients decreased. [186] The effects on T cell 
homeostasis in HC were limited to an increase in the proportion of Treg numbers, not func-
tion, while none of the proportions of other investigated immune cells (naïve and memory 
CD4
+
 T cells, naïve and memory CD8
+
 T cells, NK cells, NK-T cells, plasmacytoid dendritic 
cells, myeloid DC, monocytes and neutrophils) were affected. [192, 298] The most recent 
study in MS, reported a reduced proportion of IL-17
+
 Th cells after high dose vitamin D3 
supplementation compared to the group with low-dose vitamin D3 supplementation, while 
effects on Tregs were not reported. [305] Altogether, when reviewing those results, studies 
so far have mainly reported the positive outcomes, but neglected the negative results, which 
were actually more apparent. 
A decrease in the amount of anti-inflammatory Th cells in RRMS has been described previ-
ously. [119] Although we expect anti-inflammatory cytokine producing Th cells to be favour-
able in MS [307, 308], also anti-inflammatory Th cell cytokines with pathogenic functions 
have been described [309, 310]. Our study showed a decreased proportion of IL-4
+
 Th cells 
over time in the placebo group, which could suggest that these cells either leave the circulat-
ing immune cell compartment and enter the CNS, that they switch to another cytokine pro-
ducing phenotype [311], that there is a relative increase of other T cell subsets or that they 
are induced less. Contradictory, in supernatants of PBMC cultures we saw an increase in anti-
inflammatory cytokines such as IL-4, IL-5 and LAP upon T cell activation. It is possible that 
these cytokines were produced by other cells, like the CD8
+
 cytotoxic T cells. [312] In general, 
we saw a (trend towards an) increase in all pro- and anti-inflammatory cytokines we investi-
gated in the placebo group. Therefore, we speculate that this reflects the dysregulated im-
mune response in the early disease course of RRMS with physiological 25(OH)D levels, while 
vitamin D3 supplementation towards supra-physiological levels maintains the immunological 
homeostasis. Although we were not fully able to identify the underlying mechanism from our 
study, our data point towards a most pronounced difference in anti-inflammatory Th cell 
proportions and function between the placebo and vitamin D3 group. This difference is 
independent of any effect on proportions of circulating regulatory lymphocytes, although 
their function was not assessed. 
The current study has some limitations. First, we only included IFN-β treated patients and 
therefore cannot extrapolate our findings to other patients with RRMS, who are treatment 
naïve or are treated with other disease modifying drugs. However, add-on or synergistic 
effects between vitamin D and IFN-β have been described. [223-226] Second, as mentioned 
above, Treg functionality was not assessed. Previously, we reported a positive correlation 
between Treg suppressive capacity and vitamin D status in a cross-sectional study. [191] 
Because we could not detect any improvement of Treg suppressive function after vitamin D3 
supplementation in our pilot study [79], our current protocol did not include any functional 
tests on Tregs. Treiber et al. reported an improved Treg suppressive capacity in subjects with 
diabetes mellitus type 1 after supplementation of vitamin D3. [313] We assessed the FoxP3 
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MFI in nTregs, which could be an indirect marker of nTreg function. [314] FoxP3 MFI de-
creased in the placebo group but was stable in the vitamin D3 group (data not shown). Alt-
hough speculative, this may suggest less effective immune regulation in the placebo group, 
which is in line with the suggested disturbance in immune homeostasis due to disease activi-
ty. Lastly, we did not correct for multiple testing. Strengths of this study are that it is a blind-
ed, placebo-controlled study and that we assessed the Th cell compartment as a whole and 
did not focus on a few selective parameters. Furthermore, we measured paired samples in 
the same season of one consecutive year, thereby excluding the influence of seasonal ef-
fects. 
Since the results of our current study reveal only minor effects of vitamin D3 supplementa-
tion on immune regulation, alternative explanations for the observed associations between 
vitamin D and MS have to be considered. Firstly, we looked at the immune cell compartment 
in the circulation which is the only immune compartment easily accessible for analysis in MS 
patients, whereas the question remains what happens in the secondary lymphoid tissues and 
targeted brain tissue. [82] Secondly, it might be possible that our supplementation dose was 
too high or only effective in patients with deficient 25(OH)D at the start of the supplementa-
tion. However, when only the patients with low 25(OH)D levels (below the group median of 
56 nmol/L) at baseline were assessed (n=27 (randomization 14/13), 25(OH)D at baseline 43 
(30-52) nmol/L), we observed no trends supporting this hypothesis, although numbers were 
small (data not shown). Thirdly, it has been shown that MS patients have an impaired reac-
tion to vitamin D [297, 315] and a lower increase in serum 25(OH)D after supplementation as 
compared to HC [316]. This might indicate that the results of vitamin D supplementation in 
HC cannot be easily translated to patients with MS. Fourthly, it is possible that vitamin D is 
‘consumed’ by the ongoing inflammatory processes in MS and that low 25(OH)D levels are 
more a consequence of disease rather than a contributing factor. [317] Supplementation will 
then not influence the disease activity in ongoing disease. Lastly, it is still possible that it is 
not vitamin D itself that is the (only) etiologic environmental factor attributing to MS risk and 
disease severity, but that vitamin D status is a surrogate marker for sun and UV light expo-
sure (also affecting vitamin A [318], melatonin [318-320] and nitric-oxide release [321]) or 
reflecting patients’ general physical and health constitution. 
In summary, 48-weeks of high dose vitamin D3 supplementation in IFN-β treated RRMS 
patients does not have substantial beneficial effects on the circulating regulatory immune 
cell compartment. However, our data point towards a role of in vivo high dose vitamin D3 
supplementation in the prevention of gradual worsening or (immunological) imbalance, as 
was shown in the placebo group with a decrease in anti-inflammatory cytokine producing Th 
cells, and a general (trend towards an) increase in the production of pro- and anti-
inflammatory cytokines, while these changes were absent in the vitamin D3 group. The role 
of vitamin D in the treatment of MS is therefore much more complex than in vitro, cross-
sectional, and small high dose supplementation studies have suggested. We showed in this 
study that vitamin D may prevent the immune system from getting out of control. Since this 
imbalance has been argued to be most pronounced at the start of disease, vitamin D sup-
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plementation should than be most effective at the start and early phases of the disease 
course. Whether this also becomes evident in the clinical outcomes, will become clear in the 
near future. 
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General aim of this thesis  
The increase in vitamin D research during the past decades has raised hopes among many, 
including patients, clinicians and researchers. The main question now is whether these high 
expectations can be substantiated by conclusive data or that positive findings from in vitro 
studies, association studies and small supplementation studies, have hyped those hopes up. 
In this thesis we focussed on the clinical and immunological effects of vitamin D in multiple 
sclerosis (MS). We investigated the role of vitamin D in disease progression to enhance our 
insights in the role of vitamin D in the disease course and studied the immune regulatory 
effects of high dose vitamin D supplementation as a possible add on treatment in patients 
with MS. 
Summary of results 
In chapter 1, we first reviewed the insights in the in vivo effects on immunological outcomes 
of vitamin D in healthy controls (HC), and in patients with an auto-immune disease, at the 
start of the research described in this thesis. The hypothesized mechanism underlying the 
association between vitamin D and MS disease activity is the immune regulating capability of 
vitamin D. In vitro studies and studies in the experimental auto-immune encephalitis (EAE) 
model had previously shown that immune cells are functional targets of vitamin D, but in 
vivo studies in humans were heterogeneous and involved multiple immunological outcomes. 
Overall, there seemed to be a trend towards an anti-inflammatory role of vitamin D, but this 
was not supported by conclusive data. Therefore well powered studies, like RCTs, were 
needed before definite conclusions could be drawn. 
While such trials were executed, in the first part of this thesis, we investigated the role of 
vitamin D levels within the physiological range in disease progression, a disability hallmark 
that was not investigated in great detail so far. This was a relevant question, especially for 
the treatment of progressive patients, since no treatments have been available to stop the 
progression of disease. Vitamin D could possibly fill this gap by having a direct effect in the 
CNS itself. In chapter 2 we used the expanded disability status scale (EDSS) score to investi-
gate the relationship between vitamin D levels and disability progression over a 3 year follow 
up. Although we could confirm the known relation of a poor vitamin D status with an in-
creased relapse risk in younger MS patients, no statistically significant association was found 
with disability or disability progression in patients with either relapsing remitting or progres-
sive MS. An alternative way to investigate disease progression is described in chapter 3. 
Here, we investigated the role of vitamin D in the (time to) transition to secondary progres-
sive (SP)MS in patients with relapsing remitting (RR)MS. We could confirm that the patients 
with SPMS in our study cohort had lower serum 25(OH)D levels when compared to the pa-
tients with RRMS. Cross sectional deseasonalised serum 25(OH)D levels in patients with 
RRMS did not predict the 3 year-risk of conversion to SPMS, but vitamin D levels at diagno-
sis were significantly lower in patients with RRMS and a very rapid progression to SPMS 
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(median RRMS duration of 3.5 (1.0-5.7) years) when compared to matched RRMS patients 
with a longer RRMS duration (minimum median RRMS duration of 7.7 (6.3-10.0) years, 
p<0.01). Long term follow up of high dose vitamin D supplementation studies is warranted, 
to confirm the findings in both these studies on the relation between vitamin D and disease 
progression. 
In the second part of this thesis, the vitamin D effects on immunological outcomes are de-
scribed. The most recent Th cell, that has been discovered to have strong encephalitogenic 
capacities in the EAE animal model, is the GM-CSF producing Th cell. Although a clinical trial 
in patients with MS has been initiated (NCT01517282), data on GM-CSF producing T cells in 
humans are limited. Therefore, we assessed the role of GM-CSF producing T cells in patients 
with MS and the mechanisms that might regulate them in chapter 4. We showed that the 
proportion of GM-CSF producing T cells in the circulating immune cell compartment was 
similar in patients with MS and HC. Furthermore, GM-CSF producing Th cells formed a signif-
icant part (39%) of the total T cell fraction in CSF of both patients with MS and non-MS 
controls. These results did therefore not support a specific pathogenic role of these cells in 
MS. In vitro, GM-CSF production by peripheral blood Th cells could be controlled by regula-
tory T cells and by vitamin D. The regulation by vitamin D was less effective in patients with 
MS. 
The most important part of this thesis focuses on the immune regulatory effects of high 
dose vitamin D supplementation in a randomised placebo controlled trial in patients with 
RRMS. We expected vitamin D to have a function in the immune regulation, in which the 
cytokine IL-10 plays an important role. The detection of IL-10 producing Th cells has, howev-
er, been reported to be difficult. Appropriate detection of IL-10 is highly relevant for a cor-
rect interpretation of the vitamin D effects on immune regulation. In chapter 5 we describe 
an improved method to detect IL-10 producing Th cells using flow cytometry. We showed 
that omitting monensin, a protein transport inhibitor, from the stimulation protocol, in-
creased the detection of IL-10 producing Th cells, NK-T cells and monocytes, but not B cells. 
Chapter 6 reveals the results of the SOLARIUM study. We showed that high dose vitamin D 
supplementation did not have any substantial effects on the number of circulating patho-
genic and regulatory lymphocytes relevant for MS. The anti-inflammatory, IL-4 producing, Th 
cells decreased over time in the placebo group and were stable in the vitamin D supple-
mented group, but this was not reflected by a change in the IFN-γ/IL-4 ratio. Functional 
analyses of supernatant of PBMC upon T cell stimulation, showed an increase of cytokine 
production in the placebo group, most outstanding in the anti-inflammatory cytokine com-
partment, while the cytokine expression was stable over time in the vitamin D supplemented 
group. Altogether, this could point towards a role of in vivo high dose vitamin D3 supple-
mentation in the maintenance of homeostasis of the adaptive immune cell compartment 
during the early RRMS disease course. Importantly, lymphocytes were still reactive to in vitro 
1,25(OH)2D, irrespective of randomisation group. Whether this balancing role also becomes 
evident in the clinical outcomes will become clear in the near future. 
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Vitamin D research in auto-immunity and MS, is the star on the 
horizon still shining? 
Vitamin D was discovered as the active anti-rachitic substance in liver oil in 1922 [322] but is 
mainly obtained via UVB exposure of the skin [323]. Later, in 1960, MS was related to sun 
exposure [324] and in 1974, the hypothesis of vitamin D being necessary for optimal for-
mation of myelin was put forward. [101] Since then, many researchers, i.e. immunologists, 
chemists, epidemiologists, geneticists and neurologists, have tried to get a better insight in 
the true role of vitamin D in auto-immunity and MS. In 2008, our group at the Academic MS 
Centre Limburg/Maastricht University Medical Centre, jumped into this research line and 
started with an overview of the then available evidence of the potential immune modulating 
effect of vitamin D in MS. [131] Some years later, we reviewed the evidence for in vivo effects 
of vitamin D in the healthy situation and in auto-immunity and concluded that this evidence 
was inconclusive (chapter 1). We were not the only ones discussing the role of vitamin D 
and the potential usefulness of high dose vitamin D supplementation therapies. Vitamin D 
workshops, originally organized for basic aspects of vitamin D biochemistry and physiology, 
started to broaden their view and discussions about the pros and cons of vitamin D thera-
pies were hold. [325-328] Commercial companies started advertising campaigns to enhance 
the purchase of vitamin D supplementation products thereby making also layman aware of 
the potential beneficial role of this sunshine vitamin, beyond the scope of bone strength. 
However, this explosion of quantitative interest in vitamin D made the differentiation be-
tween firm conclusions drawn from solid scientific experiments and to-be-proven hypothe-
ses drawn from exploratory scientific studies, unclear. 
The clinical point of view  
The association between low vitamin D levels and relapse risk in patients with MS, has been 
substantiated by several studies from different research groups. [71, 72, 74, 75, 103] Howev-
er, more and more recent evidence suggest the strongest relation of vitamin D in the MS 
disease process in the early (inflammatory) phase of the disease, with the strongest associa-
tion between low vitamin D levels and relapse risk in MS patients with a short disease dura-
tion [103] and in CIS patients [206, 329]. Overall, the studies on clinical outcomes in this 
thesis confirm this line of thoughts and increase the knowledge on vitamin D and its role in 
progression of disease. Disease progression is a highly relevant outcome measure as MS is a 
chronic disease with a major impact on an individual’s quality of life and with subsequent 
consequences for the society. We, indeed, confirmed the relation of vitamin D with relapse 
rate especially in young patients with MS with a possible role of a low vitamin D at the start 
of RRMS disease as risk factor for early conversion to SPMS. However, later during the dis-
ease course, we did not find a relation between serum vitamin D levels and conversion to 
SPMS or progression of disease, neither in RRMS nor in progressive MS (chapter 2 and 3). 
Also other follow-up studies have shown that physiological vitamin D levels in (very) early 
RRMS and CIS patients were related to MRI outcomes [206, 234] and EDSS [206]. This was, 
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however, not the case in established MS where there was no relation between EDSS progres-
sion and vitamin D levels. [73, 215, 234] The dilemma in studying disease progression is that 
it is not a parameter easy to measure. Disability related outcome measures are most com-
monly evaluated by using the EDSS score (as mentioned in the general introduction of this 
thesis). This measure is not ideal, but arguably the best measure available. Besides, it is im-
portant that the follow-up period in studies on progression is long enough to measure an 
effect, keeping in mind the role of other more substantial influencing factors than vitamin D, 
like the immune modulating treatments. 
Overall, our and other studies on the role of vitamin D in MS disease progression, suggest 
that the intake of (high dose) vitamin D supplementation in patients with MS later in the 
disease course will not affect the progression of the disease. Adequate vitamin D levels 
might be most relevant for disease activity and disease progression in the very beginning or 
even before the start of the disease when the inflammatory component is most obvious and 
maintenance of a (immunological) balance is still possible. This implies a narrow window of 
opportunity for vitamin D supplementation studies. Leray et al. have postulated that disabil-
ity progression in MS may follow a two stage pattern: early progression till an irreversible 
EDSS of 3 and later progression till an irreversible EDSS of 6. They suggest the progression in 
the late stage to be independent of the duration and progression in the early phase, both in 
patients with relapsing remitting and progressive MS. Only in the early phase the number of 
relapses was an independent predictor of disability progression. [230] If vitamin D would be 
able to increase the duration of this early phase, this would mean that the onset of the sec-
ond phase progression, which is probably not caused by focal inflammation, but by diffuse 
inflammation and neurodegeneration, could be postponed. Besides, this would have im-
portant implications for decisions on the continuation of DMTs in the SPMS phase. Currently, 
most treatments are especially effective in the inflammatory phase of MS, meaning that 
guidelines advice to stop treating patients who enter a secondary progressive phase, espe-
cially if they do not experience relapses anymore. [51, 330] However, the decision to discon-
tinue treatment is often difficult to accept for patients and many neurologists continue to 
prescribe DMTs to patients with SPMS. [331] A postponement of the conversion to SPMS by 
adequate vitamin D levels early in the disease course could therefore supposedly also in-
crease the window of opportunity for DMTs.    
Although one supplementation study showed a trend towards a relation between vitamin D 
levels and EDSS in RRMS after 1 year [80], long term follow-up of high dose supplementa-
tion trials should be able to give definitive answers to the question of the role of vitamin D in 
MS disease progression. 
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Figure 1.  Proportion of IL-10+ Th cells detected in patients included in the SOLARIUM study at wk0 and wk48, 
in the presence and in the absence of monensin. The line represents the y=x.  
IL: interleukin; Th: T-helper 
The immunological point of view  
In the second part of this thesis, we assessed the mechanism underlying the associations 
between vitamin D and MS disease activity and investigated the effect on relevant immuno-
logical outcomes. A recent addition to the panel of T-cell cytokines, suggested to be detri-
mental in EAE, is GM-CSF. Its role and relevance in MS has not yet been fully consolidated, 
but it might be a relevant marker to evaluate an immune modulating effect of vitamin D in 
MS. We therefore first looked at the GM-CSF producing (GM-CSF
+
) Th cells  in patients with 
MS in a cross sectional design, and ascertained that GM-CSF
+
 Th cells are not increased in 
the peripheral blood of patients with RRMS in remission nor in the CSF (chapter 4). In suc-
cession of this finding, Noster et al. found that the number of GM-CSF+ Th cells was also not 
increased in patients with active MS disease, contrary to the numbers in CSF, which they 
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reported a borderline significant increased fraction of these cells in the circulating immune 
cell compartment of patients with MS compared to patients with other neurological diseas-
es. They also showed that DMTs could decrease the numbers of GM-CSF
+
 Th cells. [254] Up 
to now, it is still the question whether the pathogenicity of the GM-CSF
+
 Th cell holds for the 
whole group of GM-CSF
+
 Th cells or only for a subset. [39] We showed that GM-CSF
+
 Th cells 
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were sensitive to regulation by regulatory cells and vitamin D, but the in vitro inhibition by 
vitamin D was less pronounced in patients with MS than in HC (chapter 4). Possible mecha-
nism for this may lay in the genetic differences in vitamin D metabolism or vitamin D re-
sponse elements in patients with MS, or in a different composition of the gut microbiome. 
More details on this topic will be discussed in the next paragraph. 
Next we assessed the immunological effects in our high dose vitamin D supplementation 
study in patients with early RRMS. Therefore, we first improved the detection of IL-10
+
 Th 
cells, the so called iTregs, which are important cells for immune regulation and a potential 
target of vitamin D therapy. The new protocol is described in chapter 5. We used this opti-
mized protocol to assess iTregs in the SOLARIUM study were we could confirm our previous 
findings, i.e. we detected increased proportions of IL-10
+ 
Th cells after omitting monensin 
from the stimulation protocol (median proportion of IL-10
+
 Th cell in the presence of 
monensin 1.0% (0.6-1.7), in the absence of monensin 1.2% (0.7-2.2); p<0.001) (Figure 1, 
unpublished data). 
 
Previously, we [79] and others [180, 186, 192, 302, 303, 306, 320, 332] have reported positive 
outcomes of vitamin D supplementation on a diverse array of immune parameters. In the 
SOLARIUM study, we could only detect minor changes on measures of regulatory lympho-
cyte subset frequencies and lymphocyte cytokine production in the circulating immune cell 
compartment of the RRMS patient who received placebo, while the measures in the vitamin 
D group were rather stable over time. The added value of the SOLARIUM study compared to 
previous studies was that this was a placebo controlled study with relevant power, and a 
high dose (14.000 IU/day) and long term (48 weeks) vitamin D3 supplementation interven-
tion. Results indicate that vitamin D balances the disturbed adaptive immune system during 
the disease course as was observed in the placebo group. In this group, the proportion of 
anti-inflammatory IL-4
+
 Th cells decreased while a general increase in the amounts of cyto-
kines produced upon T cell activation was shown, most pronounced in the anti-inflammatory 
compartment. This might point towards a disturbed immune response with accompanying 
compensatory mechanisms early in the MS course. Vitamin D might hereby be able to better 
maintain immune homeostasis and consequently control the disease course of MS. These 
findings are subtle and not entirely in line with earlier cross-sectional findings on immuno-
logical outcomes, and their relevance for clinical MS outcomes still needs to be shown. No-
tably, an effect of vitamin D on the immune pathology of MS is not necessarily the only 
driver of the numerous associations between vitamin D status and evolution of disease 
course in MS. Possible alternative hypotheses are plentiful, but cluster around two main 
themes in which vitamin D either does or does not affect the pathophysiology of MS.  
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Food for thought - alternative hypotheses 
Our studies in the context of vitamin D as an effector in the MS pathophysiology 
When assuming that vitamin D does interfere with MS, particularly in the early or pre-clinical 
phase, our clinical studies confirm this hypothesis and the SOLARIUM study hints towards a 
more complex mechanistic role of vitamin D within the human body then in vivo animal and 
in vitro human studies have suggested. These studies showed clear inhibiting effects of 
vitamin D supplementation on the pro-inflammatory cells of the adaptive immune system, 
while regulatory lymphocytes and anti-inflammatory lymphocytes were promoted. [131] In 
the human body, compensatory mechanisms of the neuro-endocrine-immune system, in-
cluding other vitamins and (sex) hormones, may take place. These interactions may be too 
complex to observe interference with a single component of this system, like vitamin D, in 
the immune system as a whole or on broad clinical measures. Complex multidimensional 
measurements, with multiple parameters at the single cell level like those obtained in the 
SOLARIUM study, make analyses of the right parameters a challenging one. Attempts to 
translate such datasets into one relevant integrated immune parameter have already been 
made [333], but might need further investigation. 
Although we aimed to look at relevant effects of vitamin D, by taking the regulatory lympho-
cytes and cytokine producing Th cells as a read-out, measuring vitamin D effects will be 
dependent on the right location, the right timing and the investigation of the right target 
cells. The cells we isolated from blood represent a heterogeneous pool of lymphocytes. In 
contrast, in vitro experiments and in vivo models of neuroinflammation show a more homo-
geneous pool of (antigen-specific) activated cells, in which vitamin D may interfere. There-
fore, an effect of vitamin D on pathogenic T cells in MS may be diluted and not observed in 
our studies. Another option is that our hypothesis, being vitamin D an immune regulator, 
was incorrect. Natalizumab, an effective MS drug, has for example been shown to lead to 
similar or even higher levels of pathogenic IL-17
+
 Th cells in the CNS, while one would ex-
pect pathogenic Th cells to decrease in number after treatment with an effective drug. [334, 
335] This also illustrates that it is possibly not (only) the number of cells that counts but also 
the functionality of these cells. We did not include the measurement of functional regulating 
capacity of regulatory lymphocytes in vitro as an outcome measure in our RCT. Our data do 
not suggest a dramatic shift in markers of immune regulatory cells, but a recent trial showed 
an improvement of Treg function after supplementation with vitamin D in diabetes mellitus 
type 1 patients. [313] Other, newly discovered cells that could be relevant as detrimental 
cells in MS and as targets for vitamin D therapy are specific subsets of GM-CSF producing Th 
cells (GM-CSF
+
 IFN-γ
+ 
double producers or  GM-CSF-only producers) [39], IL-2 receptor 
(CD25) expressing Th cells [336], CD52 Tregs [337] and GM-CSF producing B cells [338]. 
Furthermore, we did not investigate the direct effect of vitamin D supplementation on the 
immune cells in the CNS, on the CNS-cells themselves or on the blood brain barrier, which 
are all difficult to assess in humans. Likewise, migration of lymphocytes into the CNS would 
be an interesting outcome measure. A chemokine that might be relevant in this perspective 
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is CXCR3, involved in trafficking of potential pathogenic immune cells. This trafficking was 
impaired upon vitamin D supplementation in the EAE model. [339]  
Based on previous studies and our own clinical studies, described in this thesis, we included 
a group of patients with early RRMS who have the highest chance to benefit from high dose 
vitamin D supplementation. However, the IFN-β treatment they received might have ob-
scured the vitamin D effects. Obliging patients to be treatment naïve during the vitamin D 
supplementation period was, obviously, unethical. Moreover, IFN-β was one of the most 
common MS therapies used at the start of the study. Also, associations between vitamin D 
status and MS outcomes have been predominantly reported in IFN-β treated MS patients 
[74, 206, 234, 340], suggesting this treatment not to interfere with an underlying mechanism. 
Furthermore, vitamin D supplementation might be effective only in those patients with very 
low 25(OH)D levels. Yet, the immune system of the subgroup of patients with a very low 
25(OH)D status at baseline did not show more clear-cut effects of high dose vitamin D sup-
plementation in our study (chapter 6). This makes it also likely that it is not the change in 
25(OH)D level that counts. In line with this notion, SOLAR was certainly not a dose finding 
study: too high or too low doses of vitamin D may have been supplemented. In addition, we 
still do not know whether a certain vitamin D level is equally important for each individual. 
Multiple genes do affect an individual’s vitamin D status. [341, 342] Black people have lower 
serum vitamin D levels when compared to white people, but their bone metabolism is equal. 
[343, 344] Furthermore, also the main risk allele for MS, HLA-DRB1*1501, is regulated by 
vitamin D [345] just like the risk alleles TAGAP and IL-2R in Th cells [346]. CYP27B1 and 
CYP24A1, involved in the metabolism of vitamin D, popped up in GWAS. [14] Therefore 
supplementation might be most beneficial in a certain subgroup of patients with MS, based 
on their genetic profile. Unfortunately, our group of included patients did not have sufficient 
power to perform a stratification for this. Combined results of SOLAR and other vitamin D3 
RCTs may provide more clearness on this issue.  
Our studies in the context of vitamin D not affecting the MS pathophysiology 
The main second theme of alternative hypotheses regarding the association between vitamin 
D status and MS is that findings on the effects of vitamin D in in vitro studies and in vivo 
animal studies do not reflect the situation in human MS. In the EAE animal models, the active 
component of vitamin D, 1,25(OH)2D has been shown to be beneficial, mainly in the preven-
tion of disease onset, but also in reducing severity of symptoms and increasing survival. 
[131] Substantial fewer studies have been performed on vitamin D supplementation in mice. 
Spach and Hayes showed that vitamin D supplementation before immunization inhibited 
EAE in female mice. [159] Farias et al. replicated this finding with a reduced EAE severity, 
when vitamin D supplementation was started at the moment of immunization [347] and 
mice from vitamin D deprived parents developed a precocious and more severe EAE [348]. 
Also in vitro studies have contributed to the hypothesis of vitamin D having an immune 
regulatory role by increasing regulatory cells and anti-inflammatory cells and decreasing 
pro-inflammatory cells. However, here as well, usually the 1,25(OH)2D metabolite is used. In 
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humans, though, 25(OH)D levels are associated with clinical MS outcomes, whereas that is 
less clear for 1,25(OH)2D. Besides, supplementation of 1,25(OH)2D may lead to (unaccepta-
ble) hypercalcemia risks, while increasing the 25(OH)D levels might give the body the oppor-
tunity to regulate 1,25(OH)2D levels, thereby diminishing the change to develop side effects. 
Therefore, vitamin D supplementation in humans is based on supplementation with vitamin 
D2 or D3.  
Discrepancies between in vitro and in vivo human studies may also be explained by quanti-
tative issues in the immune responses studied: the in vitro effects of 1,25(OH)2D are usually 
assessed under quite extreme stimulating conditions, boosting the immune system to a very 
strong inflammatory reaction, one that will usually not arise in vivo in the human body. A 
strong aspect of the SOLARIUM is that functional characteristics of isolated PBMC (as well as 
their responsiveness to vitamin D) were assessed both directly ex vivo as in vitro. Further-
more, in the isolated environment of in vitro experiments, the dynamics of interactions in the 
human body are lost and other important parts of the immune system, like germinal centres 
cannot be easily investigated directly ex vivo. [349] 
Another interesting point is that our GM-CSF study and another recent study [315] have 
suggested immune cells of patients with MS to be less sensitive to regulation by vitamin D 
when compared to cells of HC (chapter 4). This could be due to differences in the vitamin D 
metabolism. Previously we have shown that the gene expression of the VDR, CYP27B1 and 
CYP24A1, was not impaired in PBMC and Th cells of patients with MS compared to HC, sug-
gesting a normal vitamin D response and metabolism in both groups. [350, 351] However, 
Bhargava et al. showed that MS patients have lower 25(OH)D levels after vitamin D supple-
mentation with 5000 IU/day for 90 days than HC. [316] If it is really true that the vitamin D 
metabolism in patients with MS is different from that of controls, these differences may be 
caused by variances in gut absorption, alternations of gut microbiota or in the polymor-
phisms in genes related to vitamin D metabolism, which are reported in some, but not all, 
MS genetic studies. It might therefore be that vitamin D supplementation is most relevant 
for a subpopulation of patients with MS who have a more ‘HC-like’ microbiome or genetic 
profile. 
In contrast to our current supplementation study, previous supplementation studies, most of 
them reporting much clearer effects of vitamin D on immunological and clinical outcome 
measures, were small and uncontrolled. Thereby introducing higher odds for chance and 
regression to the mean to interfere with the results. Furthermore, the impression that there is 
an unintended, but clear, bias of positive data selected and published, cannot be banished. 
Positive results of vitamin D supplementation have been selectively emphasized reporting 
changes of single cytokines while the more apparent negative results were just briefly men-
tioned. [187, 302, 306, 352] Blind analyses of all cytokines or cytokine producing T cells 
might have given a more general view on the effects of vitamin D on the adaptive immune 
system. This might have taken away the focus on changes in the pathogenic and regulatory 
cells in MS, and might have led to different conclusions, as has recently been suggested in 
Nature. [353, 354]  
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Ultimately, vitamin D might be a correlate of the causative factor interfering with MS. It may 
not be the (only) driving force in the relation between MS and sun exposure. Vitamin D is 
synthesized in the skin upon UVB exposure, in particular UV light with a wavelength between 
280 and 310 nm. Although positive associations with vitamin D and disease severity have 
been described in the EAE animal model, suppression of EAE appeared to be most eminent 
at wavelengths of 300-315 nm and was then independent of vitamin D. [355, 356] Vitamin D 
levels might therefore be a surrogate marker of sun exposure. Other potential candidates of 
the relationship between sun exposure and MS onset and disease activity are melatonin 
[319], vitamin A [318] or nitric oxide [321]. A ‘consumopathy’ of vitamin D by the activated 
immune cells could also explain the low vitamin D levels in patients with MS. [317] Low levels 
of vitamin D are then the consequence of the inflammation rather than a cause and higher 
serum levels of 25(OH)D will not dampen the inflammatory component. Lastly, most MS 
outcomes correlate negatively with sun exposure. [73] Therefore, being less exposed to 
sunlight and vitamin D may be a consequence rather than a cause of having active MS. 
Summary  
Summing up, the studies described in this thesis provide additional support for  a role of 
vitamin D and possibly also vitamin D supplementation in the early (and maybe even pre-
clinical) state of MS. Ultimately, to draw conclusions and chose directions for further research 
on vitamin D in MS, the results of clinical trials are extremely important. These studies will 
show whether modulation of vitamin D status will affect disease outcomes in MS. One of 
these studies is the SOLAR study. Data are not yet available, but will be announced in 2016. If 
modulation of the vitamin D status indeed affects disease outcomes, the question is whether 
these effects arise from the limited effects on the immune system or that there is a more 
important target. If not, other factors interfering with both vitamin D status and MS outcome 
may be more relevant. Altogether, as will be discussed in the next paragraphs, the star on 
the horizon is sufficiently shining to warrant further research on the role of vitamin D in MS. 
Future prospects 
This thesis describes the research done to discover some missing pieces in the story of vita-
min D in MS. Although some questions have been clarified, the final answer is not there yet. 
As already mentioned, supporting evidence suggest the strongest role of vitamin D very 
early in the disease course. To enhance our knowledge on the long term effects of vitamin D, 
also on disease progression, it is important to follow up the patients in vitamin D supple-
mentation studies, such as the SOLAR study. Future research will possibly also tell us whether 
other immune modulating drugs, currently in development, might have even more relevant 
synergistic effects with vitamin D than IFN-β has. Vitamin D will probably not be of help in 
immune cell depleting therapies or therapies blocking the entrance of the immune cells into 
the CNS, but a possible role in combination with immune modulation, stem cell transplanta-
tion (SCT) or remyelination therapies is not unrealistic. Preventive treatment was beyond the 
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scope of this thesis, but other studies on vitamin D have shown also associations and effects 
of vitamin D in the pre-clinical phase of MS: i.e. CIS [206, 329] and optic neuritis patients 
[357, 358]. These findings confirm our line of thoughts on a restricted window of opportunity 
for vitamin D supplementation (very) early in (the pre-clinical phase of) MS. One step further, 
vitamin D treatment could then also be useful in any pre-clinical phase, in which the disease 
process already started, but no actual symptoms have appeared. It might even be necessary 
to move our view more towards the prevention of the development of auto-immune disease 
in children and young adults. To obtain a healthy bone and calcium metabolism, vitamin D 
supplementation of 400 IU per day is already common in children and adolescents in the 
USA. [359] In Europe, this is advised for all children till the age of 4 or 5 and till the age of 19 
for every child who is at risk of a low vitamin D level due to a dark skin or a minimal time 
spent outside. [360-362] The question for the future is then whether vitamin D supplementa-
tion should be advised for adolescents all over the (Western) world to prevent the develop-
ment of MS and possibly other diseases. Furthermore, we will have to investigate what the 
desired dose of supplementation is for this target group. 
To obtain more insights into the mechanism of vitamin D and its role in the MS pathogene-
sis, our longitudinal samples which were collected in the SOLAR and SOLARIUM study are of 
great value. There are still a couple of interesting questions that need an answer. To gain 
more insights in what happens in the vitamin D uptake, transport and metabolism in patients 
with MS, it might be interesting to measure the vitamin D metabolizing enzymes and associ-
ated genes in plasma or lymphocytes. Besides these mechanisms playing a role in the effec-
tiveness of vitamin D treatment in patients with MS, also the existence of neutralizing vita-
min D antibodies, which were found in serum of patients with systemic lupus erythematosus, 
may hamper the potency of vitamin D treatment. [363, 364] Furthermore, one could think of 
investigating the vitamin D binding protein (DBP). The effects of vitamin D supplementation 
were cancelled out in EAE mice with increased DBP expression. [365, 366] DBP levels have 
been reported to be increased in patients with MS [365], although our group could not 
confirm this [367]. Furthermore the investigation of vitamin D metabolites and the free ver-
sus bound fraction of 25(OH)D could learn us more about the actual availability of the 
25(OH)D metabolite in the microenvironment of immune- and CNS cells. [368] 
As mentioned before, it is possible to look at other target cells of the immune system that 
were not investigated so far. Furthermore, it would be compelling to know what the actual 
effects of vitamin D supplementation are on the target tissue, the CNS. However, human 
brain tissue usually originates from deceased MS patients with more advanced MS. Those 
samples will probably not be representative of MS manifestations at the start or during the 
disease course. Therefore, answers to this question will probably need an animal model, 
which is genetically linked to human MS, like EAE models in primates such as marmosets. 
Another open question is what happens in the lymph nodes of patients with MS, in reaction 
to vitamin D supplementation. It would be very interesting to investigate this in the (superfi-
cial) cervical lymph nodes were most probably antigen presentation takes place. Also 
(changes in) the gut microbiome is a hot topic in auto-immunity research. Furthermore it is 
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interesting to look at the relations and interactions of different environmental risk factors in 
MS such as the combination of vitamin D and EBV [349] and to keep our minds open for 
other underlying mechanism that could explain the relation between sun exposure and MS 
like melatonin, vitamin A and nitric oxide. 
Intriguing is the difference between in vitro and in vivo vitamin D supplementation studies. 
Instead of thinking about explanations, we could also turn this phenomenon to our ad-
vantage. By in vitro treatment of autologous immune cells, for example T cells, and replace-
ment of those cells in the human body, we could circumvent the in vivo (compensatory) 
effects. [347] Research on this topic is already ongoing in the group of B. Roep at the Univer-
sity Medical Centre in Leiden (the Netherlands). They are investigating the possibilities of in 
vitro vitamin D treatment of dendritic cells (DC) of diabetes mellitus patients. Once placed 
back in the body these DC could induce the development of Tregs. [369, 370] 
More in general, to enhance the progress in MS and environmental factor research, especial-
ly vitamin D, it is important that researchers in all fields of auto-immunity are open to each 
other and work together to disentangle the common denominators in the pathogenesis of 
auto-immune diseases. It is important that people involved continue to look beyond the own 
niche, traditionally based on the target organ that is affected. Initiatives to facilitate this have 
already been undertaken by the Dutch Society of Immunology (Balie debat, 20 Nov 2014). 
[371, 372] Another hot topic in the scientific community is the question how to obtain objec-
tive analysis and reproducibility of data, which are translatable to the clinic. [353, 354, 373, 
374] To this end, it is important that everybody involved in scientific research, i.e. tutors, 
researchers, journal editors and reviewers is aware of this challenge and continues to do 
their best to prevent the realisation and publication of low quality research. Recently, it has 
been shown that the use of positive and negative words in research papers has increased 
substantially in the last decades, while the use of neutral words decreased. It might be that 
scientific findings are sometimes overstated or exaggerated in order to be published. [375] 
Also the high rate of discontinuation and non-publication of RCTs [376] might lead to waste 
of research sources, ethical concerns, and affect research and patient care. Therefore, it is 
important to make the publication of negative results not inferior to the publication of posi-
tive results. This will overcome false hopes and hypes and will make it possible to focus 
research sources on the really relevant topics. 
Vitamin D in MS: hype or hope? 
The role of vitamin D in MS has been proposed to be twofold. First of all it is presented as 
one of the identified environmental risk factors in the development of MS. Second, vitamin D 
has been related to MS disease activity. The research in this thesis focused on the latter 
topic. Vitamin D research and papers published on this topic have increased significantly in 
the last decades. In the previous 5 years the increase in papers on vitamin D appears to be 
stronger than the increase in the total amount of papers published, confirming the gained 
interest in vitamin D in the scientific community (Figure 2). 
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Figure 2. Quantification of publications cited in Pubmed on vitamin D (MESH) in black bars and total publica-
tions (all (sb)) in grey, chronologically ordered. 
 
The proposed role of vitamin D in relation to MS and multiple other auto-immune diseases, 
but also non auto-immune diseases, like cardiovascular diseases, infectious diseases and 
cancer, has provided the ideal background for vitamin D to become a hype. Some clinicians 
already prescribe high doses of vitamin D to their patients and some countries included the 
advice to supplement patients with MS with 2000-4000 IU per day in their protocols. [377] 
However, hypes can induce false hopes and make it a challenge to disentangle the truth. We 
presume that the work in this thesis contributes to a better understanding and an increased 
nuance in the role of vitamin D in MS. Of course we will have to wait for the clinical out-
comes of high dose vitamin D supplementation studies first, but findings so far suggest a 
window of opportunity for vitamin D treatment in pre-clinical and early MS. By extrapolating 
these results, we can speculate about the relevance of vitamin D supplementation even 
before the onset of disease. The role of vitamin D later in the disease seems negligible, but 
long term follow-up of randomised controlled trials have to confirm our findings. One of the 
mechanisms involved in this might be the maintenance of immunological homeostasis. 
Immune cells of patients with MS do react differently to vitamin D than those of HC. Our 
immunological analyses of the blood of patients with MS in a high dose vitamin D3 supple-
mentation study showed that vitamin D is possibly able to maintain the immunological 
balance in the circulating immune cell compartment during the disease course. What the 
effect of vitamin D is on the immune cells in lymph nodes and in the CNS or on CNS cells 
themselves, and whether other (environmental) factors in addition to vitamin D play an 
essential causative role in reported associations, remain open questions. 
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Introductie 
In dit proefschrift hebben we een bijdrage willen leveren aan de kennis met betrekking tot 
de rol van vitamine D in multiple sclerosis (MS). We hebben ons hierbij gericht op de rol van 
vitamine D spiegels op de ziekteprogressie en beschrijven de effecten van hoge dosis vita-
mine D suppletie op het immuunsysteem van patiënten met MS.  
MS is een inflammatoire ziekte van het centrale zenuwstelstel (CZS), bestaande uit het rug-
genmerg en de hersenen. In Nederland hebben ongeveer 16.000 mensen MS, op de wereld 
ongeveer 1,3 miljoen. Het is een ziekte die zich voornamelijk bij jonge vrouwen manifesteert, 
tussen de 20 en 40 jaar. De precieze oorzaak is niet bekend; het is hoogstwaarschijnlijk een 
combinatie van genetische factoren en omgevingsfactoren die een rol speelt. De belangrijk-
ste omgevingsfactoren zijn een lage vitamine D status in het bloed, roken en infecties met 
bijvoorbeeld het Epstein Barr virus (EBV). Het meest voorkomende type MS is de zogenoem-
de relapsing remitting MS (RRMS), waarbij periodes van neurologische symptomen (relap-
sen), afgewisseld worden door periodes van herstel (remissie). De ziekte kan zich met ver-
scheidenheid aan symptomen uiten en deze kunnen bestaan uit gevoelsverlies, tintelingen, 
vermoeidheid, spierspasmes, zwakte, problemen met lopen, pijn, problemen met het zien, 
een gestoorde verstandelijke functie, depressie en het niet goed functioneren van blaas en 
darmen. Als de symptomen niet volledig herstellen en er ook tussen de relapsen verergering 
van klachten optreedt, spreken we van progressieve MS (secundair progressieve MS (SPMS) 
of primair progressieve MS (PPMS)).  
Er wordt over het algemeen gedacht dat MS een auto-immuunziekte is. Dit geldt in het 
bijzonder voor het RRMS subtype. Auto-immuunziekten ontstaan door een fout in het im-
muunsysteem waardoor dit systeem niet goed meer in staat is eigen weefsel van niet-eigen 
weefsel te onderscheiden. In MS betekent dit dat lichaamseigen weefsel van het CNS door 
het immuunsysteem wordt aangevallen. Hierdoor raken zenuwcellen (neuronen) en myeline, 
het vetachtige zenuwmerg dat normaal voor een snelle en vloeiende overdracht van prikkels 
zorgt, beschadigd. Op de lange termijn zijn deze beschadigingen niet meer te herstellen en 
treedt verergering van de klachten op. 
Vitamine D is een belangrijk vitamine dat wij voornamelijk binnenkrijgen onder invloed van 
UVB straling in zonlicht. Een goede vitamine D spiegel in het bloed, gemeten als 25(OH)D, is 
van belang voor een goede calciumregulatie en bothuishouding. Maar lage vitamine D spie-
gels worden ook in verband gebracht met het risico op het ontwikkelen van auto-
immuunziekten als MS. Daarnaast lijkt het erop dat lage vitamine D spiegels in patiënten 
met MS de kans op het ontwikkelen van relapsen kan vergroten. Een belangrijke open vraag 
was of vitamine D spiegels ook in verband kunnen worden gebracht met de mate van MS 
gerelateerde beperkingen en de achteruitgang daarin, later in het ziekteproces. Dit is een 
belangrijke uitkomstmaat omdat deze achteruitgang van ziekte voornamelijk speelt bij pati-
enten met progressieve MS, voor wie op dit moment alleen behandeling bestaat die symp-
tomen kan verminderen, maar niet de ziekte kan remmen of genezen. 
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Voor patiënten met RRMS zijn er wel al verschillende ziekte remmende medicijnen op de 
markt en vele meer in ontwikkeling. Gebaseerd op de eerdere verbanden die gelegd zijn 
tussen lage vitamine D spiegels en de kans op het ontwikkelen van een relapse, ontstond de 
gedachte dat vitamine D suppletie een goede aanvulling zou kunnen zijn op de al bestaande 
therapieën voor patiënten met RRMS. Eerdere kleine studies hebben uitgewezen dat dit 
waarschijnlijk veilig is en resultaten waren hoopgevend. Het onderliggende mechanisme van 
vitamine D is waarschijnlijk een immuunregulatoir effect, waardoor het immuunsysteem 
minder snel ontspoort.  
 
In dit proefschrift hebben we allereerst de rol van vitamine D in de achteruitgang van de 
ziekte onderzocht. Daarnaast hebben we in een grootschalige gerandomiseerde en gecon-
troleerde studie gekeken naar de effecten van vitamine D suppletie op immunologische 
uitkomstmaten (de SOLARIUM studie). 
Samenvatting van het beschreven onderzoek 
Om te beginnen, hebben we in hoofdstuk 1 de in vivo effecten van vitamine D op het im-
muunsysteem van gezonde controles en van patiënten met een auto-immuunziekte be-
schreven. Hierin wordt een overzicht gemaakt van de kennis op het moment van de start van 
het onderzoek dat in dit proefschrift is beschreven. Het mechanisme dat het verband tussen 
vitamine D en de ziekteactiviteit van patiënten met MS zou kunnen verklaren, is gebaseerd 
op de gedachte dat vitamine D immuun regulerende eigenschappen heeft. In vitro studies 
(studies buiten het lichaam van een levend organisme) en studies in het diermodel van MS, 
experimentele auto-immuun encefalitis (EAE, ontsteking van het encephalon/ brein), hadden 
eerder aangetoond dat immuun cellen functionele doelwitten zijn van vitamine D. In dit 
overzichtsartikel bleek echter dat de resultaten die tot dan toe bij mensen beschreven waren, 
heterogeen waren. Bovendien was er sprake van een grote verscheidenheid aan immuun 
parameters die bestudeerd werd. Over het algemeen leek het erop dat er een trend zicht-
baar was richting een anti-inflammatoire rol van vitamine D, maar dit kon niet bevestigd 
worden door overtuigend bewijs. Daarom waren er krachtige studies, zoals gerandomiseerde 
gecontroleerde onderzoeken nodig, voordat er definitieve conclusies met betrekking tot dit 
onderwerp getrokken konden worden.  
Terwijl dit soort gerandomiseerd en gecontroleerd, grootschalig onderzoek van start ging, 
hebben wij de rol van fysiologische niveaus vitamine D in het bloed, op progressie van de 
ziekte onderzocht. Progressie van ziekte is een belangrijke uitkomstmaat, in het bijzonder 
voor progressieve MS patiënten. Op dit moment zijn er geen medicijnen beschikbaar die ook 
daadwerkelijk de ziekteprogressie stoppen. Vitamine D zou hierin mogelijk wel een rol kun-
nen spelen, door een direct positief effect op de cellen van het brein. In hoofdstuk 2 heb-
ben we gebruik gemaakt van de EDSS score om in een retrospectieve follow-up studie van 3 
jaar, de relatie tussen vitamine D status in het bloed en progressie van de invaliditeit te 
onderzoeken. Hoewel we de relatie tussen een lage vitamine D status en een toegenomen 
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kans op het ontwikkelen van relapsen in jonge patiënten konden bevestigen, konden we 
geen statistisch significant verband aantonen tussen de mate van invaliditeit of de progres-
sie van invaliditeit in patiënten met RRMS of patiënten met progressieve MS. Een andere 
manier om ziekte progressie te onderzoeken is beschreven in hoofdstuk 3. Hier hebben we 
de rol van vitamine D bekeken in de overgang naar een secundair progressieve MS in pati-
enten met RRMS. We konden bevestigen dat patiënten met SPMS lagere 25(OH)D spiegels 
hadden dan patiënten met RRMS. Cross-sectioneel gemeten en voor het seizoen gecorri-
geerde 25(OH)D spiegels van deze RRMS patiënten voorspelden niet of zij in de daaropvol-
gende 3 jaar overgingen naar een SPMS. Vitamine D spiegels op het moment van diagnose 
waren echter wel significant lager in RRMS patiënten met een snelle progressie naar SPMS 
(mediane RRMS duur van 3.5 (1.0-5.7) jaar) vergeleken met vergelijkbare RRMS patiënten 
met een langere RRMS duur (minimum mediane RRMS duur 7.7 (6.3-10.0) jaar). Langdurige 
follow-up van hoge dosis vitamine D suppletie studies zullen de bevindingen in deze beide 
klinische studies m.b.t. de relatie tussen vitamine D en ziekteprogressie moeten bevestigen. 
In het tweede gedeelte van dit proefschrift, zijn de effecten van vitamine D op immunolo-
gische uitkomstmaten beschreven. De meest recent ontdekte T-helper cel, die in het EAE 
diermodel, sterk encephalitogeen (dat wil zeggen die een ontsteking in de hersenen kan 
veroorzaken) is, was de GM-CSF producerende T helper cel. Hoewel er een klinische trial in 
MS patiënten is geïnitieerd (NCT01517282), zijn data m.b.t. deze cellen in mensen schaars. 
Daarom, hebben wij deze cellen en de mechanismen die deze cellen reguleren bekeken in 
hoofdstuk 4. Wij hebben laten zien dat het aantal GM-CSF producerende T cellen in het 
circulerende immuun cel compartiment niet verschilt tussen patiënten met MS en gezonde 
controles. Daarnaast zagen we dat GM-CSF producerende cellen 39% van de T cellen in de 
hersenvloeistof van zowel patiënten met MS als van controle patiënten uitmaakten. Deze 
resultaten konden zodoende niet een specifieke pathogene rol van deze cellen in MS beves-
tigen. In vitro konden regulatoire T cellen uit het bloed en vitamine D de hoeveelheid GM-
CSF, geproduceerd door T cellen, beïnvloeden. Deze regulatie door vitamine D was minder 
effectief in MS patiënten. 
Het belangrijkste onderdeel van dit proefschrift richt zich op de immunologische effecten 
van hoge dosis vitamine D suppletie in een gerandomiseerde studie bij patiënten met RRMS. 
Wij verwachtten dat vitamine D een rol heeft in de immuun regulatie en hierin speelt het 
cytokine IL-10 een belangrijke rol. Het detecteren van T helper cellen die IL-10 produceren is 
echter lastig, maar wel belangrijk om de effecten van vitamine D op het immuunsysteem 
juist in te schatten. Daarom beschrijven we in hoofdstuk 5 een verbeterde methode om 
deze cellen te detecteren m.b.v. flow cytometrie. Door het weglaten van de eiwit transport 
remmer monensine uit het protocol, neemt de detectie van het aantal IL-10 producerende T 
helper, NK- en NK-T cellen toe, maar niet het aantal B-cellen. In hoofdstuk 6, worden de 
resultaten van de SOLARIUM studie beschreven. We laten zien dat hoge dosis vitamine D3 
suppletie geen duidelijke effecten heeft op het aantal, voor MS relevante, pathogene en 
regulatoire  lymfocyten. De anti-inflammatoire IL-4 producerende T helper cellen namen wel 
af over de follow-up tijd in de placebo groep en dit aantal was stabiel in de vitamine D3 
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gesuppleerde groep, terwijl dit niet terug te zien was in een verschil van de IFN-γ/IL-4 ratio. 
Functionele analyse van het supernatant van PBMC na T cel stimulatie liet een toename van 
cytokines zien in de placebo groep. Deze was het meest uitgesproken voor de anti-
inflammatoire cytokines. De cytokine expressie in de vitamine D3 gesuppleerde groep veran-
derde niet. Dit zou kunnen wijzen op een rol van in vivo vitamine D3 suppletie in het behoud 
van homeostase van het adaptieve immuunsysteem vroeg in het beloop van MS. Belangrijk 
om te vermelden is daarnaast, dat lymfocyten van beide groepen nog steeds reageerden op 
in vitro 1,25(OH)D toevoeging. Of het behoud van deze balans ook tot uiting komt in klini-
sche uitkomstmaten zal in de nabije toekomst duidelijk worden. 
Vitamine D in MS, hype of hoop? 
De rol van vitamine D in MS zou tweeledig kunnen zijn. Enerzijds is het een van de omge-
vingsfactoren die geassocieerd is met het risico op het ontwikkelen van MS. Anderzijds, is 
een lage vitamine D status in het bloed gerelateerd aan de ziekteactiviteit van MS patiënten. 
Het onderzoek in dit proefschrift heeft met name dit laatste onderwerp verder uitgediept. 
Het onderzoek naar vitamine D en het aantal artikelen dat hierover gepubliceerd is, is de 
laatste tientallen jaren enorm toegenomen. Dit feit bevestigt de toegenomen aandacht voor 
vitamine D in de medisch wetenschappelijke wereld. Daarnaast heeft de mogelijke rol van 
vitamine D in relatie tot MS en verscheidene andere auto-immuunziekten, maar ook in bij-
voorbeeld cardiovasculaire ziekten, infectieuze ziekten en kanker, de ideale voedingsbodem 
gegeven om uit te groeien tot een hype. Sommige artsen schrijven zelfs al hoge dosis vita-
mine D voor aan hun patiënten. Ook wordt er in sommige landen al geadviseerd aan patiën-
ten met MS om 2000-4000 internationale eenheden vitamine D per dag te gebruiken. Hypes 
kunnen er echter voor zorgen dat er valse hoop gecreëerd word en het wordt dan een uit-
daging om de waarheid te achterhalen. Wij zijn van mening dat het werk in dit proefschrift 
bijdraagt aan een beter begrip en een verfijndere blik op de rol van vitamine D in MS. Dit 
onderzoek zal bijdragen tot het beter onderscheiden wanneer en voor welke patiënt met 
MS, vitamine D suppletie van nut kan zijn. Natuurlijk moeten we wachten op de klinische 
uitkomsten van hoge dosis vitamine D suppletie studies, maar het onderzoek tot nu toe wijst 
op de beste kansen voor vitamine D behandeling in vroege, en misschien wel preklinische, 
MS. Als we deze resultaten extrapoleren naar preventie, is het de vraag of vitamine D supple-
tie niet zelfs het meest relevant zou kunnen zijn vóór de start van de ziekte. De rol van vita-
mine D in de latere fase van de ziekte lijkt verwaarloosbaar, maar langdurige follow-up van 
gerandomiseerde en gecontroleerde suppletie studies zal dit moeten bevestigen. Eén van de 
onderliggende mechanismen kan de invloed van vitamine D op het behoud van de immuno-
logische balans zijn. Immuun cellen van patiënten met MS reageren anders op vitamine D 
dan cellen van gezonde controles. Onze immunologisch analyses van het immuunsysteem 
van patiënten met MS in een hoge dosis vitamine D3 suppletie studie lieten zien dat vitamine 
D mogelijk in staat is de immunologische balans van het immuunsysteem, vroeg in de ziekte, 
te bewaren. Wat er echter gebeurt met immuun cellen in lymfe klieren en in het brein, of met 
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de cellen van het brein zelf, en of ook andere (omgevings) factoren naast vitamine D een 
essentiële rol spelen in de beschreven verbanden, blijven open vragen. 
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Introduction 
In the final chapter of this thesis, we will elaborate on how to make the knowledge, obtained 
in our scientific research and reported in this thesis, work. What can our results add to socie-
ty, to whom, with whom and how? From a scientific point of view, there are still a lot of open 
questions in the field of multiple sclerosis and auto-immunity. The MS society in the UK tried 
to identify a top 10 of important research questions that are most crucial to be solved ac-
cording to people having MS and their health professionals. [378] 
 
- Which treatments are effective to slow, stop or reverse the accumulation of disability 
associated with MS? 
- How can MS be prevented? 
- Which treatments are effective for fatigue in people with MS? 
- How can people with MS be best supported to self-manage their condition? 
- Does early treatment with aggressive disease modifying drugs improve the prognosis for 
people with MS? 
- Is vitamin D supplementation an effective disease modifying treatment for MS? 
- Which treatments are effective to improve mobility for people with MS? 
- Which treatments are effective to improve cognition in people with MS? 
- Which treatments are effective for pain in people with MS? 
- Is physiotherapy effective in reducing disability in people with MS? 
 
Besides the effectiveness of vitamin D supplementation, at least three others questions 
among these 10 questions were touched upon in this thesis. Behind these questions lay a 
couple of even more basic questions about the disease mechanism in MS. How would it be 
possible to prevent MS, or to treat disability, fatigue and cognitive problems, if we still don’t 
know what exactly happens in the pathophysiology, if we do not know what we measure and 
if we do not know how to measure it? In the question about the role of vitamin D we have 
made some important steps forward in the last years, investigating the disease mechanism 
and the clinical outcomes. Now, it is the question how we can continue to valorise these 
results in a process of value creation and making scientific knowledge available by transla-
tion, application, interaction and inspiration. [379, 380] 
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Translating from bench- to bedside: vitamin D in multiple sclerosis  
Purpose of studying the role of vitamin D in MS 
As has been described in the general introduction of this thesis, vitamin D deficiency has 
been associated with different diseases. [1] One of the diseases associated with a vitamin D 
deficiency, especially during childhood and adolescence, is MS. [70] Two main important 
scientific challenges in MS are to unravel the pathological mechanism and to develop new 
effective therapies with a minimum of (serious) side effects. While vitamin D deficiency has 
been identified as a risk factor for developing MS and has been proposed as a(n add-on) 
therapy decreasing disease activity, studying vitamin D in MS is very interesting from a scien-
tific point of view.  
Furthermore, there are other important reasons to study the role of vitamin D in multiple 
sclerosis. MS is a disabling disease mainly affecting young women, and to a lesser extent 
men, in the prime of their lives, many of them raising kids. Therefore, this disease will not 
only affect the physical and economic independence of those people but also of the people 
surrounding them, and of society. In the Netherlands, the total health costs for MS were 244 
million euro in 2011 (0.3% of total costs spent in the healthcare). [381] Patients with MS 
experience physical disability with the need for a walking stick or wheelchair on average 20 
years and 30 years after diagnosis, respectively. [382] Already at the time of a first clinical 
attack, 50% of the patients have cognitive impairment in at least two cognitive areas. [383] 
Together this involves a significant emotional and social burden: more than 50% of patients 
with MS have to decrease the amount of hours that they work or have to change to other 
functions [384] and they have higher probabilities to separate or get divorced compared to 
the general population [385]. Until now, there is no cure available and treatment focuses on 
the prevention of relapses and disability progression. Vitamin D could possibly be an inter-
esting and relative cheap target for prevention and treatment of MS. However, last years, 
vitamin D has become a hype, and has sometimes been presented as the new panacea. With 
that it has become increasingly difficult to get to know the truth about the efficiency of 
vitamin D supplementation. Patients and their treating physicians want to know whether or 
not they should prescribe or take (high dose) vitamin D supplementation and when and in 
which dose. Policy makers need to know what choices they should make in preventive medi-
cine and also funding bodies, who have to divide research budgets among a number of 
projects, need to be able to identify the most important research. All these decisions should 
be based on facts, not on hypes. We aimed to increase our knowledge about the role of 
vitamin D in multiple sclerosis, by collecting scientific data of well-considered research.  
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Main results described in this thesis which need further valorisation   
In this thesis, the effects of vitamin D in multiple sclerosis have been investigated from both 
a clinical and immunological perspective. With that, the research in this thesis is translational 
research (from bench to bedside) [386] and in part already entered the process of valorisa-
tion.  
- Taking immunological outcomes as a read-out, we saw that data on the in vivo effects 
of vitamin D in health and disease were heterogeneous in many aspects. A trend to-
wards an anti-inflammatory role of vitamin D seemed to be present, but it was difficult 
to draw firm conclusions (reviewed in chapter 1) 
- From a clinical point of view an important gap in our knowledge was the role of vitamin 
D in disease progression. Disease progression is one of the most important hallmarks of 
disability and has major impacts on the quality of life. We could demonstrate that vita-
min D levels are predictors of disease activity and probably also the time to conversion 
to progressive disease, but only at the start of the disease and not later on, during the 
disease course (chapter 2 and 3). 
- From the bench side view, we improved the technique to discover IL-10, one of the 
important cytokines in our body, in terms of immune regulation (chapter 4). 
- From the bench to bedside view, we looked at the role of GM-CSF in human MS: GM-
CSF
+ 
T cells were equally present in patients and controls, and were increased in CSF 
compared to blood. We discovered that the number of GM-CSF
+
 T cells are probably 
not affected by vitamin D, but functionally they were regulated by regulatory T cells and 
vitamin D, the latter one being less effective in patients with MS than in healthy controls 
(chapter 5). 
- In a RCT, already on our way to valorisation of vitamin D supplementation, we showed 
that high dose vitamin D supplementation is not able to promote immune cell balance, 
but that it is able to prevent further disturbance of the immune balance during the dis-
ease course in early MS (chapter 6) 
The innovative character of our studies 
With the results from our studies we can make some steps further in finding an answer to 
the “hype or hope” question. From our clinical studies we can make more clear what the 
target group of patients is, which will benefit most from (high dose) vitamin D supplementa-
tion. These are the patients at the start of their disease or patients or even healthy individu-
als in the pre-clinical phase of the disease. With our immunological studies on GM-CSF and 
vitamin D, we have aimed to translate findings from animal and in vitro research to in vivo 
effects in humans. The added value of the SOLARIUM study compared to previous studies 
was that this was a placebo controlled study with relevant power, and a high dose (14.000 
IU/day) and long term (48 weeks) vitamin D3 supplementation intervention. Furthermore, 
another point of interest is that we looked at the regulatory immune cell compartment and T 
cell compartment as a whole in this study, not focusing on a single cell or cytokine. [387] 
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Application, interaction and inspiration  
Applicable science 
The studies described in this thesis are able to contribute to the use of scientific knowledge 
in different ways.  
First of all, they increase our understanding in the pathophysiology and the role of environ-
mental factors in the disease multiple sclerosis and in auto-immunity. Furthermore, with our 
research on GM-CSF producing T cells, we added new information to the field, information 
that should be kept in mind when developing GM-CSF therapies in MS. [388]  
Second, with regard to the vitamin D supplementation therapy, we showed that it can over-
come a further imbalance in the immune system during the course of the disease. Of course, 
clinical outcomes have to confirm our findings, but if so, we have hints towards a narrow 
window of opportunity for vitamin D supplementation at the start of the disease and should 
further investigate the optimal dose. These recommendations should then be incorporated 
in guidelines for general practitioners and neurologists treating patients with auto-immune 
diseases like MS. With regard to high dose vitamin D supplementation two other options 
might be worthwhile to deliberate on. First, it might be worthwhile to investigate the effec-
tiveness of high dose vitamin D supplementation in the pre-clinical phase, during childhood 
and adolescence in people sensitive to developing auto-immune diseases. This probability to 
develop an auto-immune disease should possibly take into account an individuals’ genetic 
make-up, month of birth, place of birth, family history and ethnicity. Second, as already 
deliberated on in the general discussion of this thesis, it might be lucrative to think about in 
vitro treatment of autologous immune cells, for example T cells, with vitamin D and replace-
ment of those cells in the human body. Hereby, the in vivo (compensatory) effects, as shown 
in our vitamin D supplementation study, might be circumvented and efficacy increased. [347]  
Implementation by interaction and inspiration 
Implementation of scientific knowledge is not only about “knowledge, skills and cash”. It also 
includes more “soft skills” for example communication, cooperation and collaboration. [379] 
Our research is of course first of all most interesting for (future) patients with MS and their 
treating physicians. They should be informed about our research activities. Efforts have al-
ready been made via the website of the Academic MS Centre, via patient associations and 
via presentations at patient days. Our studies were published in (bio)medical journals and 
presented at national and international congresses to reach treating physicians and col-
leagues from different biomedical disciplines, like the neurology, immunology and vitamin D 
field. Future colleagues had the opportunity to learn about our research during lectures for 
students in the medical and biomedical field and for nurses, or by performing an internship 
in our group. The “7 UMC tour”, a day organised to celebrate the 50 years birthday of the 
Dutch Society of Immunology in 2014, was an example of an opportunity we took to also 
inform the general public about our research. 
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If our immunological results in the SOLARIUM study will be confirmed by positive results of 
clinical outcomes in the SOLAR trial, it will become important to reach consensus if, when 
and how to prescribe high dose vitamin D supplementation to patients with MS and to 
incorporate these advices in national and international guidelines. To fasten the process of a 
possible implementation of GM-CSF therapy and vitamin D supplementation therapy, also 
the expertise of pharmaceutical companies and policy makers should be used for optimal 
valorisation. Pharmaceutical companies will have added value by their knowledge on imple-
mentation of drugs to the market and, especially if there are more clues pointing to preven-
tive medicine, policy makers should get involved to make people aware of the sense and 
nonsense about vitamin D. Lastly, if in vitro treatment of T cells with vitamin D is promising 
enough to enter a clinical phase study, clinical immunologists should stay involved. 
Apart from these hopes for the future there are also still some challenges to tackle: MS is a 
very heterogeneous disease, and our results are not that easy translatable to all MS patients. 
Furthermore, big challenges are there for (bio)medical research in general: how to deal with 
big datasets, how to increase reproducibility, how to objectively analyse data, how to make 
translation from animal to human more efficient [353, 354, 373, 374], how to build bridges 
between the different research areas [371, 372] and different professional groups in 
healthcare, how to make it possible that negative data get the same attention as positive 
data [375] and how to reduce waste and maximise efficiency of research sources? Some 
initiatives have already started (for example the REWARD (REduce research Waste And Re-
ward Diligence) Campaign of the Lancet and the Dutch “Science in Transition” initiative that 
aims to introduce new checks and balances in the scientific system and inform layman about 
the decisions made [396, 397]), but we all have to think and work together on that. Only then 
valorisation of research as that described in this thesis will become easier and more efficient 
in the future. 
Conclusion 
Multiple sclerosis is a disabling disease, with much impact on individuals, but also on society. 
This thesis touches upon several of the most important research questions in this disease 
with a special attention to the role of vitamin D. Approached from a clinical and immunolog-
ical perspective, this thesis already describes translational research. Further valorisation 
needs to be done by staying critical towards research methods and results of ourselves and 
of others and continuing the communication and collaboration with different disciplines, 
with some important challenges for the biomedical field ahead for the future. 
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Dan in Sittard het MS-team: Bertine (mijn liefste koerier!) en het MS-research team, Sandra, 
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onderzocht worden maar zonder mensen met of zonder ziekte en enthousiaste neurologen 
en verpleegkundigen die hen begeleiden is het nauwelijks mogelijk onderzoeksresultaten te 
vertalen naar de gezondheidszorg. Bij deze dus een grote dank aan iedereen bij wie we voor 
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Natuurlijk valt niet iedereen in een hokje te plaatsen. Er waren ook nog vele anderen met wie 
ik kortdurend of minder intensief heb samengewerkt: MS collega’s uit Hasselt, de collega’s 
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